A genetically engineered bipartite cellular device for the discovery and characterization of T cell receptor interactions with cognate antigens.
The genetically engineered bipartite cellular device addresses the lack of standardized methods for analyzing TCR-antigen interactions by integrating analyte antigens and TCRs into eAPCs and eTPCs, facilitating high-throughput and reproducible functional analysis of TCR signaling output.
Patent Information
- Application Number
- JP2019546065
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-11-07
- Filing Date
- 2017-11-07
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2037-11-07
AI Technical Summary
Current techniques lack standardized methods for high-throughput generation of cells with TCR pairs expressed in their native cellular context, which is crucial for functional analysis and selection of TCRs for therapeutic and diagnostic applications, as they do not accurately reflect native TCR composition or signaling output.
A genetically engineered bipartite cellular device comprising two parts: a genetically engineered antigen presenting cell system (eAPCS) and a genetically engineered TCR presenting cell system (eTPCS), allowing for the standardized functional analysis of TCR responsiveness to antigens by integrating analyte antigens and TCRs into the genomes of eAPCs and eTPCs, respectively, ensuring presentation on the CD3 cell surface complex.
Enables high-throughput, reproducible, and cost-effective analysis of TCR-antigen interactions in the context of cell-cell communication, reducing time and cost of discovering and testing TCR and T cell antigen candidates by ensuring accurate representation of native TCR signaling output.
Smart Images

Figure 0007582779000011 
Figure 0007582779000012 
Figure 0007582779000013
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to the construction and use of a genetically engineered cell device comprising two parts, each part containing a different genetically engineered cell system that interacts with each other during the operation of the system. The first part of the bipartite cell device is an antigen-presenting cell (APC) system that has been genetically engineered by genome editing to render the APC null for cell surface presentation of human leukocyte antigen (HLA) molecules, HLA-like molecules, and different forms of antigen-presenting and antigenic molecules. In addition, the genetically engineered APC system (eAPCS) contains a genomic integration site for the insertion of an open reading frame (ORF) encoding an antigen-presenting molecule, and optionally, for the insertion of a genetically encoded analyte antigen. A gene donor vector designed to target the genomic integration site of the APC and rapidly deliver the ORF encoding the analyte antigen molecule-and / or antigen-presenting complex completes the eAPCS. The second part of the bipartite cell device is a T cell receptor (TCR)-presenting cell system that has been genetically engineered by genome editing to render the cell null for surface expression of TCR chains. This engineered TCR-presenting cell system (eTPCS) remains competent to express TCR heterodimer complexes in a CD3 complex context at the cell surface upon introduction of an ORF encoding a TCR, and is also competent to respond in a detectable manner to TCR ligation. A gene donor vector designed to target the genomic integration site of the TCR-presenting cell and rapidly deliver the analyte TCR ORF completes the eTPCS. This engineered bipartite cell device is designed for standardized analysis of TCR / antigen interactions in the native functional context of cell-cell communication. [Background technology]
[0002] Introduction to the invention Immune surveillance by T lymphocytes (T cells) is a central function in adaptive immunity of all jawed vertebrates. Immune surveillance by T cells is achieved through a rich functional diversity across T cell subtypes, which contribute to the elimination of pathogen infections and neoplastic cells, orchestrate adaptive immune responses to commensal non-self factors such as invading pathogens, commensal microorganisms, molecular components of food, and also maintain self-immune tolerance. To respond to a variety of foreign and self factors, T cells must be able to specifically detect the molecular components of these foreign and self factors. Thus, T cells must be able to detect the vast majority of self and non-self molecules that an individual encounters with sufficient specificity to mount an effective response against pathogenic organisms and pathological self, while avoiding the initiation of such a response against healthy self. The highly complex nature of this task becomes clear when considering the practically infinite diversity of both foreign and self molecules, with pathogenic organisms being under evolutionary pressure to evade detection by T cells.
[0003] T cell receptor (TCR) T cells are primarily defined by the expression of the T cell receptor (TCR). The TCR is the component of the T cell responsible for interacting with and sensing targets of T cell adaptive immunity. Generally speaking, the TCR is composed of a heterodimeric protein complex that is displayed at the cell surface. Each of the two TCR chains is composed of two extracellular domains, the variable (V) and constant (C) regions, which together belong to the immunoglobulin superfamily (IgSF) domain and form an antiparallel β-sheet. They are anchored to the cell membrane by a type I transmembrane domain adjacent to a short cytoplasmic tail. The predisposition of T cells to adapt and detect diverse molecular components results from variations in the TCR chains that occur during T cell development. This variation occurs by somatic recombination in a manner similar to antibody development in B cells.
[0004] TCR Chain Diversity The T cell pool consists of several functionally and phenotypically heterogeneous subpopulations. However, T cells can be broadly classified as αβ or γδ according to the somatically rearranged TCR isoform expressed on their surface. There are two TCR chain pair isoforms: TCRα (TRA) and TCRβ (TRB), and TCRgamma (TRG) and TCRdelta (TRD). T cells expressing the TRA:TRB pair are called αβ T cells, whereas T cells expressing the TRG:TRD pair are often called γδ T cells. Both αβ and γδ forms of TCR are responsible for the recognition of diverse ligands, or "antigens," and each T cell generates either αβ or γδ receptor chains de novo during T cell maturation. These new TCR chain pairs achieve diversity of recognition by generating receptor sequence diversity in a process called somatic V(D)J recombination, after which each T cell expresses a separate rearranged copy of a single TCR. At the TRA and TRG loci, several separate variable (V) and functional (J) gene segments are available for recombination and are juxtaposed to constant (C) gene segments, hence the term VJ recombination. Recombination at the TRB and TRD loci also involves a diversity (D) gene segment, hence the term VDJ recombination. Each engineered TCR has the potential for unique ligand specificity determined by the structure of the ligand-binding site formed by the α and β chains in αβ T cells, or the γ and δ chains in γδ T cells. The structural diversity of TCRs is primarily limited to three short hairpin loops in each chain, called complementarity determining regions (CDRs). Three CDRs are contributed from each chain of the receptor chain pair, and together these six CDR loops reside at the membrane-distal end of the TCR extracellular domain and form the antigen-binding site. Sequence diversity in each TCR chain is achieved in two ways. First, random selection of gene segments for recombination results in basic sequence diversity. For example, TRB recombination occurs between 47 unique V, 2 unique D and 13 unique J germline gene segments. Typically, V gene segments contribute both CDR1 and CDR2 loops and are thus germline encoded. The second mode for generating sequence diversity occurs within the hypervariable CDR3 loops, which arise by random deletion of templated nucleotides and addition of non-templated nucleotides at the junctions between the recombining V, (D) and J gene segments.
[0005] TCR:CD3 complex The mature αβ and γδ TCR chain pairs are presented on the cell surface as a complex with several accessory CD3 subunits called ε, γ, δ, and ζ. These subunits associate with the αβ or γδ TCR as three dimers (εγ, εδ, ζζ). This TCR:CD3 complex forms the unit to initiate a cell signaling response upon binding of the αβ or γδ TCR to its cognate antigen. The CD3 accessories bound to the TCR:CD3 complex contribute signaling motifs called immunoreceptor tyrosine-based activation motifs (ITAMs). CD3ε, CD3γ, and CD3δ each contribute a single ITAM, whereas the CD3ζ homodimer contains three ITAMs. The three CD3 dimers (εγ, εδ, ζζ) that assemble with the TCR thus contribute 10 ITAMs. Upon TCR ligation with cognate antigen, phosphorylation of tandem tyrosine residues creates paired docking sites for proteins containing Src homology 2 (SH2) domains, such as the critical ζ-chain-associated protein of 70 kDa (ZAP-70). Recruitment of such proteins initiates the formation of the TCR:CD3 signaling complex that is ultimately responsible for T cell activation and differentiation.
[0006] αβT cells αβ T cells are generally more abundant in humans than their γδ T cell counterparts. The majority of αβ T cells interact with peptide antigens presented by HLA complexes at the cell surface. Peptide-HLA (pHLA)-recognizing T cells were the first to be described and are the best characterized. A rarer form of αβ T cell has also been described. Mucosal-associated invariant T (MAIT) cells appear to have relatively limited α and β chain diversity and recognize bacterial metabolites rather than protein fragments. Invariant natural killer T cells (iNK T cells) and germline-encoded mycolyl-reactive T cells (GEM T cells) are restricted to the recognition of glycolipids cross-presented by non-HLA molecules. iNK T cells appear to interact mostly with glycolipids presented by CD1d, whereas GEM T cells interact with glycolipids presented by CD1b. Additional forms of T cells are thought to interact with glycolipids associated with CD1a and CD1c, but such cells have not yet been characterized in detail.
[0007] Normal αβT cells An important feature of most αβ T cells is the recognition of peptide antigens in association with HLA molecules. These are often referred to as "conventional" αβ T cells. Within an individual, self-HLA molecules present peptides from self and foreign proteins to T cells, providing an essential basis for adaptive immunity against malignancies and foreign pathogens, and adaptive tolerance towards commensals, food and self. The HLA loci that code for HLA proteins are the most gene-dense and polymorphic regions of the human genome, with over 12,000 alleles described in humans. The high degree of polymorphism in the HLA loci ensures diversity in peptide antigen presentation between individuals, which is important for immunity at the population level.
[0008] HLA classes I and II There are two forms of classical HLA complexes, HLA class I (HLAI) and HLA class II (HLAII). There are three classical HLAI genes, HLA-A, HLA-B and HLA-C. These genes code for transmembrane α chains that associate with the invariant β2 microglobulin (β2M) chain. The HLAI α chain is composed of three domains of the immunoglobulin fold type, α1, α2 and α3. The α3 domain is close to the membrane and is mostly invariant, whereas the α1 and α2 domains together form a polymorphic antigen-binding cavity that is far from the membrane. There are six classical HLAII genes, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA and HLA-DRB1. These genes code for paired DP, DQ and DR heterodimeric HLA complexes that contain α and β chains. Each chain has two major structural domains of the immunoglobulin fold type, in which the α2 and β2 domains contain a membrane-proximal, largely invariant module similar to that of the HLAI α3 domain, while the HLAII α2 and β2 domains together form the antigen-binding cavity distal to the membrane and are a highly polymorphic region. The antigen-binding cavity of HLAI and HLAII contains two antiparallel α-helices on a platform of eight antiparallel β-sheets. In this cavity, peptide antigens bind and are presented in an extended conformation. Peptide contact residues in HLAI and HLAII are the site of most sequence polymorphism, which constitutes the molecular basis of the diverse peptide repertoires presented by different HLA alleles. Peptides make extensive contacts with the antigen-binding cavity, so that each HLA allele imposes distinct sequence constraints and preferences on the presented peptides. A given peptide thus binds only to a limited number of HLAs, and reciprocally, each allele accepts only a specific fraction of the peptide collection from a given protein. The set of HLAI and HLAII alleles present in each individual is called the HLA haplotype. Polymorphisms in the HLAAI and HLAII genes and codominant expression of inherited alleles drive the enormous diversity of HLA haplotypes across the human population, which, when combined with the enormous sequence diversity of the αβTCR, poses major obstacles for standardizing the analysis of these HLA-antigen-TCR interactions.
[0009] αβTCR binding of HLAAI and HLAII The αβTCR recognizes peptides as part of a mixed pHLA-binding interface formed by residues from both HLA and peptide antigens (altered self). The HLAI complex is presented on the surface of nearly all nucleated cells and is generally believed to present peptides derived from endogenous proteins. T cells can thus survey the endogenous cellular proteome of HLAI-presenting cells by sampling the pHLAI complex of interacting cells. Binding of HLAI requires expression of the TCR co-receptor CD8 by the interacting T cell, so HLAI sampling is dependent on the expression of CD8 +In contrast, surface expression of HLAII complexes is primarily restricted to professional APCs, which are generally believed to present peptides derived from proteins exogenous to the presenting cell. Interacting T cells can thus survey the proteome of the extracellular microenvironment in which the presenting cell resides. Because HLAII binding requires expression of the TCR coreceptor CD4 by the interacting T cell, HLAII sampling is based on the CD4 + Restricted to αβ T cells.
[0010] Thymic selection of αβTCR The role of the αβTCR mentioned above is the detection of pHLA complexes, and TCR-presenting T cells can mount a response that is closely related to the role of that T cell in established immunity. The αβTCR repertoire generated in an individual, in association with a specific haplotype, must be the reason for the huge and unpredictable diversity of all foreign antigens that are likely to be encountered before diversity actually occurs. This result is achieved against a background in which a highly diverse and numerous αβTCRs arise in a more or less randomized manner, with the ability to recognize unspecified pHLA complexes that have only been specifically taught to avoid strong interactions with self-pHLA. This is carefully regulated during T cell maturation in a process called thymic selection. During the first step of T cell maturation in the thymus, T cells with αβTCRs that cannot interact with self-pHLA complexes with sufficient affinity are deprived of survival signals and eliminated. This step, called positive selection, ensures that surviving T cells have a TCR repertoire that is at least potentially capable of recognizing foreign or altered peptides presented in association with the correct HLA. Then, αβTCRs that strongly interact with self-pHLA and thus have the capacity to drive autoimmunity are actively eliminated by a process of negative selection. This combination of positive and negative selection results in only T cells with αβTCRs that have low affinity for self-pHLA in the periphery. This establishes an αβT cell repertoire that is self-restricted but not autoreactive. This highly individualized nature of T cell development to HLA haplotypes highlights the difficulties in standardized analysis of αβTCR-antigen-HLA interactions. Furthermore, this forms the basis of both graft rejection and graft-versus-host disease, as well as the general principle that an αβTCR identified in one individual may have a completely different effect in a second individual, with clear implications for TCR- and T cell-based therapeutic and diagnostic strategies emerging in clinical practice.
[0011] Unconventional αβT cells Non-HLA-restricted or "unconventional" forms of αβ T cells have very different molecular antigen targets. These unconventional αβ T cells do not bind classical HLA complexes, but conserved HLA-like proteins such as the CD1 family or MR1. The CD1 family contains four forms (CD1a, b, c, and d) involved in antigen cross-presentation. These cell surface complexes have an α chain that resembles HLA I, which forms a heterodimer with β2M. A small hydrophobic pocket displayed on the membrane-distal surface of the α chain forms a binding site for lipid-based antigens derived from pathogens. Innate like NK T-cells (iNK T-cells) are the best understood example of lipid / CD1 family recognition, with GEM T-cells representing another prominent example. "Type I" iNK T-cells are known to strongly interact with the lipid α-GalCer associated with CD1d. These iNK T cells display very limited TCR diversity with a fixed TCR α chain (Vα10 / Jα18) and a limited number of β chains (with restricted vβ usage), which have been likened to natural pathogen-associated molecular pattern (PAMPS) recognition receptors such as Toll-like and Nod-like receptors. In contrast, "type II" NK T cells display a more diverse TCR repertoire and appear to have more diverse forms of CD1d-lipid complex binding. GEM T cells recognize mycobacteria-derived glycolipids presented by CD1b, but the molecular details of antigen presentation by CD1a, b, and c and their T cell recognition are only beginning to be understood. MAIT cells predominantly express the invariant TCR α chain (TRAV1-2 ligated with TRAJ33, TRAJ20 or TRAJ12), which can pair with a range of TCR β chains. Instead of peptides or lipids, MAIT TCRs can bind pathogen-derived folate and riboflavin-based metabolites presented by the HLAI-like molecule, MR1. The limited but striking diversity in TCRs observed for MAIT TCRs likely allows recognition of diverse but correlated metabolites associated with the conserved MR1. How non-classical HLA-restricted αβ T cell TCRs are selected in the thymus during maturation is not well understood, but the basic processes of negative and positive selection outlined above appear to apply, and there is some evidence to suggest that this occurs in specialized niches within the thymus.
[0012] γδT cells In contrast to the detailed mechanistic understanding of αβTCR development and pHLA binding, relatively little is known about the antigen targets and their relationships with γδT cell counterparts. This is in part due to their relatively low abundance in the circulating T cell compartment. However, γδT cells are widely believed to be not strictly HLA restricted and appear to recognize surface antigens more freely, similar to antibodies. In addition, more recently, it has become recognized that γδT cells can dominate the resident T cell compartment in epithelial tissues, which are the main site of interaction of the immune system with foreign antigens. Furthermore, various mechanisms for γδT cell tumor immune surveillance and other forms of surveillance of dysregulated self are beginning to emerge in the literature. Although the specific antigen targets of both innate-like and adaptive γδT cells are still poorly defined, the tissue distribution and rapid recognition of PAMPs suggest a fundamental role for γδT cells both early in the response to foreign antigens and early in life when the adaptive immune system is still maturing. The diverse functions of γδ T cells appear to be based on different VγVδ gene segment usage and can be broadly understood in two main categories where γδ T cells mainly mediate innate-like recognition of PAMPs very early during infection together with the invariant TCR. Besides PAMPs, these types of γδ T cells are also thought to recognize self-molecules including phosphoantigens that may provide very early signs of cellular stress, infection and possibly tumor development. The recognition of PAMPs and such so-called damage associated molecular patterns (DAMPS) as well as the large number of tissue-restricted innate-like γδ T cells strongly suggests that these cells are well suited to respond rapidly to antigenic challenge without the need for prior activation, homing and clonal expansion.
[0013] The second form of γδ T cells is thought to be more adaptive in nature, with a highly diverse γδ TCR repertoire and the ability to circulate in the periphery and directly access lymphoid tissues. Such antigen-specific γδ T cells have been described for common human pathogens such as CMV and appear to form memory responses. However, γδ T cells only show relatively limited clonal expansion after activation, and little data is available on the extent of TCR diversity and specific responses of γδ T cells in the peripheral circulation or tissues. Furthermore, it is generally believed that γδ TCRs do not interact with pHLA complexes and therefore do not bind peptide antigens in this context, although only a few antigen targets of γδ T cells have been characterized and the underlying molecular framework is only poorly understood.
[0014] The low frequency of peripheral γδ T cells and the difficulty of studying tissue-resident T cells in humans have limited our knowledge of how this important and diverse type of T cell participates in adaptive immune responses. This emerging area of research requires more reliable techniques to capture and characterize rare γδ T cells, isolate their TCR pairs, and identify their cognate antigens.
[0015] Antigens and antigen-presenting cells In the context of T cells and TCR, an antigen can be defined as any molecule that can bind to the TCR and result in signal transduction in the T cell. The best-characterized T cell antigens are peptides that are presented in the HLA I and HLA II complexes and bind to conventional αβ T cells. However, in recent years, it has become clear that unconventional αβ and γδ T cells can bind a wide range of biomolecules as antigens, such as lipids, lipopeptides, glycopeptides, glycolipids, and a range of metabolites and catabolic products. Furthermore, it has become clear that γδ T cells can directly bind fully folded proteins in an antibody-like manner. Thus, the view that T cell antigens are primarily restricted to peptides presented by HLA has been expanded in the past two decades to include almost all biomolecules. With this concept in mind, it is appropriate to define what can be considered an antigen-presenting cell (APC). Antigens and antigen-presenting cells
[0016] As defined in the previous section, HLAI and HLAII have disparate expression profiles across cell types. It is widely accepted that nearly all nucleated cells present HLAI complexes on their cell surface and are therefore capable of presenting peptide antigens for T cell sampling. In contrast, HLAII has a restricted expression profile and is expressed, at least in steady-state conditions, only on the surface of cells with a specialized role in antigen presentation, including dendritic cells (DCs), macrophages, and B cells. These specialized cell types are often referred to as professional APCs. For the purposes of this document, the term "APC" is used to refer to any nucleated cell capable of presenting antigens for sampling by αβ or γδ T cells. Such antigens include, but are not limited to those presented as "cargo" in specific antigen-presenting complexes, e.g., HLA and HLA-like molecules, but can include any cell surface-presented moiety capable of binding to αβ or γδ TCR-bearing cells.
[0017] Therapeutic Use of TCRs Adoptive transfer of primary T cells was first tested in a clinical setting in the early 1990s, first using ex vivo expanded T cells directed against viral antigens to confer viral immunity to immunocompromised patients. A similar approach using ex vivo expanded primary T cells against specific cancer antigens was tested in the treatment of malignancies shortly thereafter. One limitation of these early approaches, which continues to be a challenge, is the lack of understanding of the nature and diversity of T cells, which conflicts with the need to finely optimize the composition of therapeutic products. Currently, the use of ex vivo expanded primary T cells has been largely abandoned in the pharmaceutical industry, except for a handful of initiatives using primary T cells with specificity for viral antigens.
[0018] In recent years, the ability to stably introduce genetic material into primary human cells has led to a growing class of experimental genetically modified T cell therapeutics. Such therapeutic cell products aim to harness the power of T cell responses and redirect T cell specificity to disease-associated antigen targets, e.g., antigens expressed only by malignant cells. These rely primarily on the transfer of chimeric antigen receptors (CARs) into recipient T cells, rather than actual TCR chain pairs. CARs are targeting moieties (often single-chain antibody elements that target surface-expressed proteins on malignant cells) grafted onto signal receptor elements, e.g., the ζ chain of the CD3 complex, to generate synthetic chimeric receptors that mimic CD3-TCR function. These so-called CAR T cell (CAR-T) products have shown mixed success in clinical trials to date, and despite their potential, they are not easily translated beyond tumors with their own unique molecular targets, e.g., B cell malignancies. Instead, there has been growing interest in transferring full-length TCR chain pair ORFs into T cells. Such TCR engineered T cell therapeutics are currently limited by the difficult manufacturing process and, similar to CAR-T products, the lack of validated antigen targets and targeting constructs. To date, much of the focus has been on the use of αβTCRs to recognize peptide antigens presented by HLAI on malignant cells, and a fundamental difficulty with this approach is the need for antigens specific to the malignant cells.
[0019] It is believed that native TCRs are unlikely to be optimal for TCR engineered T cell therapy because the TCR-pHLA interaction is of relatively low affinity. Several approaches have been devised for affinity maturing TCRs in vitro in the same manner as single chain antibody affinity maturation. These TCR affinity maturation approaches also generally use a single chain format where the V region of one chain is fused to the V region of another chain to create a single polypeptide construct. Such a single polypeptide can then be used in a phage or yeast display system adapted from the antibody engineering workflow and can undergo several rounds of selection based on target binding. In such single chain TCR approaches, there are two inherent limitations in obtaining functional TCR chain pairs. First, the selection is based on binding affinity with the target. However, it is well documented that TCR affinity does not always correlate with the strength or potency of TCR signaling output. Second, affinity-based selection of single chain constructs does not always translate to equivalent affinity once they are reconstituted as full-length receptors.
[0020] In the context of therapy, there is a further important limitation of affinity matured TCR pairs: given that their sequences have been altered, the resulting constructs by definition are no longer subjected to thymic selection, where TCRs that react strongly with self-antigens are deleted from the repertoire. Thus, these modified TCRs have an inherent risk of being self-reactive, which is very difficult to eliminate in vitro using current methods. For the same reason, any selected or engineered TCR for therapeutic use needs to be individualized. If TCRs are artificially engineered or natural TCRs are used across individuals, cross-reactivity must be eliminated based on the HLA haplotype and presented peptide repertoire of each specific individual to avoid potentially devastating autoimmunity. This is due to the fact that thymic selection is performed in the background of all available HLA molecules that are specific only for that given individual. The possibility of such cross-reactivity is unknown. However, the ability of our TCR repertoire to recognize pHLA complexes of other individuals of the same species as foreign is a fundamental property of adaptive immunity, supporting graft rejection and graft-versus-host disease. A recent clinical trial using mature TCR chain pairs against cancer-specific melanoma-associated antigens (MAGEs) shed light on the potential problems of bypassing thymic selection. When autologous T cells bearing the mature TCRs were infused back into two cancer patients, these patients rapidly developed fatal cardiac disease. Subsequent studies found that the MAGE-specific matured TCRs were cross-reactive with peptides presented by HLAI from the cardiac protein titin. This strongly suggests that cross-reactivity is a distinct possibility in the therapeutic use of TCRs.
[0021] Another approach to exploit TCRs for therapeutic purposes is to use them as affinity reactants in much the same way as antibody therapeutics. Single-chain TCR molecules have been tested to deliver conjugated drug substances to specific HLA-antigen expressing cell populations. Such an approach is generally considered safer than CAR-T or TCR engineered T cell therapy, because the administration of drug substances can be simply withdrawn. However, there are still possible limitations in this context due to the possibility of cross-reactivity and difficult to predict off-target effects.
[0022] TCR repertoire detection in clinical diagnosis In a related aspect, there is an increasing interest in using detection of the amount of specific TCR sequences for clinical diagnostic purposes. Especially with the rise of deep sequencing methods, it is possible to capture the complete TCR diversity in an individual, both overall and for matched αβ pairs in a specific context. This could be a means to diagnose certain conditions and disease states by simply detecting the amount of expanded T cell clones as a surrogate readout for the establishment of an immune response against disease-related antigens in patients. However, such a comprehensive approach is currently limited to very strong immune responses with established clinical time points and suffers from the underlying difficulty of identifying the specific antigen target of any particular TCR identified by sequencing.
[0023] Therapeutic and diagnostic uses of T cell antigens The fundamental strength of exploiting adaptive immune responses translates into a central technical difficulty: the exquisite specificity of TCR-antigen interactions requires detailed knowledge of the antigens specifically associated with each pathogen, cancer cell or autoimmune disease. Moreover, since each antigen may be presented by a specific antigen-presenting complex or its alleles, antigen discovery must be performed for each relevant HLA gene and allele. For several infectious diseases such as HIV, influenza and CMV, which are associated with strong adaptive immune responses and generally show a conserved epitope response hierarchy, the most important epitopes have been mapped in association with several common HLAs. Similarly, in the fields of cancer, allergy and autoimmunity, systematic attempts to map relevant T cell antigens are on the rise. However, these are challenging procedures and efforts to systematically represent T cell antigens associated with different clinical situations are hindered by the lack of efficient, robust, rapid and adaptable protocols. In particular, cancer cells are a challenging and important aspect, since most of the peptides presented on the surface of malignant cells are self-antigens or are very similar to self-antigens. Thymic selection will therefore eliminate TCRs that can strongly recognize these peptides. At the same time, tumors evolve to evade immune recognition. This means that potent immune responses against established tumors are relatively rare and targets are difficult to predict or find. However, these responses do exist and, importantly, are usually associated with better outcomes. The targets of such responses, tumor-associated antigens (TAA), most often have distinguishable characteristics from self and originate from proteins that are overexpressed during cancer development, are absent in the cell type at this stage of development, or are specifically altered by genetic mutations or post-translational modifications, such as phosphorylation.
[0024] When available, knowledge of such epitopes allows the examination of relevant T cell responses for basic discovery, diagnostic purposes, and as a test of vaccine efficacy, for example.Importantly, they provide highly specific targets for T cell tolerization in allergy and autoimmunity, and crucially, a valuable target point for specific immunotherapy and against malignant cells.Malignant lesions are particularly valuable targets for the promise of cellular immunotherapy, and progress in T cell engineering is slowed by the lack of confirmed target TAA beyond a few cases where specific markers for the cancer type happen to be available. Given the potential of cellular therapy and the lack of validated targets, the identification of promising TCR antigens remains one of the most pressing obstacles for TCR-based immunotherapy, particularly in efforts to treat cancer.
[0025] Technical aspects of TCR and T cell antigen analysis Overall, the development of TCR-based therapy is still in its early stages and has had limited success. Although it has great potential, diagnostic approaches have hardly been implemented in controlled clinical studies aimed at evaluating patients' disease states or responses to therapy. The poorly developed technology for stable capture of native TCR chain pairs and systematic analysis of TCR-antigen interactions in the functional context of cell-cell communication in a high-throughput manner is the main obstacle for the development of TCR-based therapy and diagnostics.
[0026] Deep sequencing approaches have improved our understanding of T cell receptor diversity in health and disease. However, these approaches have generally focused on short stretches spanning the CDR3 region of the TCR β chain. Most studies have ignored the contribution of the TCR α chain, and few have attempted to analyze the paired αβ chains and antigen specificity of a determined TCR of interest. Recent workflows using single cell encapsulation and genetic barcoding have enabled analysis of the pairing and full-length sequences of native TCR αβ or γδ chain pairs, but such workflows are still in the experimental stage.
[0027] Isolated TCR chain pairs can be analyzed for antigen specificity in either biophysical or functional form. Biophysical analysis requires recombinant production of both the TCR and the analyte antigen in soluble form. In the case of HLA-restricted TCRs, this would therefore require the production of all individual TCRs and cognate pHLA complexes. This is technically very challenging, slow and low throughput. Moreover, such analysis only provides interaction affinities, which correlate poorly with functional characteristics in a predictable manner. Until recently, detailed functional analysis of isolated TCR sequences in the context of cells has been limited by cumbersome protocols of transfection of analyte TCR chain pairs into primary T cells or immortal T cell lines and detection of cellular responses by traditional flow cytometric analysis of cell activation or detection of factors secreted from the transfected cells upon antigen loading. A recent publication by Guo et al. reported rapid cloning, expression, and functional characterization of paired TCR chains from single cells (Molecular Therapy - Methods and clinical development (2016) 3:15054). In this study, the analyte human αβTCR pair was expressed in a reporter cell line lacking αβTCR expression, which contained a green fluorescent protein (GFP) reporter system linked to the Nur77 promoter that is activated upon TCR stimulation. This system is still inefficient due to the lack of standardized TCR integration into the reporter cell line genome and does not provide a systematic method for cell-bound antigen loading by APC elements.
[0028] Similar to the workflow for the identification of TCRs for known T cell antigens, the de novo discovery of novel T cell antigens in health and disease is still very challenging. Most approaches are still biophysical in nature and aim to generate candidate antigens to be tested in immunization protocols or by identification of cognate TCRs as mentioned above. There is little or no standardization in the field of T cell antigen discovery and the field is mostly limited to academic research.
[0029] With the accumulating interest in TCRs and their cognates for both therapeutic and diagnostic use, and the emergence of means to capture a significant number of natural TCR αβ and γδ chain pairs, there is still a lack of reliable high-throughput and standardized techniques for the systematic analysis of TCR-antigen interactions. Importantly, there is a lack of standardized systems for the functional analysis of TCR chain pairs in the natural context of cell-cell communication, where TCR and antigen are both presented by living cells. Furthermore, there is a lack of systems that can achieve the selection of TCR candidates and / or affinity maturation of TCR chain pairs in the relevant context of cell-cell communication. Summary of the Invention [Problem to be solved by the invention]
[0030] As mentioned, there is currently a lack of standardized techniques for high-throughput generation of cells with TCR pairs expressed in a native cellular context. It is highly desirable to have a system where a full-length TCR pair can be inserted as a single copy into the genome of a TCR-presenting cell, so that the TCR is presented in a native CD3 cell surface complex for analysis and selection. TCR pairs presented in a CD3 complex ensure that affinity analysis reflects the actual native TCR composition, which is not the case for single-chain TCRs and other non-native TCR display technologies. Furthermore, presentation of TCR pairs in a CD3 complex on living cells is an absolute necessity for functional analysis of TCR pairs. Functional analysis (meaning analysis of TCR signaling output) is crucial in TCR selection and genetic engineering workflows (signal output is generally the most important parameter for use with cell therapeutics) and is not well correlated with the affinity of the TCR with cognate antigen / HLA as determined in other display platforms. [Means for solving the problem]
[0031] Detailed Description of the Invention The present invention addresses the above needs. In particular, the present invention relates to the construction and use of a genetically engineered bipartite cellular device for the discovery and characterization of TCRs and T cell antigens. The two parts of the overall cellular device are composed of distinct genetically engineered cell types that are in contact with each other during device operation. The device is used for standardized functional analysis of the responsiveness of analyte TCRs to analyte antigens. The readout of this responsiveness is used for identification and selection of TCRs, T cell antigens, and detailed functional characterization of TCR / antigen interactions. The device presents the analyte antigens by a first cell population, genetically engineered antigen presenting cells (eAPCs) generated using an eAPC system (eAPCS). The device presents the analyte TCRs by a second cell population, genetically engineered TCR presenting cells (eTPCs) generated using an eTPC system (eTPCS).
[0032] The two-part device of the present invention includes features that allow a high degree of standardization, reproducibility, and critically limit the complexity of the analyte TCR and T cell antigen collection. Primarily, this standardization is achieved by the defined and highly controlled integration of the analyte antigen-presenting complex and antigen into the genome of the eAPC and the integration of the TCR into the genome of the eTPC. This allows for rapid cycle times to generate analyte cell populations, greatly reducing the cost of current random-integration and viral vector platforms. Furthermore, the present invention allows for the generation of cell-based analyte arrays in an eAPC- and eTPC-centric manner. This means that large vector libraries can be integrated into cell populations and assayed as libraries of cells expressing a single analyte. Single copy genomic acceptor sites engineered into the genomes of the eAPC and eTPC accomplish this, so that only a single copy of the ORF can be integrated from the vector pool when provided by the ORF (for HLA, antigen or TCR chain) in the matched donor vector. This means that if the vector pool contains ORFs of mixed identity, each cell will incorporate a single identity; creating a cell-based array that is compatible with other display platforms such as bacteriophage. This high level of standardization and reduced complexity is in contrast to current methods that use primary or immortalized cell cultures, endogenous signaling responses to achieve expansion and output, or partial systemization of APC- or T cell-centric inputs. Importantly, with a two-part genetically engineered cell device, the present invention achieves standardization of functional applications that are relevant in the context of cell-cell communication. This is crucial for reducing the time and cost of discovery and clinical trials of new TCR and T cell antigen candidates, with increased predictive power of in vivo effects.
[0033] The present invention relates to the provision and operation of a two-part device, the first part of which is an engineered antigen presenting cell system (eAPCS) and the second part of which is an engineered TCR presenting cell system (eTPCS). Overall, the device is a multi-cellular analytical system for the functional analysis of T-cell antigen TCR recognition, composed of two distinct types of engineered human cells. The primary output of the device is cells expressing an analyte antigen or an analyte TCR, which can be used to determine the terminal output of the device as a specific T-cell antigen or TCR sequence, respectively (Figure 1).
[0034] The two-part device is i. Phase 1, generating cell populations bearing an analyte antigen and an analyte TCR, and assembling them into a combination system that brings the two analyte cell populations into contact. ii. Phase 2, readout of the specific response of any of the contacted cell populations of the combination system to obtain the device output. The system operates in two phases, including: (a) a step-by-step process for generating analyte eAPCs and eTPCs, respectively, that are assembled into the eAPC:eTPC combined system (FIG. 1, steps i and ii). The eAPCS is defined as a system that generates a population of analyte eAPCs in various forms that are provided to the eAPC:eTPC combination system, where the analyte eAPC population is: i.eAPC-p ii.eAPC-a iii.eAPC-pa iv. Those libraries and the selection of the input analyte eAPC population into the eAPC:eTPC combination system is determined by the nature of the antigen for which the device is operated, i.e., the eAPC population required for combination into the eAPC:eTPC system is defined by the required primary device output and / or the required terminal device output ( FIG. 1 , step i).
[0035] An eTPCS is defined as a system that generates an analyte eTPC population that is provided to an eAPC:eTPC combination system, where the analyte eTPC population is i.eTPC-t ii. eTPC-t Library and the selection of the input analyte eTPC population to the eAPC:eTPC combination system is determined by the nature of the TCR for which the device operates, i.e. the eTPC population required for combination into the eAPC-eTPC system is defined by the required primary device output and / or the required terminal device output ( FIG. 1 , step ii). The primary output of the device is a selected cell population that may or may not have responded to the analyte presented by the interrelated cells provided to the eAPC:eTPC system. That is, this primary output may be represented as a single cell or a pool of cells selected based on the presence or absence of a response reported in the eAPC:eTPC combination system (FIG. 1, step v). A response in the analyte eAPC is elicited only by binding of a cognate TCR presented by a contacting eTPC. A response in the analyte eTPC is elicited only by binding of a cognate antigen presented by a contacting eTPC (FIG. 1, step iv).
[0036] Selection of analyte eAPCs and / or analyte eTPCs from an eAPC:eTPC combination system may be based on a response in a contacting cell. That is, an analyte eAPC may be selected based on a reported response, or lack thereof, in a contacting analyte eTPC. Conversely, an analyte eTPC may be selected based on a reported response, or lack thereof, in a contacting analyte eAPC. The primary eAPC output of the device are selected cells, the selection being based on the presence or absence of a reported signal response, and these cells are i.eAPC-p ii.eAPC-a iii. eAPC-pa The selected cells may comprise a single cell, a pool of cells of the same identity or a pool of cells of different identities (FIG. 1, step v). The primary eTPC output of the device are selected cells, selection being based on the presence or absence of a reported signal response; these cells comprise eTPC-t; the selected cells may comprise a single cell, a pool of cells of the same identity or a pool of cells of different identities (Figure 1, step v). When the two-part cellular device is in operation, the choice of analyte cell populations that are generated and combined into the eAPC:eTPC system is determined by the nature of the analyte present in each of the eAPC and eTPC populations.
[0037] eAPC-p is defined as expressing an antigen-presenting complex (aAPX) on the cell surface. The aAPX may be loaded with a cargo molecule (CM) as an antigen cargo. The aAPX loaded with antigen cargo is defined as an aAPX:CM complex. eAPC-a are defined as expressing an analyte antigen molecule (aAM), which may be presented on the cell surface and / or expressed or processed intracellularly and represents a cargo aAM that may be loaded onto an aAPX. eAPC-pa is defined as expressing aAPX and aAM. aAM represents the cargo aAM that may be expressed or processed in cells and may be loaded onto aAPX. Thus, APC-pa expresses aAPX on the cell surface, but may also load the expressed aAM onto aAPX as cargo. This is defined as aAPX:aAM complex. eAPC-pa may not load aAM onto aAPX as cargo to form aAPX:aAM complex. Moreover, due to the nature of biological systems, it is inevitable that aAPX:CM complex also exists in aAPC-pa. An eTPC-t is defined as processing an analyte TCR chain pair expressed as a TCR surface protein (TCRsp) complexed with CD3, where CD3 represents the surface complex on which the TCR heterodimer pair is presented, and is defined as having ε, γ, δ and ζ subunits that bind to the complementary TCR chain pair as three dimers (εγ, εδ, ζζ). Expression of CD3 and the complementary TCR chain pair is required for cell surface presentation, and thus, absence of expression of either the TCR or CD3 prevents their presentation on the cell surface. In generating eTPC-t, expression of αβ or γδ TCR pairs and / or CD3 is utilized as a positive selection. Thus, only cells in which the complementary TCR chain pair is presented on the cell surface in complex with CD3 are referred to as eTPC-t, regardless of the nature of the TCR α, β, γ or δ chain combination used to generate the eTPC-t.
[0038] All of the above primary outputs are cell populations resulting from selection based on reported responses in the eAPC:eTPC combination system. Each analyte eAPC presents a set of potential analyte antigens, unique cargo molecules and / or analyte antigen-presenting complexes, while the eTPC presents the analyte TCRsp. It is from the selected cells that selected analyte molecules can be obtained as the final device output (FIG. 1, step vi). An eAPC-p is defined as one that presents aAPX at its cell surface and may present an aAPX:CM complex at its cell surface. Thus, an eAPC-p selected based on a response reported from an eAPC:eTPC combination system may be used to determine aAPX, CM and / or aAPC:CM terminal device output, where these output identities are selected based on the ability of the determined analyte antigen to form a complex with and / or report a signal response stimulated by an analyte TCRsp presented by an analyte eTPC-t that is contacted with the selected eAPC-p in the eAPC:eTPC combination system. An eAPC-a is defined as one that presents an aAM on the cell surface or intracellularly. Thus, an eAPC-a selected based on a response reported from an eAPC:eTPC combination system can be used to determine an aAM terminal device output, where the output identity is selected based on the ability of the determined analyte to form a complex with an analyte TCRsp presented by an analyte eTPC-t contacted with the selected eAPC-a in the eAPC:eTPC combination system and / or report a signal response stimulated by the analyte TCRsp.
[0039] eAPC-pa is defined as one that presents aAPX, aAM, aAPX, aAPX:aM or aAPX:CM on the cell surface. Thus, eAPC-pa selected based on the response reported from the eAPC:eTPC combination system can be used to determine the aAM, aAPX, aAPX:aM and / or aAPX:CM terminal device output, where the output identity is selected based on the ability of the determined analyte to form a complex with an analyte TCRsp presented by an analyte eTPC-t contacted with the selected eAPC-pa in the eAPC:eTPC combination system and / or report a signal response stimulated by the analyte TCRsp. As noted above, the selection of analyte eAPCs can be based on the response reported in the contacting eTPCs. Thus, if the TCRsp input to the eTPCS is known prior to generation of the analyte eTPC-t, any of eAPC-p, eAPC-a and eAPC-pa can be used to indirectly obtain the TCRsp output. In the context of the present invention, an eTPC-t is defined as one that presents a TCRsp. Thus, an eTPC-t selected based on a response reported from an eAPC:eTPC combination system can be used to determine a TCRsp end device output, where the output identity is selected based on the ability of the determined analyte TCRsp to form a complex with an analyte antigen presented by an analyte eAPC that has been contacted with the selected eTPC in the eAPC:eTPC combination system and / or to report a signal response stimulated by the analyte antigen. As noted above, the selection of an analyte eTPC can be based on the response reported in the contacting eAPC. Thus, if the analyte antigen input to the eAPCS is known prior to generation of the analyte eAPC, the eTPC can be used to indirectly obtain any of the analyte antigen outputs aAM, aAPX, aAPX:aM and / or aAPX:CM.
[0040] Description of eAPCS As noted above, the present invention provides a two-part cellular device in which each part is an engineered cellular system. The first engineered cellular system is an engineered multi-component eACP that is used to generate an analyte eAPC for combination into a two-part eACP:eTPC system within the device. In its minimal form, the eAPCS is a genome-wide genomic acceptor site for a first component, which is associated with a second component (component 1B 1) and a third component (called component 1C) as a gene donor vector (Figure 2). The eAPC is the fundamental component of the eAPCS to which all other components of the system relate. Thus, the eAPC contains certain characteristics, either native or engineered, that make it suitable for use in both the eAPCS and the two-part combination device.
[0041] In the context of the present invention, eAPC (component 1A) is i. lacking endogenous surface expression of at least one family of aAPX and / or aAM; ii. contains at least one genomic acceptor site (designated component 1B); wherein i) may be obtained by selection of a naturally occurring cell population lacking expression of aAPX and / or aAM or may be genetically engineered to lack said expression, and ii) may be synthetic or introduced by specific or non-specific genomic integration.
[0042] Selection of candidate eAPC cells lacking the desired aAPX and / or aAM expression from a naturally occurring cell population can be accomplished by methods well known in the art. This may be accomplished directly by staining target cells with an affinity reagent specific for the aAPX and / or aAM desired to be lacking from the eAPC, and selecting for cells lacking the target aAPX and / or aAM expression. Engineering a cell to lack aAPX and / or aAM expression may be accomplished by non-targeted or targeted means. Non-targeted mutagenesis of a cell can be achieved by providing a chemical, radiological or other mutagen to the cell and then selecting for cells lacking the targeted aAPX and / or aAM expression. Targeted mutations of genomic loci can be achieved by, but are not limited to: i. zinc finger nucleases, ii. CRISPR / Cas9-mediated targeting; iii. Synthetic Transcription Activator-Like Effector Nucleases (TALENs) This can be achieved by different means, including site-directed mutagenesis by Here, the site-specific nuclease induces site-specific DNA repair error mutagenesis (also known as non-homologous end joining) at the target locus, and mutant cells are then obtained by selection of cells lacking the targeted aAPX and / or aAM expression.
[0043] Component 1A (eAPC) may optionally contain additional T cell co-stimulatory receptors. This feature allows for robust or variable forms of communication between the analyte eAPC and the analyte eTPC, with tunable communication being suitable for identification or characterization of specific analyte TCRsp and / or analyte antigens. In the context of the present invention, different forms of CD28 ligation on the eTPC may be promoted by including one or more of CD80, CD86 and / or additional B7 family proteins. Component 1A (eAPC) may optionally further comprise the introduction of a cell surface adhesion molecule component or the removal of endogenous cell surface adhesion molecules to promote binding of eAPC with the analyte eTPC and formation of an immune synapse, or to avoid tight binding and the formation of deleterious cell clustering within the eAPC:eTPC combination system, respectively. Adhesion molecules that may be introduced as additional ORFs into component 1A or genetically removed from component 1A may be selected from the integrin family of adhesion proteins. eAPCs may, if desired, have the capacity to process antigens and load them as cargo onto aAPX via native processing and loading mechanisms. eAPCs that have the capacity to process antigens and load them as cargo onto aAPX via native processing and loading mechanisms also have the capacity to process and load cargo molecules (CMs) that are endogenous to the eAPCs or the culture system (containing the eAPCs) (aAPXs loaded with CMs are referred to as aAPX:CM complexes).
[0044] The second component of the minimal multicomponent eAPCS is a gene donor vector (component 1C) used for the integration of at least one ORF encoding at least one aAPX and / or aAM (Figure 2). Component 1C is a gene donor vector that is coupled to the genomic acceptor site of component 1B contained within the genome of an eAPC (component 1A). Component 1C is designed for integration of one or more ORFs encoding aAPX and / or aAM, encoded by the gene donor vector, into the genomic acceptor site (component 1B), where this integration results in expression of aAPX and / or aAM by the target eAPC. In the context of the present invention, the paired gene donor vector and genomic acceptor site are also described as an integration couple. In an expanded form of the multicomponent eAPCS, component 1A (eAPC) may further comprise a second genomic acceptor site (designated component 1D) coupled with a second gene donor vector (designated component 1E; this is also added to the system) (Figure 3). The multicomponent eAPCS may further comprise one or more additional integration couples.
[0045] The multicomponent eAPCS comprising an eAPC and one or two integration couples is a derivative eAPC form: i.eAPC-p ii.eAPC-a iii.eAPC-pa wherein each gene donor vector may contain one or more ORFs encoding one or more aAPXs and / or aAMs for integration into a coupled genomic acceptor site, i) expressing at least one aAPX, ii) expressing at least one aAM, and iii) expressing at least one aAPX and at least one aAM (Figure 4). The gene donor vector and genome acceptor site act as the integration couple subsystem of eAPCS. The gene donor vector must first be combined with the target ORF, where the basic donor vector encodes the target ORF. The assembled and ready donor vector is then introduced into the target eAPC to exchange the target ORF with the genome acceptor site, thus integrating the target ORF into the coupled acceptor site of the target cell (Figure 5).
[0046] A multi-component eAPCS comprising Gene Donor Vector components 1C and / or 1E may be combined with at least one ORF encoding at least one aAPX and / or aAM to obtain components 1C' and / or 1E', where combination is defined as the ligation of the genetic material in the correct orientation into the correct coding frame of the Gene Donor Vector. The combination of one or more ORFs into the Gene Donor Vectors 1C and / or 1E can be achieved using a library of unique ORFs: i. Separate reactions to obtain separate libraries of 1C' and / or 1E' vectors encoding multiple ORFs ii. A single reaction to obtain a pooled library of 1C' and / or 1E' vectors encoding multiple ORFs wherein separate libraries may be combined with component 1A multiple times to obtain separate libraries of eAPCs with unique ORFs encoding unique aAPXs and / or aAMs, and pooled libraries may be combined with component 1A as a single event to obtain a pooled library of eAPCs, each with a unique ORF encoding a unique aAPX and / or aAM. Efficient integration of one or more ORFs in a predictable copy number into the genomic acceptor site is highly advantageous for the operation of standardized eAPCs, from which analyte eAPC populations can be rapidly prepared and characterized. Thus, the genomic acceptor site and the coupled donor vector are important for the function of eAPCs. Furthermore, it is highly desirable to produce eAPCs in which components 1B and 1D are isolated from each other, such that donor vector component 1C is not integrated with component 1B, and vice versa. In addition, it is also desirable that component 1B and / or component 1D are suitable for a method of generating eAPCs in which the introduction of analyte antigens is rapid and repeatable, and the correct integration and delivery of aAPX and / or aAM in the desired copy number is highly likely.
[0047] The genomic acceptor sites are: i. Synthetic constructs designed for recombinase-mediated cassette exchange (RMCE) ii. Synthetic constructs designed for site-specific homologous recombination iii. Native genomic sites for site-specific homologous recombination where i) is preferred. The RMCE method may employ selected heterospecific sites that are specific for separate recombinase enzymes, such that each component 1B and 1D has separate specificity. In the context of the present invention, the genomic recipient site component 1B and / or component 1D comprises the following genetic elements: i. heterospecific recombinase site ii. Homology arm iii. Eukaryotic promoters iv. Eukaryotic conditional regulatory elements v. Eukaryotic terminator vi. Selection marker vii. splice acceptor site viii. Splice donor site ix. Non-protein coding genes x. Insulator xi. Mobile genetic elements xii. Meganuclease recognition site xiii. Internal ribosome entry site (IRES) xiv. Viral self-cleaving peptide elements xv. Kozak consensus sequence The present invention comprises at least one of the following:
[0048] The preferred genomic acceptor site is constructed in two different configurations using the following selected elements from the list of elements previously described: The first configuration is for accepting, by RMCE integration, a single ORF encoding one or more aAPX and / or one or more aAM chains and / or a selectable marker for integration, wherein said configuration is 5'-[A][B][C][D][E][F]-3' where: A) is element iii) a constitutive or inducible eukaryotic promoter, B) is element i) heterospecific recombinase site 1, C) is element xv) Kozak consensus sequence; D) is element vi) FACS and / or MACS compatible encoded protein marker; E) is element i) heterospecific recombinase site 2; F) is element v) a eukaryotic terminator.
[0049] The second configuration is for receiving, by RMCE integration, two ORFs encoding one or more aAPXs and / or one or more aAMs and / or a selectable marker for integration, wherein the configuration comprises: 5'-[A] [B] [C] [D] [E] [F] [G] [H] [I]-3' where: A) is element iii) a constitutive or inducible eukaryotic promoter, B) is element i) heterospecific recombinase site 1, C) is element xv) Kozak consensus sequence; D) is element vi) FACS and / or MACS compatible encoded protein marker 1; E) is element v) a eukaryotic bidirectional transcription terminator; F) is element vi) FACS and / or MACS compatible encoded protein marker 2; G) is element xv) Kozak consensus sequence; H) is element i) heterospecific recombinase site 2; I) is element iii) a constitutive or inducible eukaryotic promoter; Furthermore, in this second configuration, elements F, G and I are encoded in the antisense orientation.
[0050] Components 1C and / or 1E may comprise the following genetic elements: i. heterospecific recombinase site ii. Homology arm iii. Eukaryotic promoters iv. Eukaryotic conditional regulatory elements v. Eukaryotic terminator vi. Selection marker vii. splice acceptor site viii. Splice donor site ix. Non-protein coding genes x. Insulator xi. Mobile genetic elements xii. Meganuclease recognition site xiii. Internal ribosome entry site (IRES) xiv. Viral self-cleaving peptide elements xv. Kozak consensus sequence xvi. Integrative selectable markers xvii. Antibiotic resistance cassette xviii. Bacterial origins of replication xix.Yeast replication origin xx. Cloning site It consists of at least one of the following:
[0051] In a preferred embodiment of the gene donor vector, component 1C and / or component 1E are configured in two different, possible configurations using the following selected elements from the list of elements previously described: The first configuration is for delivery of a single ORF encoding one or more aAPXs and / or one or more aAMs and / or a selectable marker for integration by RMCE integration, wherein the configuration comprises 5'-[A][B][C][D][E]-3' where: A) is element i) heterospecific recombinase site 1, B) is element xv) the Kozak consensus sequence; C) is a cloning site for element xx) one or more aAPXs and / or one or more aAMs and / or element xvi) a single ORF encoding a selection marker for integration, D) is element i) heterospecific recombinase site 2; E) is element xvii) an antibiotic resistance cassette and element xviii) a bacterial origin of replication in a non-specific orientation; Additionally, elements viii and / or xiv may be used to link together multiple aAPXs and / or one or more aAMs and / or element xvi.
[0052] The second configuration is for delivery of two ORFs encoding one or more aAPX and / or aAM and / or a selection marker for integration by RMCE integration, wherein the configuration comprises: 5'-[A][B][C][D][E][F]-3' where: A) is element i) heterospecific recombinase site 1, B) is element xv) the Kozak consensus sequence; C) is a cloning site for the introduction of one or more aAPXs and / or one or more aAMs and / or elements xvi) two or more ORFs encoding a selection marker for integration and having a eukaryotic terminator, D) is element xv) Kozak consensus sequence (antisense orientation); E) is element i) heterospecific recombinase site 2; F) element xvii) an antibiotic resistance cassette and element xviii) a bacterial origin of replication in a non-specific orientation; Additionally, elements viii and / or xiv may be used to link multiple aAPXs and / or aAMs and / or element xvi together within each ORF.
[0053] Generation of analyte eAPC populations in eAPCS The eAPCS system described above may be used in multiple ways to generate distinct forms of analyte eAPCs or libraries thereof that serve to present analytes aAPX, aAM, aAPX:aAM and aAPX:CM to the eTPC within the eAPC:eTPC combination system during operation of the two-part device. An eAPCS comprising a single integration couple may be used to generate an eAPC-p in one step from component 1A by providing component 1C' combined with the ORF of aAPX, which is integrated into site 1B to generate component 1B'. The resulting cell line expresses the provided aAPX, which is displayed on the cell surface (Figure 6). The eAPCS comprising two integration couples may be used to generate eAPC-p in one step from component 1A by providing component 1C' combined with the ORF of aAPX. This aAPX is integrated at site 1B to generate component 1B'. The resulting cell line expresses the provided aAPX, which is displayed on the cell surface. The second integration couple 1D / 1E remains unmodified and can be used for downstream integration steps (Figure 7). An eAPCS comprising a single integration couple may be used to generate eAPC-a in one step from component 1A by providing component 1C' combined with the ORF of an aAM. This aAM integrates at site 1B to generate component 1B'. The resulting cell line expresses the provided aAM, which is either displayed on the cell surface or retained intracellularly (Figure 8). An eAPCS comprising two integration couples may be used to generate eAPC-a in one step from component 1A by providing component 1C' combined with the ORF of an aAM. This aAM is integrated at site 1B to generate component 1B'. The resulting cell line expresses the provided aAM, which is either displayed on the cell surface or retained intracellularly. The second integration couple 1D / 1E remains unmodified and can be used for downstream integration steps (Figure 9).
[0054] An eAPCS comprising a single integration couple may be used to generate eAPC-pa in one step from component 1A by providing component 1C' combined with two ORFs, one encoding aAPX and the other encoding aAM. Both aAPX and aAM are integrated at site 1B to generate component 1B'. The resulting cell line may express the provided aAPX and aAM and present aAPX:aAM on the cell surface (Figure 10). The eAPCS comprising two integration couples may be used to generate eAPC-pa in one step from component 1A by providing component 1C' combined with two ORFs, one encoding aAPX and the other encoding aAM. aAPX and aAM are integrated together at site 1B to generate component 1B'. The resulting cell line may express the provided aAPX and aAM and present aAPX:aAM on the cell surface. The second integration couple 1D / 1E remains unmodified and may be used for downstream integration steps (Figure 11). An eAPCS comprising two integration couples may be used to generate eAPC-pa in one step from component 1A by providing components 1C' and 1E', each combined with one ORF encoding either aAPX or aAM. Both aAPX and aAM are integrated at sites 1B or 1D to generate components 1B' and 1D'. The resulting cell line may express the provided aAPX and aAM and present aAPX:aAM on the cell surface (Figure 12). The eAPCS comprising two integration couples may be used to generate eAPC-pa in two steps from component 1A by first providing component 1C' combined with an ORF encoding aAPX. This aAPX is integrated at site 1B to generate component 1B'. The resulting cell line expresses the provided aAPX, which is presented on the cell surface). The second integration couple 1D / 1E remains unmodified. In a second step, 1E' is provided in which the donor vector is combined with an ORF encoding an aAM. This aAM is integrated at site 1E to generate component 1E'. The resulting cell line expresses the provided aAM, which may be processed at aAPX and loaded as cargo to form an aAPX:aAM complex on the cell surface (Figure 13). The eAPCS comprising two integration couples may be used to generate eAPC-pa in two steps from component 1A by first providing component 1C' combined with an ORF encoding an aAM. This aAM is integrated at site 1B to generate component 1B'. The resulting cell line expresses the provided aAM (eAPC-a intermediate). The second integration couple 1D / 1E remains unmodified. In a second step, 1E' is provided in which the donor vector is combined with an ORF encoding an aAPX. This aAPX is integrated at 1E to generate component 1E'. The resulting cell line expresses the provided aAPX, which is presented at the cell surface. The aAM integrated in the first step may be processed at aAPX and loaded as cargo to form an aAPX:aAM complex at the cell surface (Figure 14).
[0055] In the above example of generating analyte eAPC-p, eAPC-a and eAPC-pa populations from eAPCs, the eAPCS system is used to provide known aAPX and aAM candidates in a defined manner to generate a separate population of analyte eAPCs expressing the defined aAPX and / or aAM. This method may be repeated multiple times to build a library of eAPC-p, eAPC-a and eAPC-pa that is provided to the eAPC:eTPC combination system during device operation. An alternative approach is to take a pooled library of candidate aAPX and / or aAM ORFs that are combined with gene donor vectors and integrate them in a single reaction to obtain a pooled library of analyte eAPC-p, eAPC-a or eAPC-pa expressing multiple aAPXs, aAMs and / or aAPX:aAMs. This method of converting a vector pool into a pool of eAPC-p, -a and / or -pa is called shotgun integration. This is particularly useful when large libraries of candidate aAMs are analyzed against immobilized aAPX, or vice versa. The eAPCS comprising two integration couples may be used to generate eAPC-pa in two steps from component 1A by first providing component 1C' combined with an ORF encoding aAPX. This aAPX is integrated into site 1B to generate component 1B'. The resulting cell line expresses the provided aAPX on the cell surface (eAPC-p intermediate). The second integration couple 1D / 1E remains unmodified. In a second step, a library of multiple 1E' is provided, where the library of donor vectors comprises a vector pool, each combined with a single ORF encoding an aAM, and each aAM is integrated into site 1E in a single cell to generate component 1E'. The resulting cell pool comprises a population of cells, where each cell has integrated a single random aAM ORF from the original vector pool. The aAM incorporated in the second step may be processed by the aAPX incorporated in the first step and loaded as cargo to form an aAPX:aAM complex on the cell surface (Figure 15).
[0056] The eAPCS comprising two integration couples may be used to generate eAPC-pa in two steps from component 1A by first providing component 1C' combined with an ORF encoding an aAM. This aAM is integrated into site 1B to generate component 1B'. The resulting cell line expresses the provided aAM (eAPC-a intermediate). The second integration couple 1D / 1E remains unmodified. In a second step, a library of multiple 1E' is provided, where the library of donor vectors comprises a vector pool, each combined with a single ORF encoding an aAPX. Each aAPX is integrated into site 1E in a single cell to generate component 1E'. The resulting cell pool comprises a population of cells, where each cell has integrated a single random aAPX ORF from the original vector pool. The aAM incorporated in the first step may be processed in the aAPX incorporated in the second step and loaded as cargo to form an aAPX:aAM complex on the cell surface (Figure 16). An eAPCS comprising two integration couples may be used to generate eAPC-pa in one step from component 1A by providing components 1C' and 1E', each combined with a library of ORFs encoding either a library of aAPXs or a library of aAMs. Both aAPXs and aAMs are integrated at sites 1B or 1D to generate 1B' and 1D'. The resulting cell pool comprises a population of cells, where each cell has integrated a single random aAPX ORF and a single random aAM ORF from the original vector pool. Within each cell in the pooled library, the integrated aAM may be processed and loaded as cargo onto an aAPX integrated in the same cell to form an aAPX:aAM complex at the cell surface. This pooled library may contain all possible combinations of aAPXs:aAMs from the provided aAPXs and aAM sets (Figure 17). In the above-mentioned shotgun integration method for providing a pooled library of eAPC-pa, the robustness of the system relies on a single copy of the genomic acceptor site. This ensures that only a single analyte is introduced into each cell via the integration couple. This single copy of the genomic acceptor site is an optional aspect of eAPCS. Because multiple copies of the same genomic acceptor site can be beneficial in providing an integration step where multiple "alleles" from the library of provided vectors can be obtained in the produced eAPC.
[0057] In the context of the present invention, aAPX is: i. one or more members of HLA class I ii. One or more members of HLA class II iii. One or more non-HLA antigen-presenting complexes may be selected from one of: aAPX is as follows: i. A polypeptide or a complex of polypeptides provided as the analyte antigen ii. A peptide derived from a polypeptide provided as the analyte antigen iii. A peptide provided as the analyte antigen iv. Metabolites serving as analyte antigens v. A polypeptide or a complex of polypeptides translated from the analyte antigenic molecule ORF vi. A peptide derived from a polypeptide translated from the analyte antigenic molecule ORF vii. Peptides derived from modifications of the component A proteome viii. Polypeptides derived from the component A proteome ix. Component A Metabolites derived from alterations in the metabolome may be selected from one of:
[0058] Explanation of eTPCS As noted above, the present invention provides a two-part cellular device, each part of which is an engineered cellular system. The first engineered cellular system is the eAPCS described above. The second engineered cellular system is an engineered multi-component eTPCS that is used to produce an analyte eTPC for combination into the two-part eACP:eTPC system in the device. The eTPCS in its minimal form is a multi-component system in which the first component is the eTPC (termed component 2A) and the second component is the gene donor vector (termed component 2C) (Figure 18). The eTPC is the fundamental component of the eTPCS to which all other components of the system relate. Thus, the eTPC contains certain features, either native or engineered, that make it suitable for use in both the eTPCS and in two-part combination devices.
[0059] eTPC, component 2A, i. lacks endogenous expression of TCR α, β, δ and γ chains; ii. expresses a CD3 protein that is displayed on the cell surface only if the cell expresses a complementary pair of TCR chains; iii. a further component (designated component 2B), comprising a genomic acceptor site for integration of a single ORF encoding at least one analyte TCR α, β, δ or γ chain and / or two ORFs encoding an analyte TCR chain pair; wherein i) may be obtained by selection of a naturally occurring cell population that lacks said expression or may be genetically engineered to lack said expression, ii) may be obtained by selection of a naturally occurring cell population that contains said expression or may be genetically engineered to contain said expression, and iii) may be introduced into the genome by means of genetic engineering.
[0060] Selection of eTPC cell candidates lacking TCR α, β, δ and γ chains from a naturally occurring cell population can be achieved by methods well known in the art: staining of target cells with affinity reagents specific for the TCR α, β, δ and γ chains and selecting for cells lacking the TCR α, β, δ and γ chains can achieve this directly. Engineering eTPC to lack TCR α, β, δ and γ chain expression can be accomplished by untargeted or targeted means. Untargeted mutagenesis of cells can be achieved by providing the cells with a chemical, radiation or other mutagen and then selecting for cells that lack the targeted aAPX and / or aAM expression. Targeted mutations of genomic loci can be achieved by: i. zinc finger nucleases, ii. CRISPR / Cas9-mediated targeting (exact and acronym); iii. Synthetic Transcription Activator-Like Effector Nucleases (TALENs) This can be achieved by different means, including (but not limited to) site-specific mutagenesis with a site-specific nuclease, where the site-specific nuclease induces site-specific DNA repair error mutagenesis at the target locus, and then mutant cells are obtained by selection of cells lacking expression of the TCR α, β, δ and γ chains.
[0061] Options for the integration of CD3 and components B and / or D are well known to those skilled in the art, but may include homology directed recombination (HDR) and / or random integration methods, where HDR may be facilitated by targeted mutation of the genomic locus where HDR occurs; i. zinc finger nucleases, ii. CRISPR / Cas9-mediated targeting; iii. Synthetic Transcription Activator-Like Effector Nucleases (TALENs) This can be achieved by different means, including (but not limited to) site-specific mutagenesis by HDR, where the site-specific nuclease induces site-specific DNA repair by HDR at the target locus. After this event, some cells will have the HDR vector integrated and will be: iv. Non-destructive phenotypic expression analysis v. Disruptive phenotypic expression analysis vi. Genetic analysis can be selected and / or determined by any combination of Here, iv and vi are the preferred methods for selection and determination of successful genomic integration events. Alternatively, viral vectors can be used to deliver the necessary components in a site-specific or non-specific manner.
[0062] Given that eTPC component 2A is designed to be used together with eAPC component 1A described above in an eAPC:eTPC combination system for the analysis of TCR and T cell antigen interactions (Figure 1), in preferred embodiments the eTPC contains features that minimize the eTPC presenting factors that would interfere with such analyses. eTPC component 2A optionally lacks endogenous surface expression of at least one family of aAPXs and / or aAMs, the lack of surface expression being selected to minimize interference in matched analysis of the target analyte antigen. The family of aAPXs may be any of the following: i. HLA class I ii. HLA class II iii. Non-HLA antigen presenting complexes.
[0063] aAM is: i. A polypeptide or a complex of polypeptides translated from the analyte antigenic molecule ORF ii. A peptide derived from a polypeptide translated from the analyte antigenic molecule ORF. iii. Peptides derived from alterations in the component A proteome iv. Polypeptides derived from alterations of the component A proteome v. Component A: Metabolites derived from alterations in the metabolome is selected from. Component 2A eTPC may optionally further comprise a T cell coreceptor, a feature that allows for robust or variable forms of communication between the analyte eTPC and the analyte eAPC, with tunable communication suitable for identification or characterization of specific analyte TCRsp and / or analyte antigen.
[0064] eTPC component 2A may optionally express CD4 and / or CD8, where expression of CD4 or CD8 restricts the eTPC to binding to aAPX of HLAII and HLAI types, respectively. In the context of the present invention, eTPC component 2A may optionally express CD28 and / or CD45, where CD28 and CD45 contribute to signal sensitivity through a positive feed-forward effect on signal transduction, but may also contribute to signal specificity through a negative feedback effect on signal transduction, since they are involved in signal transduction through the expressed analyte TCRsp. Component 2A eTPC may optionally further comprise the introduction of cell surface adhesion molecule components or the removal of endogenous cell surface adhesion molecules to promote binding of eTPC with analyte eAPC and formation of an immune synapse, or to avoid tight binding and the formation of deleterious cell clustering within the eAPC:eTPC combination system, respectively. Adhesion molecules that may be introduced as additional ORFs into component 2A or genetically deleted from component 2A may be selected from the integrin family of adhesion proteins.
[0065] The second component of the minimal multi-component system is a gene donor vector (component 2C) used for integration of at least one ORF encoding at least one analyte TCR chain (Figure 18). Component 2C is a gene donor vector that is coupled to the genomic acceptor site of component 2B contained within the genome of the eTPC (component 2A). Component 2C is designed for integration of ORFs encoding one or more analyte TCR chains, encoded by the gene donor vector, into the genomic acceptor site (component 2B), where this integration results in expression of the analyte TCR chains by the target eTPC. The paired gene donor vector and genomic acceptor site are also described as an integration couple.
[0066] The eTPCs are designed to respond to stimulation with the cognate antigen represented by the eAPC in the eAPC:eTCP combination system, and therefore it is desirable to have a standardized reporter readout for the signaling response from stimulation of the expressed TCRsp. In the context of the present invention, eTPC component 2A is: i. A single-component synthetic construct containing at least one naturally occurring promoter and / or at least one synthetic promoter and at least one reporter. ii. Multi-component synthetic constructs designed with at least one naturally occurring promoter and / or at least one synthetic promoter and at least one reporter. wherein activation of i and / or ii is dependent on at least one signaling pathway selected from a synthetic pathway, a naturally occurring pathway, or a combination thereof.
[0067] The eTPC is designed to assay binding of the displayed TCRsp to an analyte antigen. Readout of binding can be achieved by induction of a synthetic reporter element in response to TCRsp binding. Thus, the eTPC can be i. A single-component synthetic construct containing at least one naturally occurring promoter and / or at least one synthetic promoter and at least one reporter. ii. Multi-component synthetic constructs designed with at least one naturally occurring promoter and / or at least one synthetic promoter and at least one reporter. wherein activation of i and / or ii is dependent on at least one signal transduction pathway selected from a synthetic pathway, a naturally occurring pathway, or a combination thereof. A synthetic TCR stimulation response element (component 2F) with a synthetic promoter as opposed to a native promoter is less likely to mimic the natural TCR stimulation response and thus represents a distant approximation to natural T cell stimulation, but the synthetic promoter offers great flexibility in tuning and regulating the reporter response for robust identification of eTPC-ts that display TCRs that productively bind to the analyte antigen.
[0068] Single-component synthetic constructs have limited scope for amplification or modulation of signal reporter responses, but are easier to implement and predict outcomes. Multi-component constructs have the advantage of virtually unlimited scope for construct complex response networks, but this comes at the cost of being more difficult to implement and predict. Networks also provide the opportunity to initiate feedback loops, inhibition and activation of secondary response reporters. The synthetic promoter can be linked to an artificial synthetic signaling component that can be downstream of or replace the original natural TCR signaling pathway. In this case, the CD3 complex can be partially or fully coupled to the artificial synthetic signaling pathway and response network. Such artificial pathways offer the advantage of being modular and highly adaptable in terms of fine-tuning or enhancing the response.
[0069] A preferred embodiment employs a multi-component synthetic construct with a synthetic promoter and at least a partial synthetic signaling pathway, which provides the most robust means of ensuring that one has a limited quiescent signal response, but a high coupled reporter signal upon ligation of the analyte antigen with the TCRsp. Regardless of the exact manner in which the TCRsp stimulus is coupled with component 2F, the desired end result is a detectable reporter. In a preferred embodiment, a reporter amenable to fluorescence detection (i.e., FACS) and / or physical selection methods (e.g., magnetic activated cell sorting (MACS)) is desired. Alternatively, the reporter can be a secreted or intracellular molecule for detection by spectrophotometric, fluorescent or luminescent assays (preferably of a non-destructive nature), where the population can then be selected based on the presence or absence of the reporter molecule. In addition, the response is not limited to a single reporter type, but can be a combination of one or more different reporters.
[0070] In one situation, a multi-component synthetic construct (driver-activator / repressor+amplifier-reporter) with a synthetic promoter and a partial synthetic signaling pathway is constructed as follows: Drivers - Activators / Repressors: a) Synthetic Promoters b) Kozak sequence c) Transcription factors d) The First Terminator Amplifier-reporter e) A second synthetic promoter f) Kozak sequence g) Reporter h) The Second Terminator wherein a) represents a synthetic promoter (driver) that is designed to be coupled with the original native signaling pathway resulting from ligation of the TCRsp to the analyte antigen. The minimal driver comprises one or more transcription factor binding sites and a core promoter, where the core promoter comprises at least a TATA box, an initiation element (Inr) and a transcription start site; b) represents a Kozak sequence for efficient translation initiation of the transcription factor; c) represents an ORF encoding a synthetic or native transcription factor (activator or repressor) that can bind to the DNA sequence of the second synthetic promoter; d) represents one or more untranslated 3' genetic elements of a transcription terminator and optional additional elements for efficient transcription and polyadenylation of the mRNA transcript of the transcription factor. These genetic elements may include, but are not limited to, elements that stabilize or destabilize the transcript and unique identification sequences; e) represents a second synthetic promoter (amplifier) encoding one or more recognition sites for binding of a transcription factor and the core promoter of c), where the core promoter comprises at least a TATA box, an Inr and a transcription start site; f) represents a Kozak sequence for efficient translation initiation of the reporter; g) represents an ORF encoding the reporter protein; h) represents one or more non-translated 3' genetic elements of a transcription terminator and optional additional elements for efficient transcription and polyadenylation of the reporter mRNA transcript. These genetic elements may include, but are not limited to, elements that stabilize or destabilize the transcript and unique identification sequences.
[0071] It is important to realize that the driver-activator / repressor coupled amplifier-reporter paradigm can be expanded to include additional driver-activator / repressor and amplifier-reporter pairs and / or additional amplifier-reporter units. Furthermore, the activator can be replaced with a repressor to shut down the amplifier-reporter unit and / or the driver-activator / repressor unit for negative selection methods and / or negative-feedback loops.
[0072] In the second situation, a single component synthetic construct with a synthetic promoter (driver-reporter) is a) Synthetic Promoters b) Kozak sequence c) Reporter d) The Terminator wherein a) represents a synthetic promoter (driver) that is designed to be coupled with the original native signaling pathway resulting from ligation of the TCRsp to the analyte antigen. The minimal driver comprises one or more transcription factor binding sites and a core promoter, where the core promoter comprises at least a TATA box, an Inr and a transcription start site; b) represents a Kozak sequence for efficient translation initiation of the reporter; c) represents an ORF encoding the reporter protein; d) represents one or more non-translated 3' genetic elements of a transcription terminator and optional additional elements for efficient transcription and polyadenylation of the reporter mRNA transcript. These genetic elements may include, but are not limited to, elements that stabilize or destabilize the transcript and unique identification sequences.
[0073] In an expanded form of a multicomponent eTPCS, the component 2A eTPC may further contain a second genome acceptor site (called component 2D) that is coupled with a second genome donor vector (called component 2E; this is also added to the system) (Figure 19). The eTPCS component 2A may further comprise one or more additional integration couples. The eTPCS, comprising an eTPC and one or two integration couples, is used to produce an eTPC-t, which is used to assemble an eAPC:eTPC combination system. The eTPC-t may be produced by incorporating two complementary TCR chains to form a TCRsp, or alternatively, may be produced in two steps by providing each complementary chain sequentially (Figure 20). The gene donor vector and the genomic acceptor site act as an integration couple subsystem of the eTPCS. The gene donor vector must first be combined with the target ORF, where the basic donor vector encodes the target ORF. The assembled and ready donor vector is then introduced into the target eTPCS to exchange the target ORF with the genomic acceptor site, thus integrating the target ORF into the coupled acceptor site of the target cell (Figure 21).
[0074] An eTPCS comprising Gene Donor Vector components 2C and / or 2E is combined with at least one ORF encoding at least one analyte TCR chain to obtain components 2C' and / or 2E', where combination is defined as the ligation of the genetic material in the correct orientation into the correct coding frame of the Gene Donor Vector. The combination of one or more ORFs into the gene donor vectors 2C and / or 2E can be carried out using a library of unique ORFs: i. A single separate reaction to obtain separate libraries of 2C' and / or 2E' vectors encoding multiple ORFs. ii. A single reaction to obtain a pooled library of 2C' and / or 2E' vectors encoding multiple ORFs where the separate libraries may be combined with component 2A multiple times to yield separate libraries of eTPCs with unique ORFs encoding unique TCR chains, and the pooled libraries may be combined once or more with component 2A to yield a library of pooled eTPC-ts, each of which incorporates a randomized ORF encoding an analyte TCR chain from the original vector pool, resulting in a library of pooled eTPC-ts, each of which expresses a single random, unique TCRsp. Efficient integration of one or more ORFs in a predictable copy number into a genomic acceptor site is highly advantageous for the operation of a standardized eTPC where analyte eTPC populations can be rapidly prepared and characterized. Thus, the genomic acceptor site and the coupled donor vector are important for the function of the eTPC. Furthermore, it is highly desirable to have an eTPC where components 2B and 2D are isolated from each other such that donor vector component 2C is not integrated with component 2B and vice versa. In addition, it is also desirable that component 2B and / or component 2D are suitable for a method of making eTPC-t where the introduction of a single complementary TCR chain pair is rapid and repeatable, with a high probability of correct integration and delivery of only a single pair.
[0075] The genomic acceptor site is: i. Synthetic constructs designed for recombinase-mediated cassette exchange (RMCE) ii. Synthetic constructs designed for site-specific homologous recombination where i) is a genomic acceptor site in a form suitable for RCME. The RMCE method may employ selected heterospecific sites that are specific for separate recombinase enzymes, such that each component 2B and 2D has isolated specificity. The genomic acceptor site, component 2B and / or component 2D, contains the following genetic elements: i. heterospecific recombinase site ii. Homology arm iii. Eukaryotic promoters iv. Eukaryotic conditional regulatory elements v. Eukaryotic terminator vi. Selection marker vii. splice acceptor site viii. Splice donor site ix. Non-protein coding genes x. Insulator xi. Mobile genetic elements xii. Meganuclease recognition site xiii. Internal ribosome entry site (IRES) xiii. Internal ribosome entry site (IRES) viral self-cleaving peptide element xiv. Kozak consensus sequence The present invention comprises at least one of the following:
[0076] The preferred genomic acceptor site is constructed in two different configurations using the following selected elements from the list of elements previously described: The first configuration is for receiving a single ORF encoding one or more TCR chains and / or a selectable marker for integration by RMCE integration, wherein the configuration comprises 5'-[A][B][C][D][E][F]-3' where: A) is element iii) a constitutive or inducible eukaryotic promoter, B) is element i) heterospecific recombinase site 1, C) is element xv) Kozak consensus sequence; D) is element vi) FACS and / or MACS compatible encoded protein marker; E) is element i) heterospecific recombinase site 2; F) is element v) a eukaryotic terminator.
[0077] The second configuration is for receiving two ORFs encoding one or more TCR chains and / or a selectable marker for integration by RMCE integration, wherein the configuration is: 5'-[A] [B] [C] [D] [E] [F] [G] [H] [I]-3' where: A) is element iii) a constitutive or inducible eukaryotic promoter, B) is element i) heterospecific recombinase site 1, C) is element xv) Kozak consensus sequence; D) is element vi) FACS and / or MACS compatible encoded protein marker 1; E) is element v) a eukaryotic bidirectional transcription terminator; F) is element vi) FACS and / or MACS compatible encoded protein marker 2; G) is element xv) Kozak consensus sequence; H) is element i) heterospecific recombinase site 2; I) is element iii) a constitutive or inducible eukaryotic promoter; Furthermore, in this second configuration, elements F, G and I are encoded in the antisense orientation.
[0078] Components 2C and / or 2E may comprise the following genetic elements: i. heterospecific recombinase site ii. Homology arm iii. Eukaryotic promoters iv. Eukaryotic conditional regulatory elements v. Eukaryotic terminator vi. Selection marker vii. splice acceptor site viii. Splice donor site ix. Non-protein coding genes x. Insulator xi. Mobile genetic elements xii. Meganuclease recognition site xiii. Internal ribosome entry site (IRES) xiv. Viral self-cleaving peptide elements xv. Kozak consensus sequence xvi. Integrative selectable markers xvii. Antibiotic resistance cassette xviii. Bacterial origins of replication xix.Yeast replication origin xx. Cloning site It consists of at least one of the following:
[0079] Suitable gene donor vectors (component C and / or component E) are constructed in two different, possible configurations using the following selected elements from the list of elements previously described: The first configuration is for receipt of a single ORF encoding one or more TCR chains and / or a selectable marker for integration by RMCE integration, wherein the configuration comprises 5'-[A][B][C][D][E]-3' where: A) is element i) heterospecific recombinase site 1, B) is element xv) the Kozak consensus sequence; C) element xx) a cloning site for a single ORF encoding one or more TCR chains and / or element xvi) a selection marker for integration, D) is element i) heterospecific recombinase site 2; E) is element xvii) an antibiotic resistance cassette and element xviii) a bacterial origin of replication in a non-specific orientation; Furthermore, elements viii and / or xiv may be used to link together multiple TCR chains and / or element xvi.
[0080] 5'-[A][B][C][D][E][F]-3' Where: A) is element i) heterospecific recombinase site 1, B) is element xv) the Kozak consensus sequence; C) a cloning site for the introduction of two or more ORFs encoding one or more TCR chains and / or elements, xvi) a selectable marker for integration and having a eukaryotic terminator, D) is element xv) Kozak consensus sequence (antisense orientation); E) is element i) heterospecific recombinase site 2; F) element xvii) an antibiotic resistance cassette and element xviii) a bacterial origin of replication in a non-specific orientation; Additionally, elements viii and / or xiv may be used to link multiple TCR chains and / or element xvi together within each ORF.
[0081] Generation of analyte eTPC populations in eTPCS The eTPCS system described above may be used in a number of ways to generate populations or libraries of distinct analyte eTPCs that act to present the analyte TCRsp to eAPCs within an eAPC:eTPC combination system in operation of a two-part device. The eTPC-t population that is generated must derive the analyte TCR chain (against which the candidate antigen is to be analyzed) from a specific source. The source of the sequences encoding the analyte TCR chains is i. Paired cloning of TCR chain ORF sequences from primary T cells ii. Unpaired cloning of TCR chain ORF sequences from primary T cells iii. Synthetic TCR chain ORF sequences wherein i) is suitable for the discovery of naturally occurring TCRs that are generally not likely to be cross-reactive to autologous aAPX and / or aAPX cargo due to thymic selection; ii) may be used to identify candidate TCR affinity reactants; and iii) may be used in affinity maturation of TCR affinity reactants.
[0082] An eTPCS comprising a single integration couple may be used to generate an eTPC-t in one step from component 2A by providing component 2C' combined with the ORF of a complementary pair of TCR chains. This analyte TCR pair is integrated into site 2B to generate component 2B'. The resulting cell line expresses the provided TCR pair, which is presented on the cell surface as TCRsp (Figure 21). An eTPCS comprising two integration couples may be used to generate an eTPC-t in one step from component 2A by providing component 2C' combined with the ORF of a complementary pair of TCR chains. This analyte TCR pair is integrated at site 2B to generate component 2B'. The resulting cell line expresses the provided TCR pair, which is presented on the cell surface as TCRsp. The second integration couple 1D / 1E remains unmodified and can be used for downstream integration steps (Figure 22). An eTPCS comprising two integration couples may be used to generate an eTPC-t in one step from component 2A by providing components 2C' and 2E', each combined with one ORF encoding one chain of a complementary TCR chain pair. Both analyte TCRs are integrated into sites 2B or 2D to generate components 2B' and 2D'. The resulting cell line expresses the provided TCR pair, which is presented on the cell surface as TCRsp (Figure 23). An eTPCS comprising two integration couples may be used to generate eTPC-x in one step from component 2A by providing component 2C' combined with the ORF of a single analyte TCR chain. This analyte TCR chain is integrated at site 2B to generate component 2B'. The resulting cell line expresses the provided TCR chain but lacks the complementary chain and therefore does not express a surface TCR. The second integration couple 1D / 1E remains unmodified and can be used for downstream integration steps (Figure 24).
[0083] An eTPCS comprising two integration couples may be used to generate an eTPC-t in two steps from component 2A by first providing component 2C' combined with an ORF of a single analyte TCR chain. This analyte TCR chain is integrated at site 2B to generate component 2B'. The resulting cell line expresses the provided TCR chain but lacks a complementary chain and therefore does not express a surface TCR (eTPC-x intermediate). The second integration couple 1D / 1E remains unmodified. In a second step, the vector is provided 2E' combined with an ORF of a second single analyte TCR chain that is complementary to the previously integrated TCR chain. This second complementary analyte TCR chain is integrated at site 2D to generate component 2D'. The resulting cell line expresses the provided complementary analyte TCR chain pair, which is presented as a TCRsp at the cell surface (Figure 25). In the above example of generating analyte eTPC-x and / or eTPC-t populations from eTPCs, the eTPCS system is used to provide known analyte TCR chains in a defined manner to generate a separate population of analyte eTPCs expressing a defined TCRsp. This method may be repeated multiple times to build a library of eTCP-x and / or eTCP-t to be provided to the eAPC:eTPC combination system upon device operation. An alternative approach is to employ a pooled library of analyte eTPC-t (each eTPC-t incorporates a single random pair of TCR ORFs from the original vector pool, thus each eTPC-t expresses a single random TCRsp, but the pool as a whole encodes multiple species of TCRsp represented in the original vector pool). The same shotgun principle can be applied to generate pools of eTPC-x. This is particularly useful when analyzing a large library of candidate TCRsp against an analyte antigen.
[0084] An eTPCS comprising one integration couple may be used to generate an eTPC-t pool in one step from component 2A by providing component 2C' combined with a library of multiple ORFs encoding a pool of analyte TCR pairs. This pair is integrated into each cell at site B to generate component B', where each eTPC-t integrates a single random pair of TCR ORFs from the original vector pool, thus each eTPC-t expresses a single random TCRsp, but collectively the pool encodes multiple species of TCRsp represented in the original vector pool. The resulting cell pool comprises a population of cells collectively expressing multiple analyte TCRsp (Figure 26). An eTPCS comprising two integration couples may be used to generate an eTPC-t pool in one step from component 2A by providing component 2C' in combination with a library of multiple ORFs encoding a pool of analyte TCR pairs. This pair is integrated into each cell at site B to generate component B', where each eTPC integrates a single random pair of TCR ORFs from the original vector pool, thus each eTPC-t expresses a single random TCRsp, but collectively the pool encodes multiple species of TCRsp represented in the original vector pool. The resulting cell pool comprises a cell population that collectively expresses multiple analyte TCRsp. The second integration couple 1D / 1E remains unmodified (Figure 27).
[0085] An eTPCS comprising two integration couples may be used to generate an eTPC-t pool in one step from component 2A by providing component 2C' in combination with a library of multiple ORFs encoding a pool of single analyte TCR chains (so that each eTPC incorporates a single randomized TCR chain ORF encoded in component 2C' at site 2B to generate component 2B') and simultaneously providing component 2E' in combination with a library of multiple ORFs encoding a pool of single analyte TCR chains that are complementary to the first library provided in component 2C' (so that each eTPC-t incorporates a single randomized complementary TCR chain ORF encoded in component 2E' at site 2D to generate component 2D'). Each resulting cell in the eTPC-t pool has a single pair of randomized complementary TCR chain ORFs, so that each cell in the pool expresses a randomized TCRsp. This pooled library contains all possible complementary TCR chain combinations from the sets provided in components 2C' and 2E' (Figure 28). In the context of the present invention, an eTPCS comprising two integration couples may be used to generate an eTPC-t pool in one step from a previously obtained e-TPC-x, where site 2B is converted to 2B' and contains a single analyte TCR chain. The eTPC-t is generated by providing a component 2E' combined with a library of multiple ORFs encoding a pool of single analyte TCR chains that are complementary to the already integrated chains. Each eTPC-t has integrated into site 2D a single randomized TCR chain ORF of the provided 2E' library, generating component 2D'. Each resulting cell in the eTPC-t pool has an analyte TCR chain provided by starting from eTPC-x and selecting each single complementary analyte TCR chain, so that each cell in the pool expresses a random pair of ORFs as TCRsp. This approach is used when analyzing the effect of different single chains on fixed chains in complementary TCR chain pairs (Figure 29).
[0086] eTPC-x may be generated from eTPC-t by providing one of the further integration vectors, components 2Y or 2Z, encoding a marker of integration or no ORF. Combination of components 2Y or 2Z with eTPC-t exchanges one of the sites to obtain eTPC-x expressing a single TCR chain. Genetic integration vectors suitable for conversion of eTPC-t to eTPC-x Components 2Y and 2Z contain the same integration vector requirements as components 2C and 2E above, but do not encode the TCR chain ORFs and preferably encode a marker of integration.
[0087] Contact of analyte eAPC with eTPC The present invention provides a genetically engineered bipartite cell device. The two parts of the device, eAPCS and eTPCS, are used to assemble analyte eAPC and analyte eTPC, respectively. These analyte cell populations are then assembled into an eAPC:eTPC combination system, from which a device output may be obtained. The eAPC:eTPC system is comprised of a selection of one or more analyte eAPC populations and one or more eTPC populations (FIG. 1), produced as described above (FIGS. 4-29). The eAPC:eTPC system is provided in a format that allows for physical contact between the analyte eAPC and the analyte eTPC populations. This contact allows for complex formation between one or more analyte antigens and the TCRsp of one or more analyte eTPC-t, where the analyte antigen is presented by the analyte eAPC together with the analyte TCRsp presented by the analyte eTPC, as follows: i.aAPX and / or ii.aAM and / or iii. aAPX:aAM and / or iv. Commercials and / or v.aAPX:CM Complex formation may lead to stabilization of the complex and induction of signaling within the analyte eAPC and / or analyte eTPC may be reported and measured.
[0088] Contacting of the analyte eAPC and analyte eTPC is performed in a permissive cell culture system, where the system comprises a cell culture medium that is permissive for function of both the eAPC and eTPC cells. The analyte eTPC obtained from the eAPC:eTPC combination system is used to characterize the signal response of the analyte eTPC expressing the analyte TCRsp to the analyte antigen presented by the analyte eAPC, where this signal response can be either binary or graded and can be measured as specific to the eTPC (Figure 30) or specific to the eAPC (Figure 31).
[0089] A method for selecting an input analyte eTPC or one or more analyte eTPCs from a library of analyte eTPCs from an eAPC:eTPC combination system to obtain one or more analyte eTPCs, wherein an expressed TCRsp binds to an analyte antigen presented by the one or more analyte eAPCs, comprising: i. combining one or more analyte eTPCs with one or more analyte eAPCs to provide contact between the analyte TCRsp and the analyte antigen; and at least one of the following: ii. if formed, measuring the formation of a complex between one or more analyte TCRsp and one or more analyte antigens; and / or iii. if induced, measuring a signal response by the analyte eTPC induced by complex formation between one or more analyte TCRsp and one or more analyte antigens; and / or iv. if induced, measuring a signal response by the analyte eAPC induced by complex formation between one or more analyte TCRsp and one or more analyte antigens; and v. selecting one or more analyte eTPCs based on steps b, c and / or d, the selection being made by positive and / or negative determinations. where i, iii and v include preferred configurations.
[0090] The analyte eAPC obtained from the eAPC:eTPC combination system is used to characterize the signal response of the analyte eAPC expressing the analyte antigen to the TCRsp presented by the analyte eTPC, where this signal response can be either binary or gradually varying and can be measured as specific to the eTPC (Figure 30) or specific to the eAPC (Figure 31). A method for selecting an input analyte eAPC or one or more analyte eAPCs from a library of analyte eAPCs from an eAPC:eTPC combination system to obtain one or more analyte eAPCs, wherein an expressed analyte antigen binds to one or more analyte TCRsps presented by the analyte eTPCs, comprising: i. combining one or more analyte eAPCs with one or more analyte eTPCs to bring the analyte antigen presented by the analyte eAPC into contact with the analyte TCRsp of the one or more analyte eTPCs; and ii. if so, measuring the formation of a complex between one or more analyte antigens and one or more analyte TCRs; and / or iii. if induced, measuring a signal response in one or more analyte eTPCs induced by complex formation between the analyte TCRsp and the analyte antigen; and / or iv. if induced, measuring a signal response by the analyte eAPC induced by complex formation between one or more analyte TCRsp and one or more analyte antigens; and v. selecting one or more analyte eAPCs from steps b, c and / or d, the selection being by positive and / or negative determination. where i, iii and v include preferred configurations.
[0091] Selection of eTPCs or eAPCs may be from an eAPC:eTPC system comprising a single manufactured analyte eAPC population and a binary culture system in which a single manufactured analyte eTPC population is provided, and responsive eAPCs or eTPCs are selected based on a binary or gradually changing response within the eTPCs (Figure 30) and / or eAPCs (Figure 31). The eAPC:eTPC system may include input of manufactured single analyte eAPCs and a pooled library of manufactured eTPCs (Figure 32). The eAPC:eTPC system may include input of a manufactured single analyte eTPC and a pooled library of manufactured eAPCs (Figure 33). Within the eATP:eTPC combination system, measuring a signal response in one or more analyte eTPCs or one or more eAPCs, if any, that may be induced by complex formation between the analyte TCRsp and the analyte antigen, is important for selecting a primary device output, where the primary device output is: i.eAPC-p ii.eAPC-a iii.eAPC-pa iv. eTPC-t wherein the selection of cells may be based on the presence or absence of a signal response reported in one or both of the contacted analyte eAPC or analyte eTPC cells.
[0092] In accordance with the present invention, a method for selecting an analyte eTPC and / or an analyte eAPC from an eAPC:eTPC combination system based on a signal response reported in the eTPC comprises: i. determining the native signaling response, and / or ii. determining the synthetic signaling response when the eTPC contains component 2F and / or when the eAPC contains an equivalent synthetic reporter element; may also include. The induced natural or synthetic signaling responses that are specific to eAPCs and / or eTPCs include: i. Secreted biomolecules ii. Secreted chemicals iii. Intracellular biomolecules iv.Intracellular chemicals v. Surface-expressed biomolecules vi. Cytotoxic effect of analyte eTPC on analyte eAPC vii. A paracrine effect of the analyte eTPC on the analyte eAPC, such that a signal response is induced in the analyte eAPC and is determined by detecting an increase or decrease in any of a to e. viii. Amplification of analyte eTPC ix. Immunological synapse between analyte eTPC and analyte eAPC the signal response is measured by detecting an increase or decrease in one or more of the following:
[0093] eAPC: Acquisition of primary system output from eTPC system The present invention provides a genetically engineered bipartite cell device. The two parts of the device, eAPCS and eTPCS, are used to assemble analyte eAPC and analyte eTPC, respectively. These analyte cell populations are then assembled into an eAPC:eTPC combination system, from which a device output may be obtained. The eAPC:eTPC system is comprised of a selection of one or more analyte eAPC populations and one or more eTPC populations (FIG. 1), produced as described above (FIGS. 4-29). The eAPC:eTPC system is provided in a format that allows for physical contact between the analyte eAPC and the analyte eTPC populations. This contact allows for complex formation between one or more analyte antigens and the TCRsp of one or more analyte eTPC-t, where the analyte antigen is presented by the analyte eAPC together with the analyte TCRsp presented by the analyte eTPC, as follows: i.aAPX and / or ii.aAM and / or iii. aAPX:aAM and / or iv. Commercials and / or v.aAPX:CM Complex formation may lead to stabilization of the complex and induction of signaling within the analyte eAPC and / or analyte eTPC may be reported and measured.
[0094] The aspects of reporting the induced signal responses are described above, and it is these reported responses that need to be measured when obtaining the primary output of the two-part device. The primary output of the device is a selected cell population that may or may not have responded to the analyte presented by the interrelated cells provided to the eAPC:eTPC system. That is, this primary output may be represented as a single cell or a pool of cells selected based on the presence or absence of a response reported in the eAPC:eTPC combination system (FIG. 1, step v). A response in the analyte eAPC is elicited only by binding of a cognate TCR presented by a contacting eTPC. A response in the analyte eTPC is elicited only by binding of a cognate antigen presented by a contacting eTPC (FIG. 1, step iv).
[0095] Selection of analyte eAPCs and / or analyte eTPCs from an eAPC:eTPC combination system may be based on a response in a contacting cell. That is, an analyte eAPC may be selected based on a reported response, or lack thereof, in a contacting analyte eTPC. Conversely, an analyte eTPC may be selected based on a reported response, or lack thereof, in a contacting analyte eAPC. In the context of the present invention, the primary eAPC output of the device are selected cells, the selection being based on the presence or absence of a reported signal response, and these cells are i.eAPC-p ii.eAPC-a iii.eAPC-pa The selected cells may comprise a single cell, a pool of cells of the same identity or a pool of cells of different identities (FIG. 1, step v). The primary eTPC output of the device are selected cells, selection being based on the presence or absence of a reported signal response; these cells comprise eTPC-t; the selected cells may comprise a single cell, a pool of cells of the same identity or a pool of cells of different identities (Figure 1, step v).
[0096] The signal reported at the analyte eAPC and / or the analyte eTPC in a combined eAPC:eTPC system may be used to select the analyte cell population and provide a primary output. Primary output of eAPC and / or eTPC types can be achieved by selecting the desired analyte eAPC and / or analyte eTPC populations from the two-part system when the eAPC:eTPC combination system is of a two-part culture nature (e.g., Figures 30 and 31). A primary output of eAPC and / or eTPC type can be achieved by selecting the desired analyte eAPC and / or analyte eTPC populations from the combined culture system when the eAPC:eTPC combined system is in the nature of fixed eAPCs and pooled library analyte eTPCs (e.g., FIG. 32) or when the eAPC:eTPC combined system is in the nature of fixed eTPCs and pooled library analyte eAPCs (e.g., FIG. 33).
[0097] There are several different embodiments in which a primary output can be obtained, where each embodiment involves a sorting step. Cell sorting may be achieved by fluorescence activated cell sorting (FACS) and / or magnetic activated cell sorting (MACS) and / or different affinity activated cell sorting methods. The primary output eAPC and / or eTPC cells may be obtained by single cell sorting to obtain single cells and / or by cell pool sorting to obtain a pool of cells. The primary output eAPC and / or eTPC cells may be subjected to single cell sorting to obtain single cells, which may then be expanded to obtain a monoclonal pool of selected eAPC or eTPC cells. The primary output eAPC and / or eTPC cells may be obtained by cell pool sorting to obtain a cell pool, which may then be expanded to obtain a pool of selected eAPC and / or eTPC cells.
[0098] eAPC: Acquiring end system output from an eTPC system Following the above method of obtaining a primary output which is a selected analyte eAPC and / or eTPC cell based on a measured signal response, a terminal output of the two-part cellular device may be obtained by further processing of the selected eAPCa and / or eTPC primary output. The terminal output from the bipartite cellular device is presented by either the analyte eAPC (i-v) or the analyte eTPC (vi) and is obtained as the primary output from the bipartite device by selection from the eAPC:eTPC combination system. i.aAPX and / or ii.aAM and / or iii. aAPX:aAM and / or iv. Commercials and / or v.aAPX:CM and / or vi. TCRsp is our identity.
[0099] In a bipartite cell device, the analyte molecules presented by the analyte eAPCs and analyte eTPCs are frequently genetically encoded, and thus genetic sequencing of the analyte molecules produced from the eAPCs or eTPCs may be performed to identify the analyte molecules presented by the analyte eAPCs or eTPCs. eAPCs are selected and / or expanded eAPC-p, eAPC-a or eAPC-pa cells, with gene sequences obtained for component 1B' and / or component 1D': i.aAPX and / or ii.aAM and / or iii.aAPX:aAM where the resulting identity represents the terminal output of the two-part cellular device. eAPCs are sequenced for the genome of selected and / or expanded eAPC-p, eAPC-a or eAPC-pa cells, and i.aAPX and / or ii.aAM and / or iii.aAPX:aAM iv. Commercials and / or v.aAPX:CM where the resulting identity represents the terminal output of the two-part cellular device.
[0100] The eTPC may be processed to obtain gene sequences for component 2B' and / or component 2D' of the sorted and / or expanded eTPC-t cells and determine the identity of the TCRsp, where the resulting identity of the TCRsp represents the terminal output of the bipartite cell device. The eTPC may be processed to obtain genetic sequences for the genomes of the selected and / or expanded eTPC-t cells and to determine the identity of the TCRsp, where the resulting identity of the TCRsp represents the terminal output of the bipartite cell device.
[0101] Gene sequencing can be accomplished in a variety of ways, from a variety of sources of genetic material, with or without specific processing. In the present invention, prior to the sequencing step i. Extracting genomic DNA; and / or ii. Extracting RNA transcripts of components 1B' and / or 1D' and / or 2B' and / or 2D'; and / or iii. amplifying the DNA and / or RNA transcripts of components 1B' and / or 1D' and / or 2B' and / or 2D' by PCR and / or RT-PCR. may be carried out. The sequencing step may be destructive to the eAPCs or eTPCs, or pools thereof, obtained as the primary output of the two-part device.
[0102] When it is desirable to obtain a primary output from a two-part device in which the sequencing process is destructive to the primary output eAPC or eTPC, the sequence information obtained as the terminal output of the two-part device may be used to generate output eAPCs and eTPCs equivalent to the analyte eAPC or analyte eTPC through the use of the eAPCS and eTPCS, respectively. In the above scenario of a genetically encoded analyte molecule, the terminal output of the two-part device may be obtained by obtaining sequence information from components 1B' and / or 1D' and / or 2B' and / or 2D' and / or the cell genome. However, in some embodiments, the antigen information is not genetically encoded. Antigens that are post-translationally modified, antigens provided to the eAPC:eTPC combination system by non-genetic means, antigens that emerge from induced or altered states of the analyte eAPC proteosome or metabolites, CMs unique to the eAPC:eTPC system may not be reasonably identified by genetic means.
[0103] In the important case of aAM that can be provided to the eACP:eTPC system by non-genetic means, there are two different modes in which the eAPC-p or eAPC-pa can present the provided aAM as an aAPX:aAM complex. In the first scenario, the aAM is provided in a form that can directly bind to aAPX and form an aAPX:aAM complex at the cell surface (Figure 34). One example of such an aAM is a peptide antigen for an HLA complex. In the second scenario, the aAM is provided in a form that can be taken up by the analyte eAPC, loaded as cargo in aAPX, and processed to form an aAPX:aAM complex at the cell surface (Figure 35). In accordance with the present invention, a method for selecting and identifying aAM or CM cargo, wherein the cargo is a metabolite and / or peptide that is loaded onto the aAPX of an eAPC selected and obtained as the primary output of a two-part device, comprises: i. isolating aAPX:aAM or aAPX:CM or cargo aM or cargo CM; ii. Identifying the cargo carried; where the loaded load being identified is the terminal output of the two-part device.
[0104] In general, there are two ways in which cargo molecules can be identified from selected eAPCs. First, forced release of cargo from aAPX:aAM or aAPX:CM results in the isolation of aAM or CM available for subsequent identification (Figure 36). An example of this is acid washing of eAPCs, which releases peptide-aAM from HLA complexes. Second, capture of aAPX:aAM or aAPX:CM (e.g., by complex release and immunoaffinity isolation) results in the isolation of aAPX:aAM or aAPX:CM complexes, allowing the identification of aAM or CM (Figure 37). Methods for identifying isolated aAM and / or CM directly or from isolated aAPX:aAM or aAPX:CM complexes include: i.Mass spectrometry ii. Peptide sequencing analysis where the identity of the aAM and / or CM involved is the termination output of the two-part device. Description of the drawings The invention is illustrated in the following non-limiting drawings. [Brief description of the drawings]
[0105] [Figure 1]Figure 1 - Operation of a two-part device comprising an eAPC and an eTPC system The two-part genetically engineered cell device is composed of two multi-component cell systems, eAPCS and eTPCS, which are brought into contact as an eAPC:eTPC combined system. The operation of the whole device comprises two phases: a manufacturing phase and an analysis phase. In one aspect of the first phase, the eAPCS system is used to produce cells expressing an analyte antigen-presenting complex (aAPX) and / or an analyte antigenic molecule (aAM) on the cell surface (step i). eAPCs presenting only aAPX are referred to as eAPC-p. eAPCs expressing only aAM are referred to as eAPC-a. eAPCs presenting aAM as cargo in an aAPX are referred to as eAPC-pa. These analytes are collectively referred to as analyte antigens. In another aspect of the first phase, the eTPCS system is used to produce cells expressing an analyte TCR chain pair (TCRsp) on the cell surface (step ii). The eTPCs presenting TCRsp on the cell surface are called eTPC-t. The second phase of the overall system is to contact the analyte-bearing cells generated in the first phase to form an eAPC:eTPC combination system (step iii). The contacted analyte eAPCs present the analyte antigen to the analyte eTPC. Within the eAPC:eTPC combination system, the responsiveness of the analyte TCR chain pair to the provided analyte antigen is determined by the readout of the contact-dependent analyte eAPC and / or eTPC response (the "*" and shaded boxes represent the change in the signal state of these reporting analyte cells) (step iv). As a result of the eAPC:eTPC system, specific eAPCs and / or eTPC-t can be selected based on their own response and / or their ability to drive a response in other contacting analyte cells. Thus, they are selected single cells or cell populations of eAPC-p, eAPC-a, eAPC-pa and / or eTPC-t type which are the primary output of the device operation (step v). By obtaining the analyte cells from step v, the presented analytes aAPX, aAM, aAPX:aAM, CM, aAPX:CM and / or TCRsp can be identified from these cells as the terminal output of the device operation (step vi). [Diagram 2]FIG. 2 - Description of the components of a single integration couple eAPCS An example of an eAPCS comprising three components. The first component 1A is the eAPC line itself with all the required engineered characteristics of the cell. The eAPC 1A contains one further component 1B which is a genomic integration site for the integration of aAPX and / or aAM. One additional component 1C represents a gene donor vector for site-specific integration of an ORF into site 1B, the arrows indicate the coupled specificity. The paired integration site / donor vector couple can be formatted to integrate a single ORF or a pair of ORFs to introduce aAPX and / or aAM expression. [Diagram 3] FIG. 3 - Description of the components of a double integration couple eAPCS An example of an eAPCS comprising 5 components. The first component 1A is the eAPC line itself with all the required engineered characteristics of the cell. eAPC 1A contains two further components 1B and 1D which are genomic integration sites for the integration of aAPX and / or aAM. Two additional components 1C and 1E represent gene donor vectors for site-specific integration of ORFs into sites 1B and 1D respectively, with arrows indicating pairwise specificity. Each of the paired integration site / donor vector couples can be formatted to integrate a single ORF or an ORF pair to introduce aAPX and / or aAM expression. [Figure 4]Figure 4 - Organization of eAPCs presenting different analyte antigens The eAPCS system starts with eAPCs and utilizes donor vectors to create cells expressing analyte antigen-presenting complexes (aAPXs) and / or analyte antigenic molecules (aAMs) on the cell surface. eAPCs presenting only aAPXs are called eAPC-p and can be created by introduction of an ORF encoding aAPX into eAPCs (step i). eAPCs expressing only aAMs are called eAPC-a and aAMs can be expressed on the cell surface and available for TCR binding or require processing and loading into aAPX as cargo (as an aAPX:aAM complex). eAPC 1A can be created by introduction of an ORF encoding aAM into eAPCs (step ii). eAPCs presenting aAMs as cargo in aAPXs are called eAPC-pa. eAPC-pa can be generated by either: simultaneous introduction of ORFs encoding aAM and aAPX into eAPC (step iii); introduction of ORF encoding aAM into eAPC-p (step iv); introduction of ORF encoding aAPX into eAPC-a (step v). [Diagram 5] Figure 5 - Operation of a Gene Donor Vector and Genomic Acceptor Site Integration Couple A gene donor vector and a genomic acceptor site form an integration couple, where one or more ORFs encoded in the gene donor vector can specifically integrate into the coupled genomic acceptor site. Step 1 in the operation of an integration couple is the introduction of one or more target ORFs into the donor vector. The original donor vector is called X, and the introduction of the target ORFs modifies it into a primed donor vector X'. Step 2 results in the combination of the primed donor vector X' with a cell Y that has a genomic acceptor site. The introduction of an ORF encoded by the primed donor vector into the acceptor site results in the creation of a cell Y' that has an integration site. [Figure 6]FIG. 6 - Example of the construction of an eAPC-p in one step using one integration couple. eAPC 1A contains genomic acceptor site 1B. Primed gene donor vector 1C' is coupled to 1B and encodes aAPX. When 1A eAPC is combined with the 1C' donor vector, the resulting cell has the ORF of 1C' swapped into the 1B genomic acceptor site to create site 1B' and introduce aAPX expression. This results in expression of aAPX at the cell surface and the creation of an eAPC-p. [Figure 7] FIG. 7 - Example of assembly of eAPC-p in one step using one integration couple and one unused integration site. eAPC 1A contains genomic acceptor sites 1B and 1D. Primed gene donor vector 1C' is coupled to 1B and encodes aAPX. When 1A eAPC is combined with 1C' donor vector, the resulting cell has the ORF of 1C' swapped into the 1B genomic acceptor site to create site 1B' and introduce aAPX expression. This results in expression of aAPX at the cell surface and creation of eAPC-p. Genomic acceptor site 1D remains unused. [Figure 8] FIG. 8 - Example of eAPC-a assembly in one step using one integration couple. eAPC 1A contains genomic acceptor site 1B. Primed gene donor vector 1C' is coupled to 1B and encodes an aAM. When 1A eAPC is combined with 1C' donor vector, the resulting cell has the ORF of 1C' swapped into the 1B genomic acceptor site to create site 1B' and introduce aAM expression. This results in one of two forms of eAPC-a that express the aAM on the cell surface or intracellularly. [Figure 9]FIG. 9 - Example of eAPC-a assembly in one step using one integration couple and one unused integration site. eAPC 1A contains genomic acceptor sites 1B and 1D. Primed gene donor vector 1C' is coupled to 1B and encodes an aAM. When 1A eAPC is combined with 1C' donor vector, the resulting cell has the ORF of 1C' swapped into the 1B genomic acceptor site to create site 1B' and introduce aAM expression. This results in one of two forms of eAPC-a that express aAM on the cell surface or intracellularly. Genomic acceptor site 1D remains unused. [Figure 10] FIG. 10 - Example of construction of eAPC-pa in one step using one integration couple. eAPC 1A contains genomic acceptor site 1B. Gene donor vector 1C' is coupled to 1B. Donor vector 1C' encodes aAPX and aAM. 1A eAPC is combined with donor vector 1C'. The resulting cell has 1C' ORFs exchanged into 1B genomic acceptor site to create site 1B' and deliver the aAPX and aAM ORFs. This results in cell surface expression of aAPX and intracellular expression of aAM, resulting in loading of aAM as cargo in aAPX to form aAPX:aAM complex at the cell surface. [Figure 11] FIG. 11 - Example of eAPC-pa construction in one step using one integration couple and one unused integration site. eAPC 1A contains distinct genomic acceptor sites 1B and 1D. Gene donor vector 1C' is coupled to 1B. Donor vector 1C' codes for aAPX and aAM. 1A eAPC is combined with donor vector 1C'. The resulting cell has 1C' ORFs exchanged into 1B genomic acceptor site to create site 1B' and deliver the aAPX and aAM ORFs. Genomic acceptor site 1D remains unused. This results in cell surface expression of aAPX and intracellular expression of aAM, resulting in the loading of aAM as cargo in aAPX to form aAPX:aAM complex at the cell surface. This creates eAPC-pa cell line. Genomic acceptor site 1D remains unused. [Figure 12] FIG. 12 - Example of construction of eAPC-pa in one step using two integration couples. eAPC 1A contains distinct genomic acceptor sites 1B and 1D. Distinct gene donor vectors 1C' and 1E' are independently coupled to 1B and 1D, respectively. Donor vector 1C' encodes aAPX, and donor vector 1E' encodes aAM. 1A eAPC is simultaneously combined with donor vectors 1C' and 1E'. The resulting cell has 1C' ORF exchanged into 1B genomic acceptor site to create site 1B' and deliver the aAPX ORF. At the same time, 1E' ORF exchanges into 1D genomic acceptor site to create site 1D' and deliver the aAM ORF. This results in cell surface expression of aAPX and intracellular expression of aAM, resulting in the loading of aAM as cargo in aAPX to form aAPX:aAM complexes at the cell surface. This creates the eAPC-pa cell line. [Figure 13] FIG. 13 - Example of eAPC-p-mediated construction of eAPC-pa in two steps using two integration couples. eAPC 1A contains distinct genomic acceptor sites 1B and 1D. Distinct gene donor vectors 1C' and 1E' are independently coupled to 1B and 1D, respectively. Donor vector 1C' codes for aAPX, and donor vector 1E' codes for aAM. In step 1, 1A eAPC is combined with 1C' donor vector. The resulting cell exchanges insert 1C' into 1B genomic acceptor site to create site 1B' and deliver the ORF of aAPX. This results in expression of aAPX on the cell surface and the creation of eAPC-p. Genomic acceptor site 1D remains unused. In step 2, eAPC-p created in step 1 is combined with 1E' donor vector. The resulting cells exchange insert 1E' into the 1D genomic acceptor site to create site 1D' and deliver the aAM ORF, resulting in cell surface expression of aAM as cargo of expressed aAPX and generation of eAPC-pa. [Figure 14]FIG. 14 - Example of eAPC-a-mediated construction of eAPC-pa in two steps using two integration couples. eAPC 1A contains distinct genomic acceptor sites 1B and 1D. Distinct gene donor vectors 1C' and 1E' are independently coupled to 1B and 1D, respectively. Donor vector 1C' encodes aAM, and donor vector 1E' encodes aAPX. In step 1, 1A eAPC is combined with 1C' donor vector. The resulting cell exchanges insert 1C' into 1B genomic acceptor site to create site 1B' and deliver the ORF of aAM. This results in cell surface expression of aAM and creation of eAPC-a. Genomic acceptor site 1D remains unused. In step 2, eAPC-a created in step 1 is combined with 1E' donor vector. The resulting cells exchange insert 1E' into the 1D genomic acceptor site to create site 1D' and deliver the aAPX ORF, resulting in cell surface expression of aAPX with aAM as cargo and generation of eAPC-pa. [Figure 15] FIG. 15 - Shotgun organization of eAPC-pa pool from eAPC-p. eAPC-p contains an exchanged genomic acceptor site 1B' expressing aAPX and an alternative genomic acceptor site 1D. A pool of gene donor vectors 1E'i-iii is coupled with 1D. Donor vectors 1E'i-iii each encode a single aAM gene. eAPC-p is combined with donor vectors 1E'i, 1E'ii, 1E'iii simultaneously. The resulting cell pool has any of the inserts 1E'i-iii exchanged into the 1D genomic acceptor site in multiple independent instances, creating sites 1D'i-iii, each delivering a single ORF of the aAM gene. The resulting eAPC-pa cell pool comprises a mixed population of three different cell cohorts, each expressing a distinct combination of 1B' to present the aAM genes contained in the original vector library as aAPX:aAM. [Figure 16]FIG. 16 - Shotgun organization of eAPC-pa pool from eAPC-a. eAPC-a contains exchanged genomic acceptor site 1B' expressing aAM and distinct genomic acceptor site 1D. A pool of gene donor vectors 1E'i-iii is coupled with 1D. Donor vectors 1E'i-iii each encode a single aAPX gene. eAPC-a is combined simultaneously with donor vectors 1E'i, 1E'ii, 1E'iii. The resulting cell pool has any of inserts 1E'i-iii exchanged into the 1D genomic acceptor site in multiple independent instances, each delivering a single ORF of the aAPX gene, creating sites 1D'i-iii. The resulting eAPC-pa cell pool comprises a mixed population of three distinct cell cohorts, each expressing a distinct combination of aAM encoded by 1B' and any of the aAPX genes contained in the original vector library. [Figure 17]FIG. 17 - Shotgun organization of pooled eAPC-pa libraries from eAPCs containing pairwise combinations of aAM and aAPX genes. eAPC 1A contains distinct genomic acceptor sites 1B and 1D. Distinct gene donor vectors 1C' and 1E' are coupled to 1B and 1D, respectively. Donor vectors 1C'i and 1C'ii each encode a single aAM gene, and donor vectors 1E'i and 1E'ii each encode a single aAPX gene. eAPC 1A is simultaneously combined with donor vectors 1C'i, 1C'ii, 1E'i and 1E'ii. The resulting cell pool has inserts 1C'i or 1C'ii exchanged into the 1B genomic acceptor site in multiple independent instances to create sites 1B'i and 1B'ii, each delivering a single ORF of aAM. The resulting cell pool further has inserts 1E i or 1E ii exchanged into the 1D genome acceptor site in multiple independent instances creating sites 1E' i and 1E' ii, each delivering a single ORF of the APX gene. The resulting eAPC-pa cell pool comprises a mixed population of four distinct cell cohorts, each expressing a distinct randomized aAPX:aAM pair (comprising one of each gene contained in the original vector library) on its surface. [Figure 18] FIG. 18 - Description of the components of a single integration couple eTPCS An example of an eAPCS comprising four components. The first component 2A is the eTPC line itself, which has all the required engineered characteristics of the cell. eTPC 2A contains a second component 2B, which is a genomic integration site for the integration of a complementary analyte TCR chain pair ORF. The third component included in eTPC 2A is a synthetic reporter construct 2F, which is induced upon TCR ligation. One additional independent component 2C represents a gene donor vector for site-specific integration of an ORF into site 2B, where the arrow indicates the coupled specificity. [Figure 19]FIG. 19 - Description of the components of a double integration couple eTPCS. An example of an eAPCS comprising six components. The first component 2A is the eTPC line itself, which has all the required engineered characteristics of the cell. eTPC 2A contains three further components, two of which are genomic integration sites 2B and 2D for integration of the analyte TCR chain pair. The third component included in eTPC 2A is a synthetic reporter construct 2F that is induced upon TCR ligation. Two additional independent components 2C and 2E represent gene donor vectors for site-specific integration of ORFs into sites 2B and 2D, respectively, where the arrows indicate the coupled specificities. Each of the paired integration site / donor vector couples can be formatted to integrate a single ORF or an ORF pair to introduce analyte TCR chain pair expression by different means. [Figure 20] Figure 20 - Organization of eTPCs presenting different analyte TCRsp. eTPCS starts with an eTPC and utilizes a donor vector to create cells expressing an analyte TCRsp or a single analyte TCR chain. An eTPC presenting a TCRsp is called eTPC-t and can be created by introduction of ORFs encoding two complementary TCR chains into the eTPC (step i). An eTPC expressing only a single analyte TCR chain is called eTPC-x and can be created by introduction of ORFs encoding a single TCR chain into the eTPC (step ii). Alternatively, an eTPC-t can be created from an existing eTPC-x where an ORF encoding a second complementary TCR chain has been introduced into the eTPC (step iii). [Figure 21] FIG. 21 - Organization of the eTPC system using a one-step and one-vector format. eTPC 2A contains a different genomic acceptor site. Gene donor vector 2C is coupled with 2D. Donor vector 2C encodes the TCR chain pair. eTPC 2A further contains the TCR signal response element 2F. eTPC 2A is combined with donor vector 2C. The resulting cell has the insert 2C exchanged into the 2B genomic acceptor site to create site 2C' and deliver the two ORFs of the TCR chain pair. This cell can display TCRsp on its surface and is therefore called eTPC-t. [Figure 22] FIG. 22 - Construction of eTPC-t in one step using one vector and unused acceptor site. eTPC 2A contains separate genomic acceptor sites 2B and 2D. Gene donor vector 2C' is coupled with 2D. Donor vector 2C' encodes the TCR chain pair. eTPC 2A further contains TCR signal response element 2F. eTPC 2A is combined with donor vector 2C'. The resulting cell has the insert 2C' exchanged into the 2B genomic acceptor site to create site 2B' and deliver the two ORFs of the TCR chain pair. Genomic acceptor site 2D remains unused. This cell can display TCRsp on its surface and is therefore called eTPC-t. [Diagram 23] FIG. 23 - Construction of eTPC-t in one step using two vectors and two integration couples. eTPC 2A contains separate genomic acceptor sites 2B and 2D. eTPC 2A further contains TCR signal response element 2F. Separate gene donor vectors 2C' and 2E' are independently coupled to 2B and 2D, respectively. Donor vector 2C' encodes a single TCR chain, and donor vector 2E' encodes a second interrelated TCR chain. eTPC 2A is combined with donor vectors 2C' and 2E'. The resulting cell has had insert 2C exchanged into 2B genomic acceptor site to create site 2B' and deliver the ORF of the first TCR chain. In addition, the resulting cell line has had insert 2E' exchanged into 2D genomic acceptor site to create site 2D' and deliver the ORF of the second TCR chain. These cells are capable of presenting TCRsp on their surface and are therefore called eTPC-t. [Figure 24]FIG. 24 - Assembly of eTPC-x in one step using one vector and unused acceptor site. eTPC 2A contains separate genomic acceptor sites 2B and 2D. Gene donor vector 2C' is coupled to 2D. Donor vector 2C' encodes a single TCR chain. eTPC 2A further contains TCR signal response element 2F. eTPC 2A is combined with donor vector 2C'. The resulting cell has insert 2C' exchanged into 2B genomic acceptor site to create site 2B' and deliver a single TCR chain ORF. Genomic acceptor site 2D remains unused. This cell expresses only a single TCR chain and is therefore called eTPC-x. [Diagram 25] FIG. 25 - Construction of eTPC-t in two steps using two vectors eTPC 2A contains separate genomic acceptor sites 2B and 2D. eTPC 2A further contains TCR signal response element 2F. Separate gene donor vectors 2C' and 2E' are independently coupled to 2B and 2D, respectively. Donor vector 2C' encodes a single TCR chain, and donor vector 2E' encodes a second interrelated TCR chain. In step 1, eTPC 2A is combined with donor vector 2C'. The resulting cell has the insert 2C' exchanged into the 2B genomic acceptor site to create site 2B' and deliver the ORF of the first TCR chain. This cell expresses only a single TCR chain, and is therefore called eTPC-x. Genomic acceptor site 2D remains unused. In step 2, eTPC-x is combined with donor vector 2E'. The resulting cells have exchanged insert 2E' into the 2D genome acceptor site to create site 2D' and deliver the ORF of the second complementary TCR chain. The cells are capable of displaying TCRsp on their surface and are therefore called eTPC-t. [Figure 26]FIG. 26 - Shotgun assembly of eTPC-t pools expressing distinct TCR chain pairs from a selected TCR chain pair library with paired analyte TCR chains in a single replicative vector from eTPC. eTPC 2A contains genomic acceptor site 2B. Gene donor vector 2C' is coupled to 2B. Donor vectors 2C' i, 2C' ii and 2C' iii encode distinct TCR chain pairs and constitute a mixed vector library of distinct TCR chain pairs. eTPC 2A further contains TCR signal response element 2F. eTPC 2A is simultaneously combined with donor vectors 2C' i, 2C' ii and 2C' iii. The resulting cell pools, in multiple independent instances, have had insert 2C swapped into the 2B genomic acceptor site to create sites 2B' i, 2B' ii and 2B' iii and deliver two ORFs of each distinct TCR chain pair contained in the original vector library. This eTPC-t cell pool comprises a mixed population of three distinct cell clones (TCRsp i, ii and iii), each expressing a distinct TCR chain pair, forming a pooled library of eTPC-t. [Figure 27]Figure 27 - Shotgun assembly of eTPC-t pools expressing distinct TCR chain pairs from a selected TCR chain pair library with paired analyte TCR chains in a single replica vector from eTPC and with unused acceptor sites. eTPC 2A contains distinct genomic acceptor sites 2B and 2D. Gene donor vector 2C' is coupled to 2B. Donor vectors 2C'i, 2C'ii and 2C'iii encode distinct TCR chain pairs, constituting a mixed vector library of distinct TCR chain pairs. eTPC 2A further contains TCR signal response element 2F. eTPC 2A is simultaneously combined with donor vectors 2C'i, 2C'ii and 2C'iii. The resulting cell pool has, in multiple independent instances, swapped insert 2C into the 2B genomic acceptor site to create sites 2B'i, 2B'ii and 2B'iii and deliver the two ORFs of each distinct TCR chain pair contained in the original vector library. This eTPC-t cell pool comprises a mixed population of three distinct cell clones (designated TCRsp i, ii and iii), each expressing a distinct TCR chain pair, forming a pooled library of eTPC-t. Genomic acceptor site 2D remains unused. [Figure 28]Figure 28 - Shotgun assembly of eTPC-t pools expressing random combinations of paired TCR chain pairs from selected single TCR chain libraries using two vectors from eTPC. eTPC 2A contains distinct genomic acceptor sites 2B and 2D. Distinct gene donor vectors 2C' and 2E' are independently coupled to 2B and 2D, respectively. Donor vectors 2C'i and 2C'ii each encode a single TCR chain, and donor vectors 2E'i and 2E'ii each encode a mutually related single TCR chain. eTPC 2A further contains TCR signal response element 2F. eTPC 2A is simultaneously combined with donor vectors 2C'i, 2C'ii, 2E'i and 2E'ii. The resulting cell pool has, in multiple independent instances, the insert 2C'i or 2C'ii exchanged into a 2B genomic acceptor site to create sites 2B'i and 2B'ii, each for delivering a single ORF of a TCR chain. The resulting cell pool has further, in multiple independent instances, the insert 2Ei or 2Eii exchanged into a 2D genomic acceptor site to create sites 2E'i and 2E'ii, each for delivering a single ORF of a TCR chain that is interrelated to that of sites 2C'i and 2C'ii. The resulting eTPC-t cell pool comprises a mixed population of four distinct cell cohorts, each expressing on its surface a distinct randomized TCRsp, each composed of one of each of the interrelated TCR chains contained in the original vector library. [Figure 29]FIG. 29 - Shotgun assembly of eTPC-t pools expressing random combinations of paired TCR chain pairs from a selected single TCR chain library from eTPC-x with unpaired analyte TCR chains. eTPC-x contains an exchanged genomic acceptor site 2B' expressing a single TCR chain and an alternative genomic acceptor site 2D. Alternative gene donor vectors E'i and E'ii are each coupled to 2D. Donor vectors 2E'i and 2E'ii each encode a single TCR chain. eTPC-x further contains a TCR signal response element 2F. eTPC-x is simultaneously combined with donor vectors 2E'i and 2E'ii. The resulting cell pools have, in multiple independent instances, the inserts 2E'i or 2E'ii exchanged into the 2D genomic acceptor site to create sites 2Ei and 2E'ii, each delivering a single ORF of a TCR chain. The resulting eTPC-t cell pool comprises a mixed population of two distinct cell cohorts expressing on their surface distinct TCRsp composed of TCR chains expressed from 2B' that pair with one of each TCR chain contained in the original vector library. [Diagram 30]Figure 30 - Operation of eAPC:eTPC combination system showing possible eTPC-t-output states The analyte eAPC contains sites 1C' and 1E', each with one ORF encoding one aAPX and one aAM, and is loaded with aAM as cargo at the cell surface aAPX. The analyte eTPC contains sites 2C' and 2E', each with one ORF encoding the surface interacting TCRsp. The eTPC-t further contains the TCR signal response element 2F. When the eTPC-t and eAPC-pa populations come into contact, four eTPC-t response states (one negative and three positive states) can be achieved. The negative state is the resting state of eTPC-t, with no signal intensity at the 2F element, indicating that the eAPC aAPX:aAM complex cannot stimulate the chain pair presented by the eTPC-t. The three positive states show increasing signal intensity from 2F. The states 2F'+, 2F'++ and 2F'+++ represent low, medium and high signal intensity, respectively. As indicated by the darker shading of the cells, the gene product of 2F, called hexagon, accumulates and reports the signal intensity of each cell state. This indicates that the response of the analyte TCRsp expressed by the eTPC-t population to the analyte aAPX:aAM presented by the eAPC-pa is graded. [Diagram 31]FIG. 31 - Operation of the eAPC:eTPC combination system showing possible eAPC-pa output states. The analyte eAPC-pa contains sites 1C' and 1E', each with one ORF encoding one aAPX and one aAM, and is loaded with aAM as cargo at the cell surface aAPX. The analyte eTPC contains sites 2C' and 2E', each with one ORF encoding the surface interacting TCRsp. The eTPC-t further contains the TCR signal response element 2F. When the analyte eTPC and eAPC-pa populations come into contact, four eAPC response states (one negative and three positive) can be achieved. The negative state is the resting state of the analyte eAPC, where the absence of signal intensity of the TCRsp chain pair indicates the inability to stimulate the aAPX:aAM complex presented by the analyte eAPC. The three positive states show increasing signal intensities from the contacted aAPX:aAM. The reported signal intensities for each cell state are indicated with *, **, and ***, and are also indicated by the dark shading of the cells. This indicates a graded response of the analyte aAPX:aAM to the analyte TCRsp chain pair. [Diagram 32]FIG. 32 - Combinatorial operation of a two-part analyte APC:eTPC system to identify TCR chain pairs reactive with an analyte aAPX:aAM from a library of eTPC-t expressing distinct analyte TCR chain pairs. The eTPC-t pool contains cells bearing sites 2C' i, ii or ii, each incorporating two ORFs encoding interrelated TCR chain pairs, such that each cell cohort in the population expresses a distinct TCRsp on the surface. The eTPC-t further contains a TCR signal response element 2F. The analyte eAPC contains sites 1C' and 1E' incorporating distinct sets of ORFs encoding one aAPX and one aAM, and is loaded with aAM as cargo at the cell surface aAPX. In this example, only the TRC chain pair expressed from 2C'i is specific for the aAPX:aAM presented by the analyte APC, such that when the eTPC-t pool and the analyte APC population are contacted, only the cell cohort of eTPC-t carrying 2C'i reports TCRsp binding by state 2F'. [Diagram 33] FIG. 33 - Combinatorial operation of a two-part eAPC:eTPC system to identify aAMs reactive with analyte eTPCs from a library of analyte eAPCs expressing distinct analyte aAPX:aAM complexes. The analyte eAPCs contain sites 1C' and 1E' with distinct sets of ORFs integrated, each encoding one aAPX and one aAM, and are loaded with aAMs as cargo at the aAPX on the cell surface. The analyte eTPCs contain swapped genomic acceptor sites 2C' that express TCRs on their surface. The analyte eTPCs further contain a TCR signal response element 2F. In this example, only the complex aAPX:aAM i is specific for the TCR presented by the analyte eTPC, such that when the analyte eAPC pool and the analyte eTPC population are contacted, only the cell cohort expressing aAM i expresses the distinct signal*. [Diagram 34]Figure 34 - Generation of eAPC-p+aAM from eAPC-p by addition of soluble presentable antigen aAM. eAPC-p contains an exchanged genomic acceptor site 1B' expressing aAPX. Soluble directly presentable antigen aAM is combined with eAPC-p. This results in the formation of an aAPX:aAM complex at the cell surface and the generation of eAPC-p+aAM. [Diagram 35] Figure 35 - eAPC-p and soluble aAM from eAPC-p and soluble aAM eAPC-p contains an exchanged genomic acceptor site 1B' expressing aAPX. The soluble antigen aAM is combined with eAPC-p, which results in the expression of aAPX on the cell surface, the presence of aAM within the cell, and thus the loading of aAM as cargo on aAPX, resulting in the formation of an aAPX:aAM complex on the cell surface and the creation of eAPC-p+aAM. [Diagram 36] Figure 36 - Identification of aAM presented by eAPC-p+aAM by forced release of aAM. eAPC-p+aAM contains an exchanged genomic acceptor site 1B' expressing aAPX as well as internalized aAM presented on the surface as an aAPX:aAM complex. aAM is released from the aAPX:aAM surface complex by incubation, and the released aAM is available for identification. [Figure 37] Figure 37 - Identification of aAM presented by eAPC-p+aAM by capturing aAPX:aAM complexes. eAPC-p+aAM contains an exchanged genomic acceptor site 1B' expressing aAPX as well as internalized aAM presented on the surface as an aAPX:aAM complex. The aAPX:aAM surface complex is captured to identify the loaded aAM. [Figure 38]Figure 38 - Selection of cells with targeted mutagenesis loci of HLA-A, HLA-B and HLA-C genes in HEK239 cell line. a) GFP fluorescent signal in two independent cell populations 48 hours after transfection with a plasmid encoding Cas9-P2A-GFP and gRNA targeting HLA-A, HLA-B and HLA-C loci (grey histogram) compared to HEK293 control cells (dashed histogram). Cells with GFP signal within the GFP subset gate were sorted as polyclonal population. b) Cell surface HLA-ABC signal observed in two sorted polyclonal populations when labeled with PE-Cy5 anti-HLA-ABC conjugated antibody (grey histogram). Single cells showing low PE-Cy5 anti-HLA-ABC signal and presented within the sort gate were sorted to establish monoclones. Unlabeled HEK293 cells (dotted histogram) and PE-Cy5 anti-HLA-ABC labeled HEK293 cells (jet black histogram) served as controls. [Figure 39] Figure 39 - Phenotypic analysis of HLA-ABC null monoclones: Monoclonal populations were stained with PE-Cy5 anti-HLA-ABC conjugated antibodies and analyzed by flow cytometry (grey histograms). Unlabeled HEK293 cells (dashed histograms) and PE-Cy5 anti-HLA-ABC labeled HEK293 cells (full black histograms) served as controls. All three monoclonal lines showed fluorescent signals consistent with the unlabeled controls, demonstrating that each line lacked HLA-ABC surface expression. [Diagram 40] Figure 40 - Genetic characterization of a selection of monoclones lacking surface HLA-ABC expression proving genomic deletion in the targeted HLA. PCR amplicons were generated using primers spanning the gRNA genomic target site of specific HLA alleles and their sizes were determined by electrophoresis. The expected sizes are 1067 bp for wild type HLA-A amplicons, 717 bp for HLA-B amplicons, and 1221 bp for HLA-C amplicons. [Diagram 41]Figure 41 - Selection of cells with targeted genomic integration of synthetic component B with or without synthetic component D. a) GFP fluorescence signal 48 hours after transfection with a plasmid encoding Cas9-P2A-GFP and a gRNA targeting the AAVS1 locus with component B genetic elements flanked by AAVS1 left and right homology arms (grey histogram). HEK293 cells served as GFP negative control (dotted histogram). Cells with GFP signal within the GFP+ gate were sorted as polyclonal population. b) GFP fluorescence signal 48 hours after transfection with a plasmid encoding Cas9-P2A-GFP and a gRNA targeting the AAVS1 locus with components B and D flanked by AAVS1 left and right homology arms (grey histogram). HEK293 cells served as GFP negative control (dotted histogram). Cells with GFP signal within the GFP+ gate were sorted as polyclonal population. c) Maintained BFP signal but no detectable RFP signal was observed within the D1 sorted polyclonal population. Single cells showing high BFP signals in the Q3 quadrant were selected, and eAPC monoclones containing synthetic component B were established. d) Maintained BFP and RFP signals were observed in the D2-sorted polyclonal population. Single cells showing high BFP and RFP signals in the Q2 quadrant were selected, and eAPC monoclones containing synthetic component B and synthetic component D were established. [Diagram 42] Figure 42 - Phenotypic analysis of eAPC monoclones a and b) Monoclonal populations displaying sustained BFP expression suggest the integration of synthetic component B. c) Monoclonal populations displaying sustained BFP and RFP expression suggest the integration of both synthetic component B and synthetic component D. [Diagram 43]Figure 43 - Genetic characterization of the selection of monoclones for integration of component B or components B and D at the AAVS1 locus a) PCR amplicons were generated using primers priming with components B and / or D and the size was determined by electrophoresis. The expected size of positive amplicons is 380 bp indicating stable integration of components B and / or D. b) PCR amplicons were generated using primers priming with AAVS1 genomic sequences distal to the region encoded by the homology arms and with the SV40 pA terminator encoded by components B and / or D and the size was determined by electrophoresis. The expected size of positive amplicons is 660 bp indicating integration of components B and / or D occurred at the AAVS1 site. [Diagram 44] Figure 44 - Selection of cells with targeted genomic integration of component C' into component B. a) GFP fluorescence signal 48 hours after transfection with a plasmid encoding Cas9-P2A-GFP and a gRNA targeting the AAVS1 locus with component C' HLA-A*24:02 (left panel) or component C' HLA-B*-07:02 (right panel). Cells with GFP signal within the GFP+ gate were sorted into polyclonal populations ACL-303 or ACL-305. b) Analyte HLA cell surface expression was observed in the two sorted polyclonal populations when labeled with PE-Cy5 anti-HLA-ABC conjugated antibodies (grey histograms). Single cells showing high PE-Cy5 anti-HLA-ABC signal and appearing within the right sort gate were sorted to establish monoclones. Signals detected from PE-Cy5 anti-HLA-ABC labeled ACL-128, HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell lines (dotted histograms) served as controls. [Diagram 45]Figure 45 - Phenotypic analysis of eAPC-p monoclones expressing analyte HLA class I proteins on their cell surface. Monoclonal populations were stained with PE-Cy5 anti-HLA-ABC conjugated antibody and analyzed by flow cytometry (grey histograms). ACL-128, HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell lines (dotted histograms) served as controls. ACL-321 and ACL-331 monoclonal cell lines showed stronger fluorescent signals compared to the HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell line controls, proving that each line expresses its analyte aAPX, HLA-A*24:02 or HLA-B*-07:02 ORF, respectively, and thus is an eAPC-p cell line. [Figure 46] Figure 46 - Genetic characterization of a selection of monoclones proving that component C' was integrated into the genome and that integration occurred at the AAVS1 genomic acceptor site to generate component B'. a) PCR amplicons confirmed the presence of the HLA insert, with the 810 bp band representing the correct CMV promoter amplicon and the 380 bp being the amplicon generated from the SV40 pA terminator. b) PCR amplicons were generated using two sets of primers, one primed with AAVS1 genomic sequence distal to the region encoded by the homology arms and one unique to the SV40 pA terminator linked to the analyte HLA ORF. The expected sizes of the positive amplicons, 1 kb and 1.1 kb, indicate the generation of component B'. [Figure 47]Figure 47 - Selection of cells with targeted genomic integration of component C' into component B. a) GFP fluorescence signal 48 hours after transfection with a plasmid encoding Cas9-P2A-GFP and a gRNA targeting the AAVS1 locus with component C' HLA-DRA*01:01 / HLA-DRB1*01:01 (left panel) or component C' HLA-DPA1*01:03 / HLA-DPB1*04:01 (right panel). Cells with GFP signal within the GFP+ gate were sorted as polyclonal population. b) Analyte HLA cell surface expression was observed in the two sorted polyclonal populations when labeled with 647 anti-HLA-DR,DP,DQ conjugated antibodies (grey histogram). Single cells showing high Alexa 647 anti-HLA-ABC signal and appearing within the right sort gate were sorted to establish monoclones. Signals detected from Alexa 647 anti-HLA-ABC labeled ACL-128 (HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell lines) (dotted histograms) and ARH wild-type cell lines (jet black histograms) served as controls. [Figure 48] Figure 48 - Phenotypic analysis of eAPC-p monoclones expressing analyte HLA class II proteins on their cell surface. Monoclonal populations were stained with Alexa 647 anti-HLA-DR,DP,DQ conjugated antibody and analyzed by flow cytometry (grey histograms). ACL-128 (HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell line) (dotted histograms) and ARH wild-type cell line (full black histograms) served as controls. ACL-341 and ACL-350 monoclonal cell lines showed stronger fluorescent signals compared to the HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell line controls, demonstrating that each line expresses its analyte aAPX, HLA-DRA*01:01 / HLA-DRB1*01:01 or HLA-DPA1*01:03 / HLA-DPB1*04:01, respectively, and thus is an eAPC-p cell line. [Figure 49]Figure 49 - eAPC-p monoclones generated by RMCE incorporation of analyte HLA class I proteins a) eAPC-p monoclonal populations ACL-421 and ACL-422 lost BFP fluorescence (grey histograms). The parental eAPC cell line ACL-385 (jet black histograms) and the BFP negative ARH wild type cell line (dashed histograms) served as controls. b) When labeled with PE-Cy5 anti-HLA-ABC conjugated antibodies, the eAPC-p monoclonal populations ACL-421 and ACL-422 achieved HLA-A*02:01 expression (grey histograms). The parental ACL-385 HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell lines (dashed histograms) and the ARH wild type cell line (jet black histograms) served as negative and positive PE-Cy5 anti-HLA-ABC labeling controls, respectively. These results strongly suggested that RMCE occurred successfully between the BFP ORF and the HLA-A*02:01 ORF in both the ACL-421 and ACL-422 cell lines. [Figure 50] FIG. 50 - Genetic characterization of a selection of monoclones confirmed HLA-A*02:01 integration by RMCE. The 630 bp amplicon demonstrated the presence of HLA-A2 in monoclones ACL-421 and 422, but not in the control line ACL-128. [Figure 51]Figure 51 - Phenotypic analysis of eAPC-pa monoclones expressing analyte HLA class I proteins on the cell surface and expressing aAM. a) eAPC-p monoclonal populations were stained with PE-Cy5 anti-HLA-ABC conjugated antibody and analyzed by flow cytometry (grey histograms). ACL-128, HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell lines (dotted histograms) served as controls. ACL-321 and ACL-331 monoclonal cell lines showed stronger fluorescent signals compared to the controls, proving that each line expressed its analyte aAPX, HLA-A*02:01 or HLA-B*35:01 ORF, respectively, and thus was an eAPC-p cell line. b) eAPC-pa monoclonal populations were assessed by flow cytometry for GFP fluorescence (grey histograms). ACL-128, HLA-ABCnull and HLA-DR,DP,DQnull eAPC cell lines (dotted histograms) served as controls. ACL-391 and ACL-395 monoclonal cell lines showed stronger fluorescent signals compared to the controls, demonstrating that each line expresses the analyte aAM selection marker, thus suggesting aAM expression in cell lines that also express the HLA-LA-A*02:01 or HLA-B*35:01 ORF, respectively. Thus, ACL-391 and ACL-395 were eAPC-pa lines. [Figure 52] FIG. 52 - Genetic characterization of monoclones containing components 1D and / or 1B. Two tables show a summary of the genetic characterization of eAPCs generated containing component 1B or components 1B and 1D, respectively. [Figure 53]Figure 53 - eACP-p constructed in one step, where component 1C' encodes a single HLAI ORF. eAPC-p was created by RMCE by electroporation of cell line ACL-402 carrying a plasmid encoding the expression of Tyr-recombinase Flp (V4.1.8) together with a plasmid encoding an aAPX selected from one component 1C' HLA-A*02:01 (V4.H.5) or HLA-A*24:02 (V4.H.6). Ten days after electroporation, individual cells positive for HLAI surface expression and reduced fluorescent protein signal RFP encoded by component 1B selection marker were selected. The resulting monoclonal eAPC-p lines were analyzed by flow cytometry in parallel with the parental eAPC lines, and two examples are shown: a) The outgrown individual monoclonal lines (ACL-900 and ACL-963) were assayed by flow cytometry for loss of RFP, presence of BFP and gain of HLA-ABC (aAPX). The left hand plot shows BFP vs. RFP, with the parental cells possessing both BFP and RFP (Q2, top plot, 99.2%), whereas both ACL-900 (Q3, middle plot, 99.7%) and ACL-963 (Q3, bottom plot, 99.9%) lacked RFP signal, indicating that an integration couple had occurred between components 1B / 1C'. The right hand plot shows BFP vs. HLA-ABC (aAPX), where both ACL-900 (Q2, top plot, 99.2%) and ACL-963 (Q2, bottom plot, 99.2%) show strong signals for HLA-ABC (aAPX), further reinforcing the 1B / 1C' integration. Crucially, both ACL-900 and ACL-963 have strong BFP signals, suggesting that component 1D remains open and isolated from the component 1B / 1C' integration couple. b) To further characterize ACL-900 and ACL-963, as well as a third eAPC-p not presented in a), ACL-907, genomic DNA was extracted and PCR was performed with primers targeting adjacent and internal to component 1B' (Table 5, 8.B.3, 15.H.2) to selectively amplify only successful integration couple events.Comparison was made to the unmodified parental strain ACL-3, which lacks component 1 B. All three eAPC-p monoclones generated amplicon products specific for component 1B', whereas no products were detected in the ACL-3 reaction, confirming that a specific integration coupling event had occurred between components 1B and 1C'. [Figure 54]Figure 54 - eAPC-pa constructed in one step from eAPC-p, where component 1D' encodes a single analyte antigen molecule (aAM) ORF. Multiple eAPC-pa, in which the genomic acceptor site (component 1D) is targeted for integration by a primed gene donor vector (component 1E' comprising a single ORF encoding an aAM), were constructed in parallel from parental eAPC-p (ACL-905). eAPC-p (ACL-900, Example 8) were independently combined by electroporation with vectors encoding the expression of RMCE recombinase enzyme (Flp, V4.1.8) and each of component 1E' of V9.E.6, V9.E.7 or V9.E.8. Ten days after electroporation, individual eAPC-pa were selected and single cells (monoclones) were selected based on the signal reduction of the selection marker BFP for integration encoded by component 1D. The resulting monoclonal eAPC-pa lines were analyzed by flow cytometry in parallel with the parental eAPC lines, and three examples are shown. In addition, the resulting monoclones were also genetically characterized to confirm the integration couple events. a) Monoclones for eAPC-pa, ACL-1219, ACL-1227 and ACL-1233 were analyzed and selected for loss of BFP signal and retention of HLA-ABC signal by flow cytometry. BFP vs. SSC plots are displayed using the BFP-gate. An increased number of BFP events compared to the parental eAPC-p was observed, suggesting that the integration couple occurred between components 1D / 1E'. Single cells from the BFP-gate were selected, sorted and expanded. b) Selected monoclones for ACL-1219, ACL-1227, ACL-1233 were analyzed by flow cytometry to confirm loss of BFP and retention of HLA-ABC signal. A plot of BFP versus HLA-ABC is shown, and all three monoclones can be seen to have lost BFP signal compared to the parental eAPC-p (right-most plot), suggesting successful integration coupling events. c) To verify that the monoclones contained the correct fragment size for the aAM ORF, polymerase chain reaction was performed using primers targeting the aAM ORF and a representative agarose gel is shown.Results from two monoclones representing each aAM ORF are shown: lane 1: 2_log DNA marker, lanes 2-3: pp28 ORF (expected size 0.8 kb), lane 4: 2_log DNA marker, lanes 5-6: pp52 ORF (expected size 1.5 kb), lane 7: 2_log DNA marker, lanes 8-9: pp65 ORF (expected size 1.9 kb), lane 10: 2_log DNA marker. All monoclones analyzed had the expected amplicon size for the respective aAM, further suggesting that integration couples had occurred. [Figure 55-1]Figure 55 - Shotgun integration of multiple antigens into eAPC-p to generate a single-step pooled eAPC-p library A pooled library of eAPC-pa was generated by single-step integration into parental eAPC-p from a pool of primed component 1E vectors (component 1E') that collectively encode multiple aAM ORFs (HCMVpp28, HCMVpp52, and HCMVpp65), where each individual cell incorporates a single random analyte antigen ORF from the original vector pool into component 1D', such that each generated eAPC-pa expresses a single random aAM, but the pooled library of eAPC-pa collectively represents all of the aAM ORFs encoded in the original pooled vector library. A library of eAPC-pa was generated by electroporation by combining eAPC-p (ACL-905, aAPX:HLA-A*02:01) with a pooled vector library comprising individual vectors (V9.E.6, V9.E.7 and V9.E.8) encoding one ORF of HCMVpp28, HCMVpp52 or HCMVpp65, mixing at a molecular ratio of 1:1:1. The resulting eAPC-pa population was analyzed and selected in parallel with the parental eAPC-p line by flow cytometry. a) 10 days after electroporation, putative eAPC-pa cells (transfectants) were analyzed and selected by flow cytometry in parallel comparison with the parental line (ACL-905). The plot shows BFP vs. SSC gated on the BFP population, where an increase in BFP-cells is observed in the BFP-gate compared to the parental line. Bulk cells were sorted to form transfectants based on the BFP- gate (referred to as ACL-1050). b) After expansion, ACL-1050 cells were analyzed for loss of BFP by flow cytometry. The plot shown is BFP vs. SSC, where ACL-1050 was enriched to 96.4% BFP-, whereas the parental line was ~4% BFP-. Single cells were subsequently sorted from the BFP- population of ACL-1050. [Figure 55]Figure 55 - Shotgun integration of multiple antigens into eAPC-p to generate a single-step pooled eAPC-p library A pooled library of eAPC-pa was generated by single-step integration into parental eAPC-p from a pool of primed component 1E vectors (component 1E') that collectively encode multiple aAM ORFs (HCMVpp28, HCMVpp52, and HCMVpp65), where each individual cell incorporates a single random analyte antigen ORF from the original vector pool into component 1D', such that each generated eAPC-pa expresses a single random aAM, but the pooled library of eAPC-pa collectively represents all of the aAM ORFs encoded in the original pooled vector library. A library of eAPC-pa was generated by electroporation by combining eAPC-p (ACL-905, aAPX:HLA-A*02:01) with a pooled vector library comprising individual vectors (V9.E.6, V9.E.7 and V9.E.8) encoding one ORF of HCMVpp28, HCMVpp52 or HCMVpp65, mixed at a molecular ratio of 1:1:1. The resulting eAPC-pa population was analyzed and selected in parallel with the parental eAPC-p line by flow cytometry. c) To prove that polyclonal ACL-1050 comprises a mixture of cells encoding HCMVpp28, HCMVpp52 and HCMVpp65, 12 monoclones were randomly selected, expanded and used for genetic characterization. Cells were characterized by PCR using primers targeted to the aAM ORF (component 1D') to amplify and detect integrated aAM. All 12 monoclones screened by PCR had detectable amplicons of one of the expected sizes: pp28 (0.8 kb), pp52 (1.5 kb), or pp65 (1.9 kb). In addition, all three aAMs were represented in the 12 monoclones. In comparison, amplicons from three separate monoclones with known aAMs were amplified in parallel as controls; all three controls produced amplicons of the correct size for pp28 (0.8 kb), pp52 (1.5 kb), and pp65 (1.9 kb).Thus, it is established that the pool contains eAPC-pa, where each cell has a single randomly selected aAM from the original pool of three vectors. [Figure 56]Figure 56 - Proof of eTPC-t generation from parental eTPC. A model TCRα / β pair (JG9-TCR), with known specificity for the HCMV antigen presented on HLA-A*02:01, was selected for integration into the eTPC parental line. The JG9-TCR-α ORF was cloned into the component 2E' context and the JG9-TCR-β into the component 2C' context. The eTPC-t was generated by RMCE by transfection of the component 2C' and 2E' plasmids and a construct encoding the flp recombinase into the eTPC line ACL-488, which harbors two genomic integration sites 2B and 2D (encoding the reporters BFP and RFP, respectively). Ten days after transfection, individual cells with reduced BFP and RFP signals encoded by the component 2B and 2D selection markers were sorted as single cells. The resulting monoclonal eTPC-t ACL-851 was analyzed in parallel with the parental eTPC. Examples are shown. a) and b) The parental eTPC cell line ACL-488 and an example monoclonal were analyzed for BFP and RFP signals by flow cytometry. The plots show viable single cells displayed as BFP vs. RFP, and show that the eTPC cell line is positive for the selection markers present in components 2B and 2D (a) and the resulting monoclones have lost these markers as expected for an integration couple event between 2B / 2C and 2D / 2E (b). The ratio values represent the proportion of double positive cells in a) and double negative cells in b). c)-f) eTPC ACL-488 and the monoclonal eTPC-t ACL-851 were stained with antibodies against CD3 and TCRα / β (TCRab) and with an HLA multimer reactive agent specific for JG9-TCR (Dex HLA-A*02:01-NLVP), analyzed by flow cytometry and gated for viable single cells. The parental eTPC line showed no positive staining for either CD3 or TCR at the cell surface (c) and was negative for staining with HLA multimer reagents (d). In contrast, the resulting monoclones showed positive staining for both CD3 and TCR at the cell surface (e) and positive staining with multimer reagents specific for the expressed JG9-TCR.The ratio values represent the percentage of CD3 / TCRab double positive cells in c) and e) and CD3 / HLA-multimer double positive cells in d) and f). g) Genomic DNA was prepared from monoclonal eTPC-t ACL-851 and subjected to PCR with primers specific for JG9-TCR-α chain encoded by component 2D' or JG9-TCR-β chain encoded by component 2B'. PCR products were separated on agarose gel and observed as expected band sizes. h) Genomic DNA was prepared from monoclonal eTPC-t ACL-851 and subjected to digital drop PCR with primers and probes specific for JG9-TCR-α chain encoded by component 2D' or JG9-TCR-β chain encoded by component 2B'. A reference amplicon primer / probe pair for the intron of TCR alpha constant (TRAC) was included. The table shows the ratio of the references to TCR alpha and TCR beta. A ratio of around 0.33 indicates that a single copy of each of the TCR α and β chains is present in eTPC-t strain ACL-851, ie, eTPC-t strain ACL-851 is a triploid strain. [Figure 57]Figure 57 - Proof of eTPC-x reversion from eTPC-t. The parental eTPC-t cell line ACL-851, expressing TCR α and β chains at sites 2D' and 2B', respectively, was reverted to an eTPC-x line by replacing component 2D' with a donor vector (component 2Z) encoding GFP. Component 2Z contains recombinase heterospecific F14 / F15 sites flanking the GFP ORF and was therefore compatible with component 2D'. The eTPC-t line ACL-851 was transfected with component 2Z together with a construct encoding the flp recombinase. Seven days after transfection, individual cells positive for GFP signal were selected and expanded as monoclones. The resulting monoclonal eTPC-x lines were analyzed by flow cytometry in parallel with the parental eTPC-t. An example is shown. a) and b) Monoclonal eTPC-x ACL-987 derived from parental eTPC-t ACL-851 was analyzed by flow cytometry together with the parental line for GFP expression. The plots show the SSC vs. GFP parameters of gated live single cells. The parental cell line has no GFP expression (a), whereas monoclonal ACL-987 has acquired GFP as expected (b), indicating that the TCRα ORF has been exchanged for the GFP ORF. C) and D) Monoclonal eTPC-x ACL-987 derived from parental ACL-851 together with parental eTPC-t ACL-851 were stained with antibodies against CD3 and TCRab and analyzed by flow cytometry. The plots show the CD3 vs. TCRab parameters gated on live single cells. The parental cells showed positive staining for both CD3 and TCRab (c), whereas the derived monoclones showed negative staining for both (d), confirming the loss of the TCRα ORF in the derived eTPC-x lines. [Figure 58]Figure 58 - Demonstration of shotgun integration into eTPC-x to generate a pool of eTPC-t. The eTPC-t pool was generated from a parental eTPC-x line expressing a single TCR β chain in component 2B'. The eTPC-x line expressed GFP as a reporter at the available site 2D. A pool of 64 variant TCR α chains was constructed, including the parental chains. The parental TCR chain pair represents JG9-TCR with known specificity for HCMV antigens presented in HLA-A*02:01. The pool of component 2E was transfected into the parental eTPC-x ACL-987 together with a construct encoding the flp recombinase. Polyclonal lines were selected by sorting for GFP positive cells 10 days after transfection. The resulting ACL-988 polyclonal eTPC-t were then sorted based on negative staining for GFP and positive or negative staining for HLA multimer reagent (DEX HLA-A*02:01-NLVP). Recovered single cells were sequenced to identify the encoded TCR-α chain and compared with parallel analysis of each of the TCR-α chain variants paired with the native TCR-β chain for staining with HLA multimer reagent specific for the parental TCR chain pair. a) and b) The parental eTPC-x ACL-987 line and the resulting polyclonal eTPC-t ACL-988 line were analyzed by flow cytometry for GFP expression. The plot displays the SSC vs. GFP parameters of viable single cells. The parental cell line showed a positive signal for GFP, indicating an intact component 2D (a). The derived polyclonal lines were semi-positive and semi-negative for GFP (b), indicating that half of the cells in the polyclonal population may have exchanged the GFP ORF for the TCRα ORF at D to form component 2D'. c) and d) The parental eTPC-x ACL-987 line and the resulting polyclonal eTPC-t ACL-988 line were stained with CD3 antibody and HLA multimers specific for the parental JG9-TCR (DEX HLA-A*02:01-NLVP) and analyzed by flow cytometry. The plots display the CD3 vs. HLA multimer parameters of viable single cells.The parental cell line is negative for both CD3 and HLA multimer staining (c). D) Left panel shows gated GFP negative events, right panel shows GFP positive events. Only GFP negative events where component 2D was converted to D' show positive staining for CD3, a subset of which shows positive staining for HLA multimer. Single cells were sorted by gating with HLA multimer negative and positive gates, and the ORF integrated in component 2D' was sequenced to determine the identity of the TCRα ORF. e) All 64 JG9-TCR-α variants were cloned into expression constructs such that each could be transfected independently into the parental eTPC-x (ACL-987). The relative staining units (RSU) for each were determined against the HLA-A*02:01-NLVP tetramer reactant. RSU was calculated as the ratio of the mean fluorescence intensity (MFI) of the HLA-A*02:01-NLVP tetramer signal for the CD3 positive population to the CD3 negative population and is an indication of the binding strength of each TCR chain pair variant to the HLA multimer reactants. Each point plotted in figure e) represents the RSU observed for each of the 64 variants. Open circles correlate to sequenced cells recovered from the GFP negative / HLA multimer positive gate. Open triangles correlate to sequenced cells recovered from the GFP negative / HLA multimer negative gate. [Figure 59]Figure 59 - Functional proof of component 2F in eAPC:eTPC system with eAPC-p and exogenous aAM. eTPC-t cell line (ACL-1277) with component 2F, where the TCR chains in components 2B' and 2D' encode a TCR pair specific for the HMCV antigenic peptide NLVPMVATV presented in HLA-A*02:01. The component 2F reporter was RFP. This eTPC-t was contacted with various eAPC lines differing in -p characteristics in the presence and absence of model peptide antigen for 24 hours, and the contacted cultures were analyzed by flow cytometry. Flow cytometry histogram plots show event counts versus RFP signal of viable single T cells identified by antibody staining for specific surface markers not presented by eAPC. a) and b) eAPC-p cells (ACL-209) expressing only HLA-A*02:01 were pulsed with NLVPMVATV (a) or VYALPLKML (b) peptides and then co-cultured with eTPC-t for 24 hours. c) and d) eAPC-p cells (ACL-963) expressing only HLA-A*24:02 were pulsed with NLVPMVATV (c) or VYALPLKML (d) peptides and then co-cultured with eTPC-t for 24 hours. e) eAPC-p cells (ACL-209) expressing only HLA-A*02:01 were left without peptide pulsing and then co-cultured with eTPC-t for 24 hours. f) eAPC parent cells (ACL-128) that do not express HLA on the cell surface were pulsed with NLVPMVATV and then co-cultured with eTPC-t for 24 hours. RFP signal was significantly increased in eTPC-t ACL-1277 only in the presence of HLA-A*02:01 expressing eAPC-p pulsed with NLVPMVATV (representing a known target of the expressed TCR). The gates and values of the histograms reflect the percentage of events in the RFP positive and RFP negative gates. This shows the specific response of component 2F to binding of TCRsp expressed by eTPC-t to cognate HLA / antigen (aAPX:aAM). [Figure 60]Figure 60 - Functional proof of component 2F in eAPC:eTPC system with eAPC-pa integrated with aAM. eTPC-t cell line (ACL-1150) with component 2F, where the TCR chains in components 2B' and 2D' encode a TCR pair specific for the HMCV antigenic peptide NLVPMVATV presented in HLA-A*02:01. The component 2F reporter was RFP. This eTPC-t was contacted with various eAPC lines with different -p characteristics for 24 hours in the absence of exogenous antigen. a) eAPC-pa line (ACL-1044) expressing HLA-A*02:01 and the full-length ORF of HCMV protein pp52. pp52 does not contain the antigenic sequence recognized by JG9-TCR. b) eAPC-pa strain (ACL-1046) expressing HLA-A*02:01 and the full-length ORF of HCMV protein pp65. pp65 contains the antigenic sequence recognized by JG9-TCR when presented in HLA-A*02:01. c) eAPC-pa strain (ACL-1045) expressing HLA-B*07:02 and the full-length ORF of HCMV protein pp52. pp52 does not contain the antigenic sequence recognized by JG9-TCR. d) eAPC-pa strain (ACL-1048) expressing HLA-B*07:02 and the full-length ORF of HCMV protein pp65. pp65 contains the antigenic sequence recognized by JG9-TCR when presented in HLA-A*02:01. After independent co-culture of each eAPC-pa line with eTPC-t for 48 hours, RFP expression in eTPC-t was measured by flow cytometry. RFP signal was significantly increased in eTPC-t ACL-1150 only when it was contacted with eAPC-pa ACL-1046. This was the only eAPC-pa in which both the antigenic peptide sequence encoded by the integrated aAM ORF and the correct HLA restriction were recognized. The gates and values of the histogram reflect the percentage of events in the RFP positive and RFP negative gates. This shows the specific response of component 2F to the binding of TCRsp expressed by eTPC-t with cognate HLA / antigen (aAPX:aAM). EXAMPLES
[0106] Materials and Methods All cell lines used in this application are either ARH or HEK293 background. They are designated with a number suffix "ACL". A summary of the cell lines used in this application is shown in Table 1.
[0107] Transfection of cells One day before transfection / electroporation, cells were cultured at 1.2–1.4 × 10 6 Cells were seeded at a density of 1000 cells / 60 mm dish in 90% DMEM + 2 mM L-glutamine + 10% HI-FBS (Life Technologies). The next day, 65% confluent cells were transfected with a total of 5 μg DNA and jetPEI® (Polyplus transfection reagent, Life Technologies) (N / P ratio 6). The medium was replaced before transfection. DNA and jetPEI® stock solutions were diluted in sterile 1 M NaCl and 150 mM NaCl, respectively. The final volume of each solution was 50% of the total mixed volume. The PEI solution was then added to the diluted DNA and the mixture was incubated for 15 min at room temperature. Finally, the DNA / PEI mixture was carefully added to the 60 mm dish, without disrupting the cell film. The cells were incubated (at 37°C, 5% CO2, 95% relative humidity) for 48 h before DNA delivery marker expression analysis. The medium was replaced before transfection.
[0108] Fluorescence-activated cell sorting (FACS) Single cell or polyclonal sorting was achieved by standard cell sorting methods using a BD Influx instrument. Briefly, ACL cells were cultured using TrypLE TMAfter harvesting with Express Trypsin (ThermoFisher Scientific) and resuspending in an appropriate volume of DPBS 1× (Life Technologies), cell sorting was performed in DMEM 1× medium containing 20% HI-FBS and anti-Anti 100X (Life Technologies). Table 2 summarizes the antibodies and multimers used for FACS in this application.
[0109] [Table 1]
[0110] [Table 2]
[0111] HLA-A in eAPC cell lines * Flp-mediated integration of 02:01 sequences The eAPC cells were transfected with a vector encoding Flp, DNA encoding a marker for tracking delivery (a vector encoding GFP), and HLA-A * Electroporated with vector containing 02:01. HLA-A * The 02:01 sequence also encoded a linker and a 3xMyc-tag at the 3' end. The electroporation conditions used were 258V, 12.5ms, 2 pulses, 1 pulse interval. The ratio of each integration vector to Flp-vector was 1:3. To set the gate for GFP selection after 2 days, cells electroporated with GFP-vector only and cells not electroporated, respectively, were used as controls. The next day (2 days after electroporation), cells were analyzed and sorted based on GFP expression. Cells were sorted using a BD Influx cell sorter. Three days after electroporation, sorting based on GFP expression was performed to enrich for electroporated cells. Seven to eight days after electroporation, cells were harvested and surface stained for HLA-ABC expression. BFP+ve RFP-ve HLA+ve cells were single-cell sorted to become monoclonal. To genotype the cells, PCR reactions were performed using 100 ng of DNA as template to verify whether integration had occurred at the expected integration site. The PCR products were run on a 1% agarose gel using a forward primer (Pan_HLA_GT_F1) targeting the integration cassette and a reverse primer (SV40pA_GT_R1) targeting just outside the integration site.
[0112] Flp-mediated integration of HCMV ORF sequences in eAPC-p cell lines eAPC-p cells were electroporated with a vector encoding Flp, DNA encoding a marker to track delivery (vector encoding GFP) and vector containing HCMV pp28, pp52 or pp65 aAM-ORF. The HCMV-ORF sequence also encoded a linker and a 3×Myc-tag at the 3′ end. The electroporation conditions used were 258V, 12.5ms, 2 pulses, 1 pulse interval. The ratio of each integration vector to Flp-vector was 1:3. To set the gate for GFP sorting after 2 days, cells electroporated with GFP-vector only and cells not electroporated were used as controls, respectively. The next day (2 days after electroporation), cells were analyzed and sorted based on GFP expression. Cells were sorted using a BD Influx cell sorter.
[0113] Flp-mediated shotgun integration of three HCMV ORF sequences in eAPC-p cell line eAPC-p cells were electroporated with a vector encoding Flp, DNA encoding a marker to track delivery (vector encoding GFP) and vectors containing HCMV pp28, pp52 or pp65 aAM-ORF. The HCMV-ORF sequence also encoded a linker and 3xMyc-tag at the 3' end. The electroporation conditions used were 258V, 12.5ms, 2 pulses, 1 pulse interval. For shotgun integration, the vectors containing HCMV-ORF were pooled in a ratio of 1:1:1 and the mixture was electroporated into eAPC-p cells. The resulting eAPC-pa cells were polyclonal. Individual monoclonal cells were selected and genetically characterized to demonstrate that the polyclone was composed of cells containing all three HCMV-ORFs.
[0114] Genetic characterization of monoclones PCR reactions assessing RMCE-integration of HCMV ORFs into component D Primers used to assess HCMV ORF integration annealed to the linker (forward primer 10.D.1) and the EF1aplha promoter (reverse primer 15.H.4). Expected sizes were 0.8 kb for pp28, 1.5 kb for pp52, and 1.9 kb for pp65. PCR products were run on 1% agarose gels in 1×TAE buffer using a PowerPac Basic (Bio-Rad), stained with 10,000 dilution of sybersafe, and analyzed using Fusion SL (Vilber Lourmat).
[0115] [Table 3]
[0116] [Table 4]
[0117] RMCE between pairwise embedded couples For RMCE integration, cells were transfected with 0.6 μg of DNA vector (V4.I.8) encoding FLP, 2 μg of components C / Y, 2 μg of components E / Z, and 0.4 μg of DNA encoding a marker to track DNA delivery. Two days after transfection, cells positive for either the DNA delivery marker GFP or RFP positive were sorted by FACS. Four to ten days after transfection, individual cells showing a decrease in the fluorescent protein signal encoded by the component D and B selection markers were sorted by FACS. With the exception of the generation of ACL-987, individual cells showing GFP positivity were sorted by FACS.
[0118] Transient expression of TCR chain pairs to characterize the RSU For transient expression, cells were transfected with DNA vectors encoding FLP (V4.I.8), JG9-TCR-α variants (VP.7751.RC1.A1 to VP.7751.RC1.H8), JG9-TCR-β WT chain (V3.C.5) and DNA vector vehicle (V1.C.2). Two days after transfection, all cells were transfected with DNA vectors encoding HLA-A * Staining was performed with 02:01-NLVP tetramer and anti-CD3 antibody. RSU was used to determine the HLA-A binding affinity for CD3 positive populations versus CD3 negative populations. * The MFIs were calculated as ratios of the mean fluorescence intensity (MFI) of the 02:01-NLVP tetramer signal and were an indication of the binding strength of each TCR chain pair to the variant.
[0119] HLA multimer staining Cells were stained with HLA-multimer reagents for 10 minutes on ice, followed by staining with CD3 and / or TCRab antibodies. Specific cell fluorescence signatures detected by the BD Influx instrument are shown in Table 6. For single cell sorting for monoclonal generation, cells displaying the phenotype of interest were placed in 96-well plates containing 200 μl of growth medium. One to two plates were sorted per sample. Polyclonal cell sorting was performed using the cell sorter Influx in FACS tubes containing medium.TM (BD Biosciences) using a bimodal sorting setup. For molecular characterization, single cells of the JG9-TCR-α variant were sorted and placed into PCR plates prefilled with 5 μl of nuclease-free water, and specimens were snap-frozen until further processing.
[0120] Genomic DNA extraction for genetic characterization DNA was diluted to 5 × 10 using the QIAamp DNA Mini Kit (Qiagen). 6 DNA was extracted from cells and stored in 1x TE (10 mM Tris pH 8.0 and 0.1 mM EDTA).
[0121] [Table 5]
[0122] PCR reactions to evaluate RMCE-integration of TRA-ORF and TRB-ORF into components 2B or 2D The primers used to assess TCR-α integration annealed to the TRAC segment (forward primer 1.F.7) and to the sv40pA terminator (reverse primer 15.H.2), a pre-existing part of the genomic acceptor site. Expected size 566 bp. The primers used to assess TCR-β integration annealed to the TRBC segment (forward primer 1.F.9) and to the sv40pA terminator (reverse primer 15.H.2), a pre-existing part of the genomic acceptor site. Expected size 610 bp. PCR products were run on 1% agarose gels in 1×TAE buffer using a PowerPac Basic (Bio-Rad), stained with 10,000 dilution of sybersafe, and analyzed using Fusion SL (Vilber Lourmat).
[0123] [Table 6]
[0124] [Table 7]
[0125] ddPCR reaction to evaluate the copy number of TRA-ORF and TRB-ORF in the genome after DNA delivery DNA of selected ACL-851 monoclones was analyzed by using specific primers and probes targeting the TCR_ORF C segment of interest (TRAC). The primers and probes used to assess TRA-ORF copy number (forward primer 1.F.7, reverse primer 1.F.8, and probe 1.G.1) were annealed to the TRAC segment. The primers and probes used to assess TRB-ORF copy number (forward primer 1.F.9, reverse primer 1.F.10, and probe 1.G.2) were annealed to the TRB-C segment. In all cases, the reference gene (TRAC) was screened simultaneously to determine chromosomal copy number using primers 10.A.9 and 10.A.10 and fluorescent probe 10.B.6 conjugated with HEX. From the integration copy number, HEK293 cells were considered triploid for the reference gene (TRAC). Prior to digital drop PCR, DNA was digested with MfeI (NEB) to separate tandem integrations. Reaction set-up and cycling conditions were performed using a QX200 TM Droplet Reader and Droplet Generator and C1000 Touch TM ddPCR using a deep-well Thermal cycler (Bio-Rad) TM The protocol for Supermix for Probes (No dUTP) (Bio-Rad) was followed. QuantaSoft TM The software was used to acquire data, using Channel 1 for detection of FAM and Channel 2 for HEX.
[0126] [Table 8]
[0127] [Table 9]
[0128] Sequencing of TCR α and β chains from single T cells FACS-sorted individual eTPC-t cells were subjected to a two-step amplification process with V-region-specific primer collections for TRA and TRB, respectively, followed by paired nested PCR reactions that yielded TRA and TRB amplicons for sequence analysis. This procedure has been previously described (Han et al., Nat Biotechnol. 2014 32(7): 684-692). The following materials were used in the described procedure:
[0129] [Table 10]
[0130] Functional Proof of Component F eTPC-t and APC cells were cultured at 0.2 × 10 6 ~1.5×10 6 The cells were routinely cultured at 37°C, 90% relative humidity and 5% CO2 for 100 cells / ml. Peptide NLVPMVATV was synthesized by Genescript and received lyophilized. Primary stocks of peptides were suspended in 10% DMSO and stored at -80°C. Working stocks were prepared fresh in complete medium (50x concentrated) at 50 μM. The following HLA-A * The following eAPC-p presenting HLA-B*07:02 (ACL-906), or aAPX and exogenous aAM, HLA-A * 02:01+HCMVpp52(ACL-1044) or HLA-A * 02:01+HCMVpp65(ACL-1046) or HLA-B *07:02+HCMVpp52(ACL-1045) or HLA-B * eAPC-pa with 07:02+HCMVpp65 (ACL-1048) or parental eAPC (ACL-128) were used. Two different eTPC-t cell lines were used: the first eTPC-t, ACL-1277 (component A), was engineered to have two unique genomic acceptor sites, utilized native CD3 expression and had a genomic two-component synthetic response element (component F, RFP reporter) (see Example 14). The second eTPC-t, ACL-1150 (component A), was engineered to have two unique genomic acceptor sites, utilized native CD3 expression and had a genomic one-component synthetic response element (component F, RFP reporter) (see Example 15). Both eTPC-ts expressed HLA-peptide complexes (HLA), HLA-A, and HLA-P in components 2B' and 2E'. * 02:01-NLVPMVATV was loaded with a TCR chain ORF encoding a specific TCR pair.
[0131] Antigen pulsing procedure Actively proliferating cultures of eAPC cells (0.4–1.0 × 10 6 The cells were then suspended in 100 ml of PBS (10–200 ml) and samples were taken and counted to determine the cell concentration. One million cells were then harvested and washed once with Dulbecco's phosphate-buffered saline (DPBS, Gibco) before being incubated at a cell concentration of 1–2 × 10 6 Cells were suspended in complete medium with or without peptide at 1 μM cells / ml. Cells were incubated in 24-well culture plates under standard culture conditions for 2 hours. After 2 hours, cells were harvested, pelleted by centrifugation (400 rcf, 3 min) and washed 3×10 ml with DPBS. Cells were then diluted in complete medium at 0.2×10 6 Suspended at 100 cells / ml.
[0132] eTPC-t collection Actively proliferating cultures of eTPC-t cells (0.4–1.0 × 10 6The cells were then suspended at 0.4 × 10 cells / ml, a sample taken, and counted to determine the cell concentration. Cells were harvested, washed once with DPBS, and then diluted at 0.4 × 10 cells / ml in complete medium. 6 cells / ml (for endogenous assays) or 0.6 x 10 6 Cells were suspended at a concentration of 100 cells / ml (for exogenous assays).
[0133] Contact of eTPC-t and eAPC with exogenous antigenic molecules in the eTPC:eAPC system To each well of a 96-well round-bottom plate, 50 μl of complete medium, 50 μl of eAPCs, followed by 50 μl of eTPC-t were added, for a 1:3 ratio of approximately 10,000 eAPCs and 30,000 eTPC-t, yielding approximately 0.27 × 10 6 The total cell concentration was 1000 cells / ml. The cell mixture was then incubated under standard culture conditions for approximately 24 hours.
[0134] Contact of eTPC-t and eAPC with endogenous antigenic molecules in the eTPC:eAPC system To each well of a 96-well round-bottom plate, 50 μl of complete medium, 50 μl of eAPCs, followed by 50 μl of eTPC-t were added, for a 1:2 ratio of approximately 10,000 eAPCs and 20,000 eTPC-t, yielding approximately 0.2 × 10 6 The total cell concentration was 1000 cells / ml. The cell mixture was then incubated under standard culture conditions for approximately 48 hours.
[0135] Staining and analysis After 24 or 48 hours of incubation, cells were harvested, transferred into 0.75 ml V-bottom Micronic tubes, washed once with 500 μl DPBS, and then stained with a dead cell marker (DCM-APC-H7) as follows: To each well, 25 μl of staining solution was added, the cells were suspended by mixing, and then incubated for 15-20 minutes. The staining solution consisted of 0.5 μl of DCM-APC-H7 per 100 μl staining solution. After incubation, the cells were washed twice with 500 μl DPBS+2% FCS (wash buffer). The cells were then stained for surface markers unique to eTPC-t. To each well, 30 μl of staining solution was added, the cells were suspended by mixing, and then incubated for 30-45 minutes. The staining solution consisted of 2.5 μl of anti-myc-AF647 (clone 9E10, Santa Cruz Biotech) per 100 μl staining solution. After incubation, cells were washed twice with 500 μl of wash buffer, then suspended in 200 μl of wash buffer, and then analyzed by FACS on an LSR-Fortessa (BD Biosciences).
[0136] Working Example Example 1: Deletion of the APX gene family by targeted mutagenesis This example describes how targeted mutagenesis of genes encoding a family of antigen-presenting complexes (APXs) was achieved to generate a first trait of engineered antigen-presenting cells (eAPCs), the trait being the loss of surface expression of at least one member of the APX family. In this example, the targeted APX comprised three members of the major HLA class I family, HLA-A, HLA-B, and HLA-C, in the HEK293 cell line. The HEK293 cells were derived from human embryonic kidney cells that exhibit endogenous surface expression of HLA-ABC. Cytogenetic analysis demonstrated that this cell line had a near triploid karyotype, and thus HEK293 cells encoded three alleles of each HLA-A, HLA-B, and HLA-C gene. Targeted mutagenesis of HLA-A, HLA-B and HLA-C genes was performed using an engineered CRISPR / Cas9 system, in which Cas9 nuclease activity was targeted to the HLA-A, HLA-B and HLA-C loci by synthetic guide RNAs (gRNAs). Four to five unique gRNAs were designed to target conserved nucleotide sequences for each HLA gene locus, and the targeted site was directed toward the start of the gene coding sequence, because this was more likely to generate null alleles. The efficiency of the gRNAs to induce mutations at the targeted loci was determined, and the most efficient gRNAs were selected to target HLA-A, HLA-B and HLA-C null (HLA-ABC) alleles. null ) were selected to give rise to the HEK293 cell line.
[0137] Plasmids encoding optimal gRNAs targeting the HLA-A, HLA-B and HLA-C loci were transfected into HEK293 cells along with a plasmid encoding Cas9-P2A-GFP as described in Methods. Cells positive for Cas9-P2A-GFP plasmid uptake were FAC sorted based on GFP fluorescence 2 days after transfection (Fig. 38a). GFP-sorted cells were further propagated for 5+ days to allow sufficient time for gene editing events to occur and, in the case of deleterious mutations, for loss of expression of remaining endogenous HLAI proteins. After this growth period, cells were stained with pan-HLA-ABC antibody to identify cells with reduced HLA-ABC expression at the surface (Fig. 38b). Lack of pan-HLA-ABC antibody staining suggested that each HLA-A, HLA-B and HLA-C allele was mutated. Individual HLA-ABC negative cells were sorted and expanded into monoclonal populations.
[0138] HLA-ABC nullMonoclones were confirmed by lack of HLA-ABC surface expression. A subset of monoclones demonstrated lack of HLA-ABC surface expression. Three example monoclones, ACL-414, ACL-415 and ACL-416, are shown in FIG. 39. Further genetic characterization of monoclones lacking HLA-AI surface expression was performed by determining that the cell lines had underlying genetic mutations in all alleles of HLA-A, HLA-B and HLA-C genes (FIG. 40). Genetic characterization was performed by PCR using primers spanning the gRNA genomic target site for detection of amplicon size changes and / or primers used as templates for sequencing. FIG. 40 shows HLA-ABC containing genetic deletions in alleles of HLA-A, HLA-B and HLA-C genes detected by shorter PCR amplicons compared to the amplicon size of the base cell line (e.g., ACL-414). null Selection of monoclones is shown. In conclusion, genetically modified HEK293 cell lines (including ACL-414, ACL-415 and ACL-416) were demonstrated to lack surface expression of HLA-ABC and thus possessed the primary trait of engineered antigen-presenting cells (eAPCs).
[0139] Example 2: Generation of eAPCs containing component 1B In this example, component 1B is HLA-ABC null We describe a method to stably integrate into the monoclonal line ACL-414 to generate a second trait of eAPCs, which contains at least one genomic acceptor site for integration of at least one ORF, where the genomic acceptor site was a synthetic construct designed for recombinase-mediated cassette exchange (RMCE). In this example, the genomic integration site (component 1B) is composed of selected genetic elements: two unique heterospecific recombinase sites FRT and F3, which flank an ORF encoding the selectable marker blue fluorescent protein (BFP). The 5' side of the FRT site encoded the EF1a promoter, and the 3' side of the F3 site encoded the SV40 polyadenylation signal terminator. The advantage of locating non-coding cis-regulatory elements outside the heterospecific recombinase sites is that they are not required for the matched gene donor vector (component 1C). Thus, no transient expression of the encoded ORF is observed after cellular delivery of the gene donor vector. This makes the selection of successful RMCE more reliable, as cellular expression of the ORF from the gene donor vector likely occurs only after correct integration into component 1B, since the appropriate cis-regulatory elements are included (see example 6).
[0140] To facilitate stable genomic integration of component 1B into the genomic safe harbor locus (AAVS1), we constructed a plasmid in which the DNA element of component 1B was flanked by AAVS1 left and right homology arms, each of which consisted of >500 bp of sequence homologous to the AAVS1 genomic locus. Stable integration of component 1B was achieved by the process of homology-directed recombination (HDR) at the genomic safe harbor locus AAVS1. The ACL-414 cell line was transfected with a plasmid encoding an optimal gRNA targeting the AAVS1 locus, a plasmid encoding Cas9-P2A-GFP, and a plasmid encoding the component 1B genetic element flanked by AAVS1 left and right homology arms. Cells positive for Cas9-P2A-GFP plasmid integration were FACS-sorted based on GFP fluorescence 2 days after transfection (Figure 41a). GFP-sorted cells were further grown for more than 7 days to allow sufficient time for HDR to occur and for the loss of transient expression of the selection marker BFP. After this growth period, cells were analyzed on a FACS machine and individual BFP-positive cells were selected and expanded into monoclonal populations (Figure 41c).
[0141] Individual monoclonal lines were selected as eAPCs for single integration of component 1B into the desired AAVS1 genomic location based on maintained BFP expression. Cell lines ACL-469 and ACL-470 were monoclonal with maintained BFP expression (Fig. 42a and b). Genetic characterization was performed on DNA extracted from monoclones ACL-469 and ACL-470 to demonstrate their integration of component 1B into their genomes and that component 1B had integrated into the AAVS1 site (Fig. 43). Confirmation of genomic integration was determined by detection of PCR amplicons of the expected size using primers specific for component 1B (Fig. 43a). Confirmation of integration of component 1B into the AAVS1 site was determined by detection of PCR amplicons of the expected size using primers designed against AAVS1 genomic sequences distal to the region encoded by the homology arms and primers unique to the SV40 pA terminator encoded by component 1B (Fig. 43b). The copy number of component 1B was determined by digital drop PCR, where the number of component 1B and reference gene DNA molecules was measured and the ratio was calculated (Table 1). The monoclonal ACL-469 and ACL-470 contained component 1B and reference gene molecules in a ratio of 1 to 3. Considering that the basic HEK293 cell line has a near triploid karyotype, this demonstrates the single integration of component 1B into the ACL-469 and ACL-470 cell lines. In conclusion, the genetically modified ACL-469 and ACL-470 cell lines are HLA-ABC null and contains a single copy of a synthetic genomic acceptor site designed for RMCE, thus demonstrating the generation of eAPCs with a single synthetic integration acceptor site.
[0142] Example 3: Generation of eAPCs containing component 1B and component 1D In this example, component 1B and component 1D are HLA-ABC nullWe describe a method to stably integrate into the monoclonal line ACL-414 to generate a second trait of eAPCs, which contains two genomic acceptor sites for integration of at least one ORF, where the genomic acceptor sites were synthetic constructs designed for recombinase-mediated cassette exchange (RMCE). This example uses the same methods and components as described in Example 2, except for the addition of a second genomic acceptor site (component 1D). The component 1D genetic element consisted of two unique heterospecific recombinase sites, F14 and F15, distinct from component 1B. These sites flanked an ORF encoding the selectable marker red fluorescent protein (RFP). The 5' side of the F14 site encoded the EF1a promoter, and the 3' side of the F15 site encoded the SV40 polyadenylation signal terminator. As in Example 2, the component 1D genetic element was flanked by AAVS1 left and right homology arms, each consisting of >500 bp of sequence homologous to the AAVS1 genomic locus. Components 1B and 1D were assembled into AAVS1 as described in Example 2, except for the addition of a plasmid encoding the component 1D element to the transfection mix. Cells positive for Cas9-P2A-GFP plasmid uptake were FACS sorted based on GFP fluorescence 2 days after transfection (Figure 41b). GFP sorted cells were further expanded for 7 days or more, after which the cells were analyzed on a FACS machine and individual BFP and RFP positive cells were sorted and expanded into monoclonal populations (Figure 41d).
[0143] Individual monoclonal lines were selected as eAPCs for single integration of component 1B and single integration of component 1D into different AAVS1 alleles based on maintained BFP and RFP expression. Cell line ACL-472 was a representative monoclone with maintained BFP and RFP expression (Figure 42c). Genetic characterization was performed on DNA extracted from monoclone ACL-472 as described in Example 2, demonstrating that components 1B and 1D were integrated into their genomes and that both components were integrated into the AAVS1 site (Figure 43). The copy numbers of both components 1B and 1D were determined by digital drop PCR, where the number of components 1B, 1D and reference gene DNA molecules was measured and the ratio was calculated. Monoclone ACL-472 contained a ratio of 2 to 3 of components 1B and 1D molecules to reference gene molecules (Table 2). Considering that the basic HEK293 cell line has a near triploid karyotype, this demonstrates a single integration of component 1B and a single integration of component 1D into the ACL-472 cell line. In conclusion, the genetically modified ACL-472 cell line is HLA-ABC null and contains a single copy of the synthetic genomic acceptor sites component 1B and component 1D designed for RMCE, demonstrating the generation of eAPCs with two unique synthetic integration acceptor sites.
[0144] Example 4: eAPC-p, constructed in one step using one integration couple, with component 1C' encoding a single HLAI ORF This example describes a method to construct eAPC-p in one step using one integration couple, in which the genomic acceptor site (component 1B) is a native genomic site and the gene donor vector (component 1C') contains a single ORF encoding one analyte antigen-presenting complex (aAPX). In this example, the eAPC is a genetically modified ARH-77 cell line (designated ACL-128) in which two families of APX major HLA class I family and HLA class II are mutated. The base cell line ARH-77 is a B-lymphoblast derived from plasma cell leukemia that shows strong HLA-A, B, C and HLA-DR, DP, DQ cell surface expression. Cytogenetic analysis demonstrated that the base ARH-77 cell line has a near-diploid karyotype, but also shows a deletion of chromosome 6p21, the region that codes for the HLA locus. DNA sequencing of the ARH-77 locus confirmed that ARH-77 only codes for single alleles of HLA-A, HLA-B and HLA-C, as well as HLA-DRA, HLA-DRB, HLA-DQA, HLA-DQB, HLA-DPA and HLA-DPB gene families. HLA-ABC null and HLA-DR,DP,DQ null The cell line ACL-128 was generated by CRISPR / cas9 targeted mutagenesis with gRNAs targeting HLA-A, HLA-B and HLA-C, and HLA-DRA, HLA-DRB, HLA-DQA, HLA-DQB, HLA-DPA and HLA-DPB gene families using the methods described in Example 1. Surface labeling with pan-anti-HLA-ABC or pan-anti-HLA-DR,DP,DQ confirmed that ACL-128 lacks surface expression of both APX families (Figures 44b and 45 and Figure 47b, respectively).
[0145] In this example, the genomic acceptor site component 1B is a native AAVS1 genomic site, and targeted integration was achieved by HDR. A gene donor vector (component 1C) was matched to component 1B, with component 1C encoding AAVS1 left and right homology arms, each consisting of >500 bp of sequence homologous to the AAVS1 genomic locus. Between the AAVS1 left and right homology arms, the plasmid encoded a CMV promoter and an SV40 terminator. An aAPX of interest was cloned between the promoter and terminator to generate component 1C'. In this example, component 1C' contains one aAPX, HLA-A *24:02 or HLA-B * -07:02 (respectively, component 1C' HLA-A*24:02 and component 1C' HLA-B*-07:02 (called ". The method to construct eAPC-p was by HDR-induced integration of component 1C' into component 1B to generate component 1B'. Cell line ACL-128 was electroporated with plasmids encoding optimal gRNAs targeting the AAVS1 locus, Cas9-P2A-GFP and component 1C'. Cells positive for Cas9-P2A-GFP plasmid uptake were FAC-sorted 2 days after electroporation based on GFP fluorescence (Figure 44a). GFP-sorted cells were further grown for 7 days or more to allow sufficient time for HDR to occur and for the loss of transient expression of aAPX. After this growth period, cells were stained with pan-HLA-ABC antibody to identify cells that had acquired surface expression of analyte HLA (Figure 44b). The presence of pan-HLA-ABC antibody staining indicated that the analyte HLA ORF encoded by component 1C' had been integrated into the genome. Individual HLA-ABC positive staining cells were sorted and expanded into eAPC-p monoclonal populations.
[0146] Individual monoclonal lines were selected as eAPC-p based on maintained analyte HLA surface expression and integration of the analyte ORF into the genomic acceptor site (creating component 1B'). Cell lines ACL-321 and ACL-331 each express HLA-A. * 24:02 or HLA-B *Representative monoclones maintained analyte HLA surface expression at -07:02 (Figure 45). Genetic characterization was performed on DNA extracted from selected monoclones ACL-321, ACL-327, ACL-331 and ACL-332, demonstrating that their genomes had integrated component 1C' and that the integration occurred at the AAVS1 genomic acceptor site, generating component 1B' (Figure 46). Confirmation of genomic integration was determined by detection of a PCR amplicon of the expected size using primers specific for component 1C' (Figure 46a). The presence of component 1B' was confirmed by detection of a PCR amplicon of the expected size using primers designed against AAVS1 genomic sequences distal to the region encoded by the homology arms and unique to the SV40 pA terminator linked to the analyte HLA ORF (Figure 46b). In conclusion, aAPX and HLA-A * 24:02 or HLA-B * Generation of genetically modified ACL-321 and ACL-331 cell lines containing a copy of the -07:02 ORF within the genomic acceptor site component 1B' resulted in the analyte aAPX being the only major HLA class I member expressed on the cell surface, thus demonstrating the generation of two defined eAPC-p cell lines using a multicomponent system.
[0147] Example 5: eAPC-p, in which component 1C' encodes a paired HLAII ORF, constructed in one step using one integration couple In this example, we describe a one-step construction of eAPC-p using an integration couple, in which the genomic acceptor site component 1B was the native genomic site and the gene donor vector (component 1C') comprised a single ORF encoding two aAPX chains. This example utilized eAPC, ACL-128 and component 1B, all as defined in Example 4. However, component 1C' does not target HLA-DRB1 * HLA-DRA linked to the 01:01 allele by a viral self-cleaving peptide element *01:01 allele, or HLA-DPB1 * 04:01 HLA-DPA1 allele linked by a viral self-cleaving peptide element * Each contained a single ORF encoding the 01:03 allele (component 1C' HLA-DRA*01:01 / HLA-DRB1*01:01 and component 1C' HLA-DPA1*01:03 / HLA-DPB1*04:01 The viral self-cleaving peptide element encoded a peptide sequence that, when transcribed, led to self-cleavage of the synthesized peptide to produce two polypeptides that define each HLA chain.
[0148] The method for constructing eAPC-p was as described in Example 4, except that cells that had acquired surface expression of the analyte HLA were identified by cell surface labeling with pan-anti-HLA-DR,DP,DQ antibody (Figure 47). The presence of pan-anti-HLA-DR,DP,DQ antibody staining indicated that the analyte HLA ORF encoded by component 1C' had been integrated into the genome. Individual HLA-DR,DP,DQ positive staining cells were selected and expanded into eAPC-p monoclonal populations. Individual monoclonal lines were selected as eAPC-p based on maintained analyte HLA surface expression and integration of the analyte ORF into the genomic acceptor site (creating component 1B') as described in Example 4. Cell lines ACL-341 and ACL-350 were selected based on HLA-DRA * 01:01 / HLA-DRB1 * 01:01 or HLA-DPA1 * 01:03 / HLA-DPB1 * The 04:01 analyte was a representative monoclone with maintained HLA surface expression (Figure 48). In conclusion, aAPX HLA-DRA * 01:01 / HLA-DRB1 * 01:01 or HLA-DPA1 * 01:03 / HLA-DPB1 *Generation of genetically modified ACL-341 and ACL-350 cell lines containing a copy of the 04:01 ORF within the genomic acceptor site component 1B' resulted in the analyte aAPX being the only major HLA class II member expressed on the cell surface, thus demonstrating the generation of two defined eAPC-p cell lines using a multicomponent system.
[0149] Example 6: eAPC-p, where component 1B is a synthetic construct, constructed in one step using one integration couple In this example, we describe a method to construct eAPC-p in one step using one integration couple, where the genomic acceptor site component 1B was a synthetic construct designed for the RMCE genomic site, and the gene donor vector (component 1C') contained a single ORF encoding one aAPX. In this example, the genomic integration site (component 1B) was composed of the selected genetic elements: two unique heterospecific recombinase sites FRT and F3, which flank an ORF encoding the selectable marker blue fluorescent protein (BFP). The 5′ side of the FRT site encoded the EF1a promoter, and the 3′ side of the F3 site encoded the SV40 polyadenylation signal terminator. The genetic elements of component 1B were integrated into the cell line ACL-128 by electroporation using the same plasmid as described in Example 2. As described in Example 2, individual monoclonal lines were selected on the basis of maintained BFP expression and genetically characterized to contain a single integration of component 1B into the desired AAVS1 genomic location (Figure 49a). The resulting eAPC cell line ACL-385 was characterized as containing the HLA-ABC expression vector. null and HLA-DR,DP,DQ null and contained a single copy of the synthetic genomic acceptor site component 1B designed for RMCE.
[0150] The gene donor vector (component 1C) was matched to component 1B such that component 1C encodes the same heterospecific recombinase sites FRT and F3. The aAPX ORF of interest (additionally encoding a Kozak sequence immediately before the start codon) was cloned between the two heterospecific recombinase sites to generate component 1C'. In this example, component 1C' encodes one aAPX HLA-A * 02:01(Component 1C' FRT:HLA-A*02:01:F3 The gene contained a single ORF encoding the ribosomal protein (referred to as ribosomal protein). eAPC-p was ligated with a plasmid encoding the Tyr-recombinase Flp and component 1C' FRT:HLA-A*02:01:F3 RMCE was generated by electroporation of the cell line ACL-385 with and . 4-10 days after electroporation, individual cells were selected that were positive for HLAI surface expression and negative / reduced for the fluorescent protein marker BFP encoded by the component 1B selection marker. The more mature individual monoclonal lines were selected based on maintained HLAI allele expression and loss of BFP fluorescence (indicating that the expected RMCE had occurred). Both phenotypic and genetic tests were performed to identify the monoclones. First, all monoclonal cell lines were screened for cell surface HLA-ABC expression and lack of BFP fluorescence (Figure 49). Genomic DNA was extracted from the cell lines, e.g., ACL-421 and ACL-422, and the integration of component 1C' into component 1B, giving rise to component 1B', was confirmed by detection of a PCR product specific for component 1B' (Figure 50). In conclusion, aAPX and HLA-A * Generation of genetically modified ACL-421 and ACL-422 cell lines containing a copy of the 02:01 ORF within the synthetic genomic acceptor site component 1B' resulted in the analyte aAPX being the only major HLA class I member expressed on the cell surface, thus demonstrating the generation of two defined eAPC-p cell lines using a multicomponent system.
[0151] Example 7: eAPC-pa constructed in two steps using two integration couples In this example, a two-step method for constructing eAPC-pa is described. Step 1 Genomic acceptor site component 1B was a native genomic site and the gene donor vector (component 1C') comprised a single ORF encoding one aAPX. Step 2 Genomic acceptor site (component 1D) was a second native genomic site and the gene donor vector component 1E' contained a single ORF encoding one analyte antigen molecule (aAM). In this example, the eAPC is ACL-128 and the genomic acceptor site component 1B is the variant HLA-A allele genomic site (HLA-A null Component 1C is a chromosome 1B clone that is a chromosome 1C clone that is a chromosome 1D ... null HLA-A consists of >500 bp of sequence homologous to a genomic locus null The gene donor vector (component 1C) was matched to component 1B by encoding the left and right homology arms. HLA-A null Between the left and right homology arms, the plasmid encoded a CMV promoter and an SV40 terminator. The aAPX of interest was cloned between the promoter and terminator to generate component 1C'. In this example, component 1C' contains one aAPX HLA-A * 02:01 or HLA-B * -35:01 (respectively, component 1C' HLA-A*02:01 , component 1C' HLA-B*-35:01 (called ". Incorporation of component 1C' into component 1B and selection of monoclonal eAPC-p cell lines were performed using HLA-A to promote HDR incorporation of component 1C' into component 1B. null As in Example 4, except that gRNAs targeting genomic loci were used. Monoclonal eAPC-p ACL-191 and ACL-286 express HLA-A, HLA-B, and HLA-C on the cell surface, respectively. * 02:01 or HLA-B * -35:01 was expressed (Figure 51a).
[0152] In this example, the genomic acceptor site (component 1D) was a native AAVS1 genomic site, and step 2 was performed to achieve targeted integration by HDR. Gene donor vector component 1E was matched to component 1D by component 1E encoding AAVS1 left and right homology arms, each consisting of >500 bp of sequence homologous to the AAVS1 genomic locus. Between the AAVS1 left and right homology arms, the plasmid encoded a CMV promoter and an SV40 terminator. The aAM of interest was cloned between the promoter and terminator to generate component 1E'. In this example, component 1E' contained a single ORF encoding the selectable marker GFP linked to an aAM ORF encoding hCMV-pp65 (component 1E' GFP:2A:pp63 The viral self-cleaving peptide element encoded a peptide sequence that, when transcribed, led to self-cleavage of the synthesized peptide to generate two polypeptides, GFP and the intracellular hCMV-pp65 protein. Integration of component 1E' into component 1D was as in Example 4. The individual monoclonal lines ACL-391 and ACL-395 were selected as eAPC-pa based on sustained expression of the selection marker GFP (Figure 51b). In conclusion, aAPX and HLA-A * 02:01 or HLA-B * Genetically modified ACL-391 and ACL-395 cell lines were generated that contain a copy of the -35:01 ORF in the genomic acceptor component 1B' and the aAM ORF pp65 in the genomic acceptor component 1D'. These genetic modifications resulted in the aAPX being the only major HLA class I member expressed on the cell surface, where the aAM was also expressed. This therefore demonstrated the generation of two defined eAPC-pa cell lines using a multicomponent system.
[0153] Example 8: eACP-p constructed in one step, component 1C' encodes a single HLAI ORF This example describes the conversion of eAPCs to eAPC-p in one step by a single integration couple event to integrate a single HLAI ORF encoding an analyte antigen-presenting complex (aAPX), where the eAPC contains two synthetic genomic acceptor sites, component 1B and component 1D, designed for RMCE-based genomic integration. The generated eAPC-p has one genomic acceptor site (component 1B') occupied by the HLAI ORF, while the remaining component 1D is available for an additional integration couple event. This example utilized the eAPC (ACL-402) generated in Example 3, which contains components 1B and 1D. Here, component 1B contains two unique heterospecific recombinase sites F14 and F15, which flank an ORF encoding the selectable marker red fluorescent protein (RFP). The 5' side of the F14 site encoded an EF1a promoter, and the 3' side of the F15 site encoded an SV40 polyadenylation signal terminator. Component 1D contains two unique heterospecific recombinase sites FRT and F3, which flank an ORF encoding the selectable marker blue fluorescent protein (BFP). The 5' side of the FRT site encoded an EF1a promoter, and the 3' side of the F15 site encoded an SV40 polyadenylation signal terminator. This example uses a component 1C gene donor vector that contains the heterospecific recombinase sites F14 and F15, and thus matches component 1B. Two independent components 1C' were generated from component 1C, where one vector (V4.H.5) contains a Kozak sequence, an initiation codon and an HLA-A codon between the F14 / F15 sites. * The second vector (V4.H.6) contains an aAPX ORF encoding 02:01, and a Kozak sequence, an initiation codon and an HLA-A * Contains the aAPX ORF encoding 24:02.
[0154] eAPCs (ACL-402) were combined by electroporation with a vector (Flp, V4.1.8) encoding expression of the RMCE recombinase enzyme and with each component 1C' of either V4.H.5 or V4.H.6, independently. Cells were cultured for 4-10 days. Cells were then selected and sorted based on loss of the integrated selection marker RFP and acquisition of HLAI at the cell surface. The more grown individual monoclonal lines were then characterized, validated and selected based on acquisition of HLAI surface expression and loss of RFP fluorescence, indicating that the expected conversion of component 1B to 1B' had occurred. The selected eAPC-p monoclonal line, ACL-900 (V4.H.5, HLA-A * 02:01) and ACL-963 (V4.H.6, HLA-A * eAPC-p monoclones (24:02) were negative for RFP and maintained HLAI surface expression compared to the parental ACL-402 cell line (Figure 53a). Moreover, both monoclones retained expression of the selection marker for BFP integration, indicating that component 1D was not coupled to the component 1B integration couple event and was isolated. To further characterize the eAPC-p monoclones, genomic DNA was extracted from the cells and confirmation of the integration couple between component 1C' and component 1B (resulting in component 1B') was performed by detection of a PCR product specific for component 1B' (Figure 53b). Primers were designed that targeted a region adjacent to the genomic acceptor site (primer ID 8.B.3) and a region within the integration couple event (primer ID 15.H.2). Amplification occurred only in the case of specific integration, and no products were generated from control recombination (ACL-3) or from off-target recombination. In summary, this example demonstrates two specific examples of eAPC to eAPC-p conversion using a multicomponent system, where two different aAPXs are delivered individually (component 1C') and integrated into a single genomic acceptor site (component 1B) by RMCE genomic integration, generating a limited library containing two distinct eAPC-p. Furthermore, the second genomic acceptor site (component 1D) is shown to be isolated and unaffected by the component 1B / component 1C' integration couple.
[0155] Example 9: eAPC-pa constructed in one step from eAPC-p, with component 1D' encoding a single analyte antigen molecule (aAM) ORF This example describes a method to construct multiple eAPC-pa in parallel from a parental eAPC-p (described in Example 8), in which a genomic acceptor site (component 1D) is targeted for integration with a primed gene donor vector (component 1E' comprising a single ORF encoding an aAM). In this example, the parental eAPC-p line used contained a single aAPX (HLA-A * The eAPC-p component 1D was an ACL-900 expressing the aAM gene (V9.E.02:01) (described in Example 8). The eAPC-p component 1D was left open and contained two unique heterospecific recombinase sites FRT and F3 flanking an ORF encoding the selectable marker blue fluorescent protein (BFP). The 5' side of the FRT site encoded the EF1a promoter, and the 3' side of the F15 site encoded the SV40 polyadenylation signal terminator. In this example, the gene donor vector component 1E was used, which contained two heterospecific recombinase sites F14 and F15, and thus matched component 1D. In this example, component 1E was further primed with one aAM ORF of interest selected from HCMVpp28 (V9.E.6), HCMVpp52 (V9.E.7) or HCMVpp65 (V9.E.8), which each encode a glycine-serine rich linker and a c-myc tag at the C-terminus. Additionally, each component 1E' further contains a Kozak sequence and a start codon immediately 5' to the aAM ORF. Thus, a small separate library of component 1E' containing three vectors was generated.
[0156] eAPC-p (ACL-900) were combined by electroporation with vectors encoding the expression of RMCE recombinase enzyme (Flp, V4.1.8) and V9.E.6, V9.E.7 or V9.E.8 components 1E' independently. After incubating the cells for 4-10 days to allow integration couples to occur, individual eAPC-pa were selected and single cells (monoclones) were selected based on the signal reduction of the integration selection marker BFP encoded by component 1D (Figure 54a). Then, more mature individual monoclonal eAPC-pa, ACL-1219 (pp28), ACL-1227 (pp52) and ACL-1233 (pp65), were characterized and confirmed and selected based on the loss of BFP expression and the maintained surface expression of HLAI (aAPX to component 1B'), indicating that the expected conversion of component 1D to 1D' had occurred (Figure 54b). Furthermore, the maintained surface expression of aAPX indicated that component 1B' was not affected by and was isolated from the integration coupling event between components 1D and 1E'. To further characterize the selected eAPC-pa monoclones, genomic DNA was extracted and confirmation of the integration coupling between components 1E' and 1D (resulting in component 1D') was performed by detection of polymerase chain reaction (PCR) amplicon products (10.D.1, 15.H.4) specific for component 1D'. Figure 54c shows two monoclones of each of the three eAPC-pa, where amplicon products of the expected size were observed for the aAM ORFs pp28 (0.8 kb), pp52 (1.5 kb) and pp65 (1.9 kb), further confirming that the expected integration events had occurred. In summary, this example demonstrates three specific examples of eAPC-p to eAPC-pa conversion using a multicomponent system, where three different aAMs are delivered individually (component 1E') and integrated into a single genomic acceptor site (component 1D) by RMCE genomic integration, generating three separate small libraries of eAPC-pa carrying three different aAM ORFs. Furthermore, it was shown that the loaded second genomic acceptor site (component 1B') is isolated and unaffected by the component 1D / component 1E' integration couple.
[0157] Example 10: Shotgun integration of multiple analyte antigen molecule ORFs into eAPC-p to generate a pooled eAPC-p library in a single step This example describes a method for integrating a pool of primed component 1E vectors (component 1E') that collectively encode multiple aAM ORFs (HCMVpp28, HCMVpp52, and HCMVpp65) into parental eAPC-p (described in Example 8) in a single step to generate a pooled eAPC-p library, where each individual cell integrates a single random analyte antigen ORF from the original vector pool at component 1D' such that each eAPC-pa expresses a single random aAM, but the pooled library of eAPC-pa collectively represents all of the aAM ORFs encoded in the original pooled vector library. This method of generating a pool of eAPC-pas, each expressing a single random ORF from the vector pool, is referred to as shotgun integration. In this example, the parental eAPC-p line used was aAPX (HLA-A * The cell line was ACL-905 expressing aAM ORF V9.E.02:01) on the cell surface (cell line construction described in Example 8), and component 1D and component 1E' were as described in Example 9. In this example, the individual component 1E' vectors V9.E.6, V9.E.7 and V9.E.8 from Example 9, containing aAM ORFs encoding HCMVpp28, HCMVpp52 and HCMVpp65, respectively, were mixed together in a 1:1:1 molar ratio to generate a vector pool. eAPC-p (ACL-905) was combined with the vector pool and a vector encoding expression of the RMCE recombinase enzyme (Flp, V4.1.8) by electroporation. After incubating the cells for 4-10 days, the cells were bulk sorted based on a decrease in the signal of the selectable marker for integration, BFP, encoded by component 1D (Figure 55a) to generate the pooled cell population ACL-1050 (Figure 55b).
[0158] To confirm that the eAPC-pa pool ACL-1050 is composed of a mixture of eAPC-pa each encoding one of HCMVpp28, HCMVpp52 or HCMVpp65 in component 1D', individual cells were single-cell sorted from the polyclonal population and 12 cells were randomly selected for genetic characterization. Amplification of component 1D' was performed using primers spanning each aAM (10.D.1 and 15.H.4). Figure 55c shows the amplicons generated for the 12 cells along with the controls. Here, for all 12 cells, a single amplicon product was observed that matched the expected size for one of the aAM ORFs pp28 (0.8 kb), pp52 (1.5 kb) and pp65 (1.9 kb). Furthermore, each aAM ORF was identified at least once. This indicates that the eAPC-pa pool is composed of a mixture of eAPC-pa in which each eAPC-pa in the pool incorporates a single random aAM ORF from the original pool of three vectors. In conclusion, this example demonstrates the use of a multi-component system for the single-step conversion of eAPC-p to a pooled library of eAPC-pa by combining eAPC-p with a pooled library of three vectors (component 1E') encoding three different analyte antigen molecules and utilizing an RMCE-based shotgun integration approach. Furthermore, this example demonstrates that each eAPC-pa in the generated eAPC-pa pool incorporates a single random aAM ORF from the original vector pool by an integration couple event between component 1D and component 1E' and that all three aAM ORFs are represented in the generated pooled eAPC-p library.
[0159] Example 11: Demonstration of one-step eTPC-t production This example describes the generation of eTPC-t in a standardized fashion, where the parental eTPC contains distinct synthetic genomic acceptor site components 2B and 2D. All eTPC parental lines described in this and all further examples were generated by the same technique as the eAPC lines shown in the previous examples. Gene donor vector components 2C' and 2E' are HLA-A* It contained a single chain TCR pair (JG9-TCR) known to bind the antigenic peptide NLVPMVATV (NLVP) derived from human cytomegalovirus polypeptide 65 (HCMV pp65) when presented in the 02 allele. Components C' and E' were designed for RMCE and were derived from the parent components 2C and 2E. This example uses the parental eTPC cell line ACL-488, which is TCR-null, HLA-null, CD4-null and CD8-null, and further contains components 2B and 2D. Component 2B contains two unique heterospecific recombinase sites FRT and F3, which flank an ORF encoding a Kozak sequence and a selection marker blue fluorescent protein (BFP). The 5' side of the FRT site encoded an EF1a promoter, and the 3' side of the F3 site encoded an SV40 polyadenylation signal terminator. Component 2D contains two unique heterospecific recombinase sites F14 and F15, which are different from component 2B. These sites flank an ORF encoding a Kozak sequence and a selection marker red fluorescent protein (RFP). The 5' side of the F14 site encoded an EF1a promoter, and the 3' side of the F15 site encoded an SV40 polyadenylation signal terminator. This example uses gene donor vectors (component 2C' and component 2E'), each containing two heterospecific recombinase sites FRT / F3 (2C') and F14 / F15 (2E'), thus matching components 2B and 2D, respectively. Component 2C' further contains, between the FRT / F3 sites, a Kozak sequence, a start codon and a TCR ORF encoding the JG9-TCR-β chain. Component 2E' further contains, between the F14 / F15 sites, a Kozak sequence, a start codon and a TCR ORF encoding the JG9-TCR-α chain.
[0160] eTPC-t were generated by RMCE via electroporation of ACL-488 (eTPC). Four to 10 days after electroporation, individual cells with reduced fluorescent protein signals BFP and RFP encoded by the component 2D and 2B selection markers were sorted by FACS. Individual monoclones were expanded and then assessed for phenotype. The resulting monoclone, ACL-851, was BFP and RFP negative (Figure 56 a and b). ACL-851 also showed TCR and CD3 surface expression, whereas the parental cell line did not (Figure 56 c and e). Furthermore, the transferred JG9-TCR was able to express HLA-A * It showed specific staining with 02:01-NLVP tetramer, suggesting that the JG9-TCR is a functional TCRsp on the surface of eTPC-t (Fig. 56d-f). It was confirmed by PCR that ACL-851 contains the TCRsp encoded by component 2B' and component 2D' integrated into the genome (Fig. 56g and h). In summary, eTPC was converted to eTPC-t by incorporating TCR ORFs delivered to components 2C' and 2E' using RMCE-based integration method (so that components 2B and 2D were converted to components 2B' and 2D'). This eTPC-t expressed functional TCRsp on the cell surface. Furthermore, this example shows that the binary composition of eTPC-t and analyte antigen was combined to allow eTPC-t to express soluble analyte antigen (HLA multimer: HLA-A * This demonstrates the operation of a simple eTPC:A system in which selection is based on complex formation with a target protein (eTPC:A-T).
[0161] Example 12: Proof of conversion of eTPC-t to eTPC-x This example describes the conversion of eTPC-t to eTPC-x, where eTPC-x has component 2B' encoding a TCR chain ORF and component 2D is available for incorporation of a complementary TCR chain ORF. Conversion of component 2D' of eTPC-t to component 2D of eTPC-x is accomplished by use of a gene donor vector (component 2Z) that matches component 2D'. In this example, the parental eTPC-t cell line ACL-851, generated in Example 11, was used. Component 2Z is a plasmid vector composed of two heterospecific recombinase sites F14 / F15 matching component 2D', a Kozak sequence, a start codon and an ORF encoding green fluorescent protein (GFP) as a selection marker for integration. eTPC-t was combined with component 2Z and a vector encoding the RMCE recombinase enzyme by electroporation. Cells were then selected for loss of CD3 presentation and acquisition of the selection marker for GFP integration. Monoclone ACL-987 was phenotypically characterized by FACS. It was observed that ACL-987 had acquired GFP and lost CD3 and TCRab (Figure 57b, d), indicating that the exchange of JG9-TCR-α with the GFP ORF and the conversion of component 2D' to component 2D was successful, thus generating eTPC-x. In contrast, the parental eTPC-t, ACL-851, lacks GFP expression and has CD3 and TCRab surface expression (FIG. 57 a, c). In summary, this example demonstrates the conversion of eTPC-t to eTPC-x by removing the JG9-TCR-α TCR ORF of component 2D' and replacing it with a selection marker for GFP integration, creating component 2D for further integration coupling events of alternative complementary TCR chain ORFs. This conversion was performed using the RMCE method for genomic integration.
[0162] Example 13: Demonstration of the generation of eTPC-t pool by shotgun integration into eTPC-x This example describes how a pool of vectors (component 2E') encoding 64 single JG9-TCR-α variants can be integrated into the parental eTPC-x cell line (described in Example 12) in a single step to generate a pooled eTPC-t library (each cell integrates a single random TCR ORF encoding an α chain from the original vector pool, so that each eTPC-t expresses a single random pair of TCR ORFs as TCRsp). The individual eTPC-ts are combined together to form a library of pooled eTPC-ts, where the cell pool potentially represents all possible combinations of 64 TCR-α and original defined TCR β chain pairs. Such a method is referred to herein as "shotgun" integration. The 64 JG9-TCRα variants were generated by modifying the CDR3 sequences at the junctions of the V and J fragments. In this example, JG9-TCR-β (component 2B') and the parental eTPC-x cell line ACL-987 (see Example 12), which does not surface express the CD3 complex, were used. Component 2D encodes the selection marker GFP, as described in Example 12. In this example, 64 JG9-TCR-α variant fragments were cloned into the component 2E donor vector to generate component 2E', which is flanked by F14 / F15 sites and matches component 2D. The 64 vectors were then combined into a single vector pool. The eTPC-t pool was generated by RMCE-based genomic integration, where eTPC-x (ACL-987) was combined with 64 component 2E' and RMCE recombinase vector by electroporation. Polyclones were selected based on GFP expression. The resulting polyclonal ACL-988 was composed of both GFP-positive and GFP-negative cell populations, unlike the parent line, which was composed only of GFP-positive cells (Figure 58 a and b). However, only the GFP-negative population consistently showed strong CD3 expression, indicating that the conversion of component 2D to component 2D' was successful, and thus the eTPC-x was converted into an eTPC-t pool (Figure 58 c and d). Furthermore, the ACL-988 GFP-negative population was positively expressed by the JG9-TCR specific multimer reactant (DEX HLA-A * When stained with 02:01-NLVP, the cells showed two distinct intensities, suggesting that this population contains cells expressing TCR variants with different binding efficiencies.
[0163] In parallel, all 64 JG9-TCR-α variants were cloned into expression constructs allowing transient transfection into parental eTPC-x (ACL-987). HLA-A was identified for each TCR pair presented in the pooled eTPC-t expressing variant JG9-TCR. * The relative staining units (RSU) of the 02:01-NLVP multimer reagent versus the reference were determined. RSU was calculated as the ratio of the mean fluorescence intensity (MFI) of the HLA multimer signal for the CD3 positive population versus the CD3 negative population and was an indication of the binding strength of each TCR chain versus variant. After independent transfection of the parental ACL-987 line with each JG9-TCR-α variant, cells were stained with antibodies against CD3 and HLA-multimer reagent and analyzed by flow cytometry. Each point plotted in Figure 58e represents the RSU observed for each of the 64 variants. Individual cells of the ACL-988 pool were single-cell sorted from the HLA-multimer positive and HLA-multimer negative populations. For each single cell, the component 2D' encoding the variant JG9-TCR-α ORF was amplified and sequenced and compared with the results of the transiently expressed RSU units described above (Figure 58e). Indeed, individual ACL-988 cells that were HLA-multimer positive encoded JG9-TCR-α variants that predominantly displayed high RSU results in the individually tested variants (Figure 58e, open circles). Furthermore, individual ACL-988 cells that were pHLA-multimer negative encoded JG9-TCR-α variants that predominantly displayed low RSU results (Figure 58e, open triangles). In conclusion, this example demonstrates the use of a multicomponent system for the conversion of eTPC-x and pooled vector (component 2E') libraries into a pooled library of TPC-t containing multiple different TCRspe. This was achieved in a single step using shotgun integration. Furthermore, this example demonstrated that eTPC-t pools were combined with analyte antigens (as soluble affinity reactants) in the eTPC:A system. It was shown that single cell pools could be selected based on complex formation with analyte antigens (HLA-multimers) and then the TCR chain ORFs encoded in component 2D' could be extracted and DNA sequences obtained.
[0164] Example 14: Functional demonstration of component 2F in eAPC:eTPC combined system using exogenous aAM In this example, we describe an eTPC cell line (ACL-1063, component 2A) engineered to be HLA null with two unique genomic acceptor sites (components 2B, 2D), utilizing native CD3 expression, and carrying an engineered genomic two-component synthetic response element (component 2F). In this example, the eTPC cell line was converted to the eTPC-t cell line (ACL-1277) as described in Example 11. In the eTPC-t cell line, the TCR chain ORFs of components 2B' and 2E' bind to the HLA-peptide complex (HLA) HLA-A. *02:01-NLVPMVATV-specific TCR pair was encoded. The eTPC-t was combined with the eAPC-p in the presence of exogenous aAM in the form of a soluble peptide to assemble the eAPC:eTPC system. The readout of these combined systems was the reporter RFP signal from component 2F in the eTPC-t. The response element was defined as component 2F, consisting of a driver-activator component and an amplifier-report component, both of which utilized synthetic promoters. The driver is a synthetic promoter responsive to the native TCR signaling pathway that encodes three sets of tandem transcription factor binding sites for NFAT-AP1-NFkB (3xNF-AP-NB). Upon transcriptional activation, the driver induces expression of the activator protein, a synthetic designed transcription factor derived from the fusion of a herpes VP16 activation domain, a GAL4 DNA binding domain, and two nuclear localization signals at the N- and C-terminus (NV16G4N), with six tandem occurrences of their cognate DNA recognition sequences in the amplifier promoter. Both driver and amplifier promoters utilized core promoter sequences from the HCMV IE1 promoter, immediately 3' to their respective transcription factor binding sites, including the B recognition element (BRE), TATA box, initiator (INR), and transcription start site. The amplifier, upon transcriptional activation, drives expression of the reporter red fluorescent protein (RFP).
[0165] The eTPC-t cell line was then cloned into a 3-mer of the HLA-A * 02:01 (ACL-209) or HLA-A *eAPC-p were challenged with eAPC-p presenting HLA-24:02 (ACL-963) or HLA-null (ACL-128). Here, analyte eAPC-pa were prepared by pulsing eAPC-p with or without peptides NLVPMVATV or VYALPLKML. eTPC-t and analyte eAPC-pa were then organized into an eAPC:eTPC system consisting of 30,000 eTPC-t co-cultured with 10,000 eAPC-pa for 24 hours. After 24 hours, cells were harvested, washed, stained with markers specific for eTPC-t and analyte eAPC-pa to differentiate the populations, and analyzed by flow cytometry, using techniques known to those skilled in the art. The strong activation of eTPC-t (component 2F) was confirmed by the activation of analyte eAPC-pa presenting the known cognate antigen pHLA complex, i.e., HLA-A. * RFP expression was only observed in eTPC-t challenged with eAPC-pa bearing 02:01 and NLVPMVATV (Figure 59a). In contrast, only quiescent RFP expression was observed in eAPC:eTPC formations composed of non-specific analyte eAPC-pa (Figure 59b, c, d) or control parental eAPC lacking HLA (Figure 59f) or eAPC-p lacking exogenous aAM peptide. In conclusion, eTPC-t cell lines containing functional component 2F were genetically engineered and then used to generate eTPC-t. Upon interaction of eTPC-t with analyte eAPC-pa presenting its cognate target T cell antigen (provided as exogenous soluble aAM), the response was measurable as an increase in RFP expression. Conversely, when contacted with analyte eAPC or eAPC-p or eAPC-pa that does not present cognate T cell antigen and HLA or does not present HLA, eTPC-t did not show a measurable increase in RFP expression above background. Furthermore, this example demonstrates an eAPC:eTPC system in which analyte eAPC-pa and analyte eTPC-t are organized into separate binary compositions and the eTPC-t response (a cooperative complex between TCRsp and analyte antigen occurs) is used to identify both analyte eAPC-pa and eTPC-t.
[0166] Example 15: Functional demonstration of component 2F in the eAPC:eTPC combined system with the aAM ORF integrated into the eAPC-pa state This example shows the construction of an HLA-peptide complex (HLA) HLA-A with two unique genomic acceptor sites at components 2B' and 2E'. * We describe the use of eTPC-t(ACL-1150) (component 2A) engineered to be loaded with TCR chain ORFs encoding TCR pairs specific for 02:01-NLVPMVATV, utilizing native CD3 expression, and assembled into an eAPC:eTPC system with an eAPC-pa that has a genomic one component synthetic response element (component 2F) and was created by integrating an ORF encoding an aAM at site 1D'. In this example, four different eAPC-pa variants were assembled such that four distinct eAPC-pa lines were generated using two different HLA alleles and two different aAM ORFs derived from the HCMV genome. The response element was defined as component 2F, which is composed of a driver-reporter component. The driver is a synthetic promoter responsive to the native TCR signaling pathway that encodes six sets of tandem transcription factor binding sites for NFAT-AP1 (6xNF-AP). Upon transcriptional activation, the driver induces expression of the activator protein, a synthetic designed transcription factor derived from the fusion of a herpes VP16 activation domain, a GAL4 DNA binding domain, and two N- and C-terminal nuclear localization signals (NV16G4N) with six tandem occurrences of their cognate DNA recognition sequences within the amplifier promoter. Both the driver and amplifier promoters utilize the core promoter sequence of the HCMV IE1 promoter (B recognition element (BRE), TATA box, initiator (INR), and transcription start site) immediately 3' to their respective transcription factor binding sites. Upon transcriptional activation, the driver induces expression of the reporter red fluorescent protein (RFP).
[0167] The first eAPC-pa line (ACL-1046) was identified as HLA-A *02:01 and the full length ORF of the HCMV protein pp65, where pp65 is * The second eAPC-pa line (ACL-1044) contains an antigenic peptide that is recognized by eTPC-t TCRsp when presented at 02:01. * The third eAPC-pa strain, ACL-1045, expresses HLA-B*07:02 and the full-length ORF of HCMV protein pp52. The fourth eAPC-pa strain (ACL-1048) expresses HLA-B*07:02 and the full-length ORF of HCMV protein pp65. The second, third and fourth eAPC-pa express aAPX:aAM complexes that are not recognized by eTPC-t TCRsp. The eTPC-t cell line ACL-1150 was organized into independent eAPC:eTPC systems with each of the four eAPC-pas mentioned above. After 48 hours, cells were harvested, washed, and stained with markers specific for eTPC-t and analyte eAPC-pa to differentiate the populations and analyze by flow cytometry. The strong activation of eTPC-t (component 2F) was confirmed by the activation of analyte eAPC-pa presenting the known cognate antigen pHLA complex, i.e., HLA-A. * RFP expression was only observed in eTPC-t challenged with eAPC-pa bearing 02:01 and pp65 (Figure 60b). In contrast, only quiescent RFP expression was observed in eAPC:eTPC formations composed of the non-specific analyte eAPC-pa (Figures 60a, c, d). In conclusion, eTPC-t cell lines containing functional component 2F were genetically engineered and then used to generate eTPC-t. Upon interaction of eTPC-t with analyte eAPC-pa presenting its cognate target T cell antigen (provided as an endogenous aAM ORF by integration), the response was measurable as an increase in RFP expression. Conversely, when contacted with analyte eAPC-pa not presenting cognate T cell antigen and HLA, eTPC-t did not show a measurable increase in RFP expression above background. Furthermore, this example demonstrates an eAPC:eTPC system in which analyte eAPC-pa and analyte eTPC-t are organized into separate binary compositions and the eTPC-t response (a cooperative complex between TCRsp and analyte antigen occurs) is used to identify both analyte eAPC-pa and eTPC-t.
[0168] SEQUENCE LISTING <110> Genovie AB <120> An engineered two-part cellular device for discovery and characterization of T-cell receptor interaction with cognate antigen <130> ANO15 <160> 104 <170> BiSSAP 1.3 <210> 1 <223> Analyte Antigenic Peptide <210> 2 <223> Analyte Antigenic Peptide <210> 3 <223> HCMV Antigen <210> 4 <223> HCMV Antigen <210> 5 <223> pcDNA3.1_GFP vector V1.A.4 <210> 6 <223> pcDNA3.1_RFP vector V1.A.6 <210> 7 <223> pMA-SV40pA vector V1.C.2 <210> 8 <223> pMA-CS-JG9-TCRbeta vector V3.C.5 <210> 9 <223> pMA-F14-GFP-F15 vector V4.H9 <210> 10 <223> pMA-F14-TCR-JG9-alpha-F15 vector V7.A.3 <210> 11 <223> pMA-FRT-TCR-JG9-beta-F3 vector V7.A.4 <210> 12 <223> F14-TCRaF15 CDR3degen.64mix vector V8.F.8 <210> 13 <223> CMVpro-Flp-sv40pA-V2 vector V4.I.8 <210> 14 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A1 <210> 15 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A2 <210> 16 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A3 <210> 17 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A4 <210> 18 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A5 <210> 19 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A6 <210> 20 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A7 <210> 21 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_A8 <210> 22 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B1 <210> 23 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B2 <210> 24 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B3 <210> 25 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B4 <210> 26 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B5 <210> 27 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B6 <210> 28 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B7 <210> 29 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_B8 <210> 30 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_C1 <210> 31 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_C2 <210> 32 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_C3 <210> 33 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_C4 <210> 34 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_C5 <210> 35 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_C6 <210> 36 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_C7 <210> 37 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D1 <210> 38 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D2 <210> 39 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D3 <210> 40 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D4 <210> 41 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D5 <210> 42 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D6 <210> 43 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D7 <210> 44 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_D8 <210> 45 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E1 <210> 46 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E2 <210> 47 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E3 <210> 48 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E4 <210> 49 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E5 <210> 50 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E6 <210> 51 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E7 <210> 52 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_E8 <210> 53 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F1 <210> 54 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F2 <210> 55 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F3 <210> 56 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F4 <210> 57 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F5 <210> 58 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F6 <210> 59 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F7 <210> 60 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_F8 <210> 61 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G1 <210> 62 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G2 <210> 63 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G3 <210> 64 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G4 <210> 65 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G5 <210> 66 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G6 <210> 67 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G7 <210> 68 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_G8 <210> 69 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H1 <210> 70 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H2 <210> 71 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H3 <210> 72 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H4 <210> 73 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H5 <210> 74 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H6 <210> 75 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H7 <210> 76 <223> CDR3 sequence of a JG9-TRA 64 variant VP.7751.RC1_H8 <210> 77 <223> pMA_F14_HLA-A*02:01-6xHis_F15 vector V4.H.5 <210> 78 <223> pMA_F14_HLA-A*24:02-6xHis_F15 vector V4.H.6 <210> 79 <223> pMA_F14_HLA-B*07:02-6xHis_F15 vector V4.H.7 <210> 80 <223> pMA_F14_HLA-B*35:01-6xHis_F15 vector V4.H.8 <210> 81 <223> FRT_HCMVpp28-3xMYC_F3 vector V9.E.6 <210> 82 <223> FRT_HCMVpp52-3xMYC_F3 vector V9.E.7 <210> 83 <223> FRT_HCMVpp52-3xMYC_F3 vector V9.E.8 <210> 84 <223> SpCas9-2A-GFP Vector V1.A.8 <210> 85 <223> HLA-A-sg-sp-opti1 vector V2.A.1 <210> 86 <223> HLA-B-sg-sp-3 vector V2.A.7 <210> 87 <223> HLA-C-sg-sp-4 vector V2.B.3 <210> 88 <223> HLA-A-ex2-3_sg-sp-opti_1 vector V2.I.10 <210> 89 <223> HLA-A-ex2-3_sg-sp-opti_2 vector V2.J.1 <210> 90 <223> AAVSI_sg-sp-opti_3 vector V2.J.6 <210> 91 <223> TRAC-GT-F1 ddPCR primer / probe <210> 92 <223> TRAC-GT-R1 ddPCR primer / probe 1.F.8 <210> 93 <223> TRAC-probe-FAM ddPCR primer / probe <210> 94 <223> TRBC2-GT-F1 ddPCR primer / probe 1.F.9 <210> 95 <223> TRBC2-GT-R1 ddPCR primer / probe 1.F.10 <210> 96 <223> TRBC2-probe-FAM ddPCR primer / probe 1.G.2 <210> 97 <223> TRAC-TCRA-ex1-F1 ddPCR primer / probe 10.A.9 <210> 98 <223> TRAC-TCRA-ex1-F1 ddPCR primer / probe 10.A.10 <210> 99 <223> TRAC-probe(HEX) ddPCR primer / probe 10.B.6 <210> 100 <223> HCMVpp65_GT_F2ddPCR primer / probe 21.I.1 <210> 101 <223> HCMVpp28_GT_F1 ddPCR primer / probe 21.I.2 <210> 102 <223> HCMVpp52_GT_F1 ddPCR primer / probe 21.I.3 <210> 103 <223> Myc-Tag_GT_R1 ddPCR primer / probe 20.H.10 <210> 104 <223> Linker-Myc_Probe_Fam ddPCR primer / probe 20.H.9
[0169] abbreviation リスト aAPX Analyte Antigen Prescribing Complex aAM Analyte Antigenic Molecule aCT Analyte TCR APC antigen presenting cells APX antigen presenting complex BFP Blue fluorescent protein CAR-T CAR T cells CM cargo molecule CRISPR Clustered Regularly Interspaced Short Palindromic Repeats gRNA Cas9 guide RNA
[0170] CAR Chimeric Antigen Receptor CDR Complementarity Determining Region C region Steady region CMV cytomegalovirus DAMPS Danger Associated Molecular Patterns DC dendritic cells DNA deoxyribonucleic acid D Area Diversity Area eAPCs engineered antigen-presenting cells eAPC-p Genetically engineered antigen-presenting cells presenting analyte antigen-presenting complexes eAPC-pa Genetically engineered antigen-presenting cells that present analyte antigen-presenting complexes and analyte antigenic molecules eAPC-a Genetically engineered antigen-presenting cells expressing the analyte antigenic molecule eAPCS engineered antigen presenting cell system eTPC engineered TCR-presenting cells
[0171] eTPCS engineered TCR-presenting cell system eTPC-t: Genetically engineered TCR-presenting cells that display full-length TCR pairs FACS Fluorescence Activated Cell Sorting GEM T cells: germline-encoded mycolyl-reactive T cells GFP Green Fluorescent Protein HLAI HLA class I HLAII HLA class II HDR homology-directed recombination HLA Human Leukocyte Antigens IgSF immunoglobulin superfamily
[0172] IRES internal ribosome entry site iNK T cells Invariant natural killer T cells J area Consolidated area MACS magnetically activated cell sorting MAGE melanoma-associated antigens MAIT Mucosa-associated invariant T NCBP Non-cell-based particles ORF Open Reading Frame PAMPS Pathogen-Associated Molecular Patterns PCR Polymerase Chain Reaction
[0173] RMCE Recombinase-Mediated Cassette Exchange RFP Red fluorescent protein DNA ribonucleic acid SH2 Src homology 2 T cell T lymphocyte TCR T cell receptor TRA TCRα TRB TCRβ TRD TCRδ
[0174] TCRsp TCR surface protein complexed with CD3 TALEN transcription activator-like effector nucleases TRG TRCγ TAA Tumor-associated antigens V region Variable region β2M β2-microglobulin ZAP-70 70 kDa ζ-chain associated protein
[0175] definition Complementary TCR chain pair: two TCR chains whose translated proteins are capable of forming a TCRsp on the surface of a TCR-presenting cell. affinity dynamic or equilibrium parameter of the interaction between two or more molecules or proteins Affinity Reagent: Any reagent designed to have a specific affinity for an analyte. Often used for affinity for HLA-antigen complexes. Allele: A variant form of a given gene. AM: analyte antigenic molecule. Generally, it is a protein expressed by cells from genomic DNA and / or specific transgene sequences, but it can also be a metabolic product. AMs are expressed in cells and fragments can then be presented on the cell surface by APX or by themselves as cargo. Whether as cargo or not, AMs can then be targeted to T cell receptor-bearing cells or associated affinity reactants. Amplicon: A piece of DNA or RNA that is the source and / or product of artificial amplification using various methods, including PCR.
[0176] Analyte: A substance of interest that is identified and / or measured and / or interrogated in a combination system. Antibody: Affinity molecule containing two chains expressed by specialized cells of the immune system called B cells. B cells express a large and highly diverse repertoire of antibodies that do not generally bind to self-proteins but can bind to and neutralize pathogens or toxins that threaten the host. Natural or artificially engineered antibodies are often used as affinity reactants. antigen any molecule (often presented by an antigen-presenting complex) that can be bound by a TCR and results in a signal that is transduced within a T cell Analyte Antigen: Collectively, refers to any substance that presents an antigen for analytical measurement eAPC: eTPC System APC: Antigen-presenting cell. A cell that carries AM, APX, and APX on its cell surface. APX: Antigen Presenting Complex. Proteins expressed and presented at the cell surface by nucleated cells from genes / ORFs encoding genomic DNA and / or specific transgene sequences. APX presents cargo that can be peptides or other metabolite molecules. C region: constant region. One of the gene segments used to assemble the T cell receptor. The c region is a separate segment that does not drive TCR diversity but rather determines its general function in the immune system.
[0177] Cargo loading apparatus: A set of cellular proteins that generate and load cargo molecules onto APX from proteins or other displayed molecules found in the cell. CDR: Complementarity Determining Region. Short sequences at the antigen-facing ends of TCRs and antibodies that perform most of the target binding function. Each antibody and TCR contains six CDRs, which are generally the most variable parts of the molecule, allowing detection of a large number of different target molecules. CM: cargo molecule. A peptide or metabolite presented by an antigen-presenting complex, e.g., HLA I or HLA II. CMs can be expressed by cells inherently from genomic DNA, or from genetic sequences introduced into the culture medium or specifically introduced. Copy Number: The total number of occurrences of a defined sequence encoded within the genome of a cell. Cytogenetic: The genetics of the structure and function of chromosomes; i.e., the determination of a cell's karyotype. Cytotoxicity / Cytotoxicity: The process by which T cells release factors that directly and specifically damage target cells. D region: Diversity region. One of the gene segments used to assemble the T cell receptor. Each individual has many different variations of these regions, which allows each individual to be armed with T cells that have a wide variety of different TCRs. DNA: Deoxyribonucleic Acid, the chemical name for the molecules that make up the genetic material that codes for genes and proteins. eAPC System: eAPCS: A system in which eAPC-pa, eAPC-p and eAPC-a cells or libraries thereof are produced for combination in the eAPC:eTPC system eTPC system: eTPCS: a system in which eTPC-t cells or libraries thereof are produced for combination in the eAPC: eTPC system eAPC:eTPC system: a system in which an analyte antigen presented by an eAPC is combined with an analyte TCR presented by an eTPC Endogenous: Substances that originate within the cell.
[0178] Genetically Engineered Cell: An altered cell whose genome has been genetically engineered through genetic modification. eukaryotic conditional regulatory element DNA sequence that can affect the activity of a promoter, either induced or repressed under defined conditions Eukaryotic promoter: A DNA sequence that encodes an RNA polymerase binding site and response elements. The sequence of the promoter region controls the binding of RNA polymerase and transcription factors, and thus the promoter plays a large role in determining where and when a gene of interest is expressed. Eukaryotic terminator / signal terminator: DNA sequence recognized by protein factors that bind RNA polymerase II and trigger the transcription termination process. It also codes for a polyA signal. FACS / Flow Cytometry: Fluorescence Activated Cell Sorting. An analytical technique in which individual cells can be analyzed for the expression of specific cell surface and intracellular markers. A variation of this technique, cell sorting, allows cells bearing a defined set of markers to be recovered for further analysis. APX family: A set of several similar genes that code for functionally related proteins that constitute the antigen-presenting complex. Fluorescent (protein) marker: a molecule that has specific quenching and emission characteristics and can be detected by microscopy, FACS and related techniques. Gene Donor Vector: A gene-based vector for delivering genetic material to a genomic recipient site.
[0179] Genomic acceptor site: A site within a genome for targeted integration of donor genetic material encoded in a gene donor vector. Heterospecific recombinase site: A DNA sequence recognized by a recombinase enzyme to promote the crossover of two DNA molecules. HLA I: Human Leukocyte Antigen Class I. A gene expressed in all nucleated cells in humans. Expressed HLA I is transported to the cell surface where it presents short fragments of internal proteins, peptides, as cargo to the T cell receptor. In this way, it presents fragments of unique proteins that may be of ongoing infection. HLA I can additionally present as cargo peptides that are added to the culture medium, generated from proteins expressed from transgene elements, or generated from proteins taken up by the cell. HLA class I genes are polymorphic, meaning that different individuals may have variations in the same gene that lead to variations in presentation. Associated with HLA class II. HLA II: Human Leukocyte Antigen Class II. Genes expressed in certain cells (e.g. dendritic cells) that coordinate and aid the adaptive immune response in humans. Related to HLA Class I. HLA Class II proteins are transported to the cell surface where they present short fragments of foreign proteins, peptides, as cargo to T cell receptors. In this way, they present fragments of native proteins that may be of ongoing infection. In addition, HLA II can present peptides as cargo generated from proteins added to the culture medium, expressed from transgene elements, or taken up by the cells. HLA Class II genes are polymorphic, meaning that different individuals may have variations in the same gene that lead to variations in presentation.
[0180] Homologous arm: a stretch of DNA that has nearly identical sequence identity to the complementary homologous arm, thus facilitating the exchange of two DNA molecules by the cellular process of homology-directed repair. Immunosurveillance: The process by which the immune system detects and is activated by infection, malignancy, or other potentially pathogenic changes. insulator: a DNA sequence that prevents genes from being affected by the activation or repression of nearby genes. Insulators also prevent the spread of heterochromatin from silenced genes to actively transcribed genes. Integration: The physical ligation of a DNA sequence into a cell's chromosome. Integration couple: paired integration vector and genomic acceptor site Internal ribosome entry site (IRES): A DNA sequence that encodes an RNA element that, when transcribed, allows for the initiation of translation in a cap-independent manner. J region: Joining region. One of the gene segments used to assemble the T cell receptor. Each individual has many different variations of these regions, allowing each individual to be armed with T cells that have a wide variety of different TCRs. Karyotype: The chromosomal composition of a cell. Kozak sequence short sequence required for efficient initiation of translation
[0181] Major HLA class I: APX family composed of the genes HLA-A, HLA-B and HLA-C. Matched: When two components encode genetic elements that guide and limit the interaction between complementary components. meganuclease recognition site DNA sequence recognized by endodeoxyribonucleases commonly called meganucleases metabolite molecule produced or modified by a metabolic pathway of a cell Mobile genetic element: a DNA sequence that allows for the integration of DNA that has the activity of a transposase enzyme. Monoclonal cell line: A defined population of cells generated from a single founder cell by repeated cell replication. Native: A substance that occurs naturally in cells. Noncoding gene: a non-protein-coding DNA sequence that is transcribed into a functional non-coding RNA molecule. ORF: Open Reading Frame. A stretch of genetic material that codes for the translation frame for synthesis of a protein (polypeptide) by ribosomes. Paracrine: signaling by soluble factors that act directly on nearby cells.
[0182] PCR polymerase chain reaction in which specific target DNA molecules are exponentially amplified Peptide: a short stretch of amino acids between 6 and 30 amino acids in length. Phenotypic analysis: analysis of the observable characteristics of cells. Polymorphism: the occurrence of different forms in individuals of the same species due to the presence of different alleles of the same gene. Polypeptide: A protein consisting of a series of peptides that form a three-dimensional structure. Primary Output: eAPC and eTPC cells from which terminal output can be derived and / or from which terminal output can be measured Primer: A short DNA sequence that allows for specific recognition of a target DNA sequence, for example during PCR. Promoter: A regulatory DNA element for the controlled initiation of gene expression. Selectable marker: a DNA sequence that confers a trait suitable for artificial selection procedures. Shotgun integration: A process in which a library of vectors is introduced into a cell population such that only a single copy of any given vector insert can be integrated into the genome of each single cell. Used to refer to the integration of pooled vectors into a given cell population via integration couples.
[0183] Splice acceptor site: A DNA sequence at the 3' end of an intron AM, APX CM, or affinity reagent for interaction with a cell bearing a TCRsp on its surface or a TCRsp-based reagent. Splice donor site: A DNA sequence at the 5' end of an intron. Synthetic: A substance produced or introduced into a cell artificially. T cell: T lymphocyte. A white blood cell that expresses the T cell receptor on its surface. It is selected by the immune system for its ability to not react with self, but to recognize infections and malignant disease, and to reject grafts from most members of the same species. TCR: T cell receptor. Affinity molecule expressed by a subpopulation of lymphocytes called T lymphocytes. In humans, TCR recognizes cargoes presented by APX CM or APX AM, including fragments from viral or bacterial infections or cancerous cells. Thus, TCR recognition is an essential part of the adaptive immune system. TCR consists of two chains paired on the cell surface. The TCRs expressed on the surface of each cell are randomly assembled from a large pool of different genes (v, d, j and c regions), thus each has a pool of T cells that express a very large and diverse repertoire of different TCRs. TCRsp: A complementary TCR chain pair expressed as a surface protein in complex with CD3, or as a protein in the form of a soluble reactant, an immobilized reactant, or as a protein presented by an NCBP. Terminal output: analyte antigen and TCR sequence in the form of AM, APX, APX:CM, APX:AM or TCRsp.
[0184] TRA: TCR alpha-encoding locus. One of four distinct loci that encode genes capable of forming VDJ recombined TCR chains. The translated TCR alpha chain protein typically pairs with the translated TCR beta chain protein to form the alpha / beta TCRsp. TRB: TCRβ-encoding locus. One of four different loci that encode genes capable of forming VDJ recombined TCR chains. The translated TCRβ chain protein typically pairs with a TCRα chain protein to form an α / βTCRsp. TRD: TCR delta-encoding locus. One of four distinct loci that encode genes capable of forming VDJ recombined TCR chains. The translated TCR delta chain protein typically pairs with the translated TCR gamma chain protein to form a gamma / delta TCRsp. TRG: TCR gamma-encoding locus. One of four distinct loci that encode genes capable of forming VDJ recombined TCR chains. The translated TCR gamma chain protein typically pairs with the transcribed TCR delta chain protein to form the gamma / delta TCRsp. V region: variable region. One of the gene segments used to assemble a T cell receptor. Each individual has many different variations of these regions, allowing each individual to be armed with T cells that have a wide variety of different TCRs.
[0185] item 1. A two-part device in which the first part is an engineered antigen presenting cell system (eAPCS) and the second part is an engineered TCR presenting cell system (eTPCS). 2. eAPCS is as follows: a. eAPC-p, and / or b. eAPC-a, and / or c. eAPC-pa, and / or One or more libraries of da and / or b and / or c 2. The two-part device of item 1, providing one or more analyte eAPCs selected from: 3. eAPC-p, eAPC-a or eAPC-pa is: a.aAPX, or b. aAM, or c. aAPX:aAM, or d. aAPX:CM, or e. combinations thereof 3. The two-part device of item 2, expressing an analyte antigen selected from: 4. eTPCS a. eTPC-t, and / or b. One or more of its libraries 3. The two-part device according to item 1 or 2, 5. The two-part device described in item 4, wherein the analyte TCR chain pair is expressed by the analyte eTPC as a TCR surface protein (TCRsp) complexed with CD3.
[0186] 6. The two-part device of any one of items 1 to 5, wherein one or more analyte eAPCs are combined with one or more analyte eTPCs. 7. The two-part device of item 6, wherein the combination results in contact between the analyte TCRsp and the analyte antigen defined in item 3. 8. The two-part device of item 7, wherein the contact can result in complex formation between the analyte TCRsp and the analyte antigen. 9. The two-part device of item 8, wherein complex formation, when induced, can induce a signal response in the analyte eTPC and / or the analyte eAPC. 10. The two-part device of item 9, wherein the response is used to select analyte eTPCs or pools of analyte eTPCs with or without a signal response and / or analyte eAPCs or pools of analyte eAPCs with or without a signal response.
[0187] 11. An analyte eTPC obtained from a two-part device according to any one of items 1 to 10 for use in characterizing the signal response of an analyte eTPC expressing an analyte TCRsp to an analyte antigen. 12. A method for obtaining one or more analyte eTPCs by selecting one or more analyte eTPCs from an input analyte eTPC or a library of analyte eTPCs, wherein the expressed TCRsp binds to one or more analyte antigens as defined in item 3, a. combining one or more analyte eTPCs with one or more analyte eAPCs to create contact between the analyte TCRsp and the analyte antigen, and b. if formed, measuring the formation of a complex between one or more analyte TCRsp and one or more analyte antigens; and / or c. if induced, measuring a signal response by the analyte eTPC induced by complex formation between one or more analyte TCRsp and one or more analyte antigens; and / or d. if induced, measuring a signal response by the analyte eAPC induced by complex formation between one or more analyte TCRsp and one or more analyte antigens; and e. selecting one or more analyte eTPCs based on steps b, c, and / or d, where the selection is by positive and / or negative determination. The method comprises at least one of the following: 13. The method according to item 12, wherein the selection step is carried out by single cell sorting and / or cell sorting into pools. 14. The method of claim 13, wherein sorting precedes expansion of the sorted single cells. 15. The method of claim 13, wherein sorting precedes expansion of the sorted cell pool.
[0188] 16. The method according to any one of items 13 to 15, further comprising a step of sequencing component 2B' and / or component 2D' of the selected and / or expanded cells. 17. The sequencing step comprises: a. Extracting genomic DNA; and / or b. Extracting RNA transcripts of component 2B' and / or component 2D', and / or c. amplifying the DNA and / or RNA transcripts of component 2B' and / or component 2D' by PCR and / or RT-PCR. 17. The method according to item 16, following item 16. 18. The method according to item 16 or 17, wherein the sequencing step is destructive to the cell and the sequencing information obtained is used to produce an eTPC of the analyte selected in step e of item 12. 19. The selected analyte eTPC is subjected to signal response characterization; a. determining the native signaling response, and / or b. Determine the composite signaling response if the eTPC contains component 2F 19. The method according to any one of items 12, 13, 14, 15, 18, further comprising: 20. The effect of an induced signal response compared to a non-induced signal response condition: A secreted biomolecule B secreted chemicals C. Intracellular biomolecules d. Intracellular chemicals e. Surface-expressed biomolecules f. Cytotoxic effect of analyte eTPC on analyte eAPC g. A paracrine effect of the analyte eTPC on the analyte eAPC, such that a signal response is induced in the analyte eAPC and is determined by detecting an increase or decrease in any of a to e. h. Amplification of analyte eTPC i. The immunological synapse between the analyte eTPC and the analyte eAPC 20. The method according to item 19, wherein the method is determined by detecting an increase or decrease in one or more of the following:
[0189] 21. An analyte eAPC obtained from a two-part device as defined in items 1 to 10 for identifying an analyte antigen that induces a signal response to an expressed analyte antigen of one or more analyte eTPCs expressing an analyte TCRsp. 22. A method for selecting one or more analyte eAPCs from an input analyte eAPC or a library of analyte eAPCs to obtain one or more analyte eAPCs that induce a signal response to an analyte antigen as defined in item 3 expressed by one or more analyte eTPCs expressing an analyte TCRsp, comprising: a. combining one or more analyte eAPCs with one or more analyte eTPCs to create contact between the analyte antigens presented by the analyte eAPCs and the analyte TCRsp of the one or more analyte eTPCs; and b. if so, measuring the formation of a complex between one or more analyte antigens and one or more analyte TCRs; and / or c. if induced, measuring a signal response in one or more analyte eTPCs induced by complex formation between the analyte TCRsp and the analyte antigen; and / or d. if induced, measuring a signal response by the analyte eAPC induced by complex formation between one or more analyte TCRsp and one or more analyte antigens; and e. Selecting one or more analyte eAPCs from steps b, c, and / or d, wherein the selection is by positive and / or negative determination. The method comprising: 23. The method according to item 22, wherein the selection step is carried out by single cell sorting and / or cell sorting into pools. 24. The method according to item 23, wherein sorting precedes expansion of the sorted single cells. 25. The method according to item 24, wherein sorting precedes expansion of the sorted cell pool.
[0190] 26. The method according to any one of items 23 to 25, further comprising the step of sequencing component 1B' and / or component 1D' of the selected and / or expanded cells. 27. The sequencing step comprises: a. Extracting genomic DNA; and / or b. Extracting RNA transcripts of component 1B' and / or component 1D', and / or c. Amplifying the DNA and / or RNA transcripts of component 1B' and / or component 1D' by PCR and / or RT-PCR. 27. The method according to item 26 following item 26. 28. The method according to item 26 or 27, wherein the sequencing step is destructive to the cell and the sequencing information obtained is used to produce the analyte eAPCs selected in step e of item 22. 29. A selected analyte eAPC is selected based on a signal response of the analyte eTPC; a. determining the native signaling response, and / or b. Determining the composite signaling response 29. The method according to any one of items 22, 23, 24, 25, 28, further comprising: 30. The effect of an induced signal response compared to a non-induced signal response condition: A secreted biomolecule B secreted chemicals C. Intracellular biomolecules d. Intracellular chemicals e. Surface-expressed biomolecules f. Cytotoxic effect of analyte eTPC on analyte eAPC g. A paracrine effect of the analyte eTPC on the analyte eAPC, such that a signal response is induced in the analyte eAPC and is determined by detecting an increase or decrease in any of a to e. h. Amplification of analyte eTPC i. The immunological synapse between the analyte eTPC and the analyte eAPC 30. The method according to item 29, wherein the method is determined by detecting an increase or decrease in one or more of the following:
[0191] 31. The cargo is a metabolite and / or peptide loaded onto the aAPX of the analyte eAPC selected and obtained by the method defined in items 22 to 30; a. isolating the aAPX:aAM or aAPX:CM or cargo aM or cargo CM; and b. Identifying the load on board A method for selecting and identifying an AM or CM load. 32. Step b comprises: a.Mass spectrometry B. Peptide sequencing analysis 32. The method according to claim 31, comprising subjecting the compound to one or more of the following: 33. Below: Diagnosis b. Medicine c. Beauty d. Research and Development A TCR chain pair sequence or a library of TCR chain pair sequences selected by the method defined in any one of items 12 to 20, for use in at least one of the above. 34. Below: Diagnosis b. Medicine c. Beauty d. Research and Development An antigenic molecule and / or an ORF encoding said antigenic molecule selected by the method defined in any one of Items 22 to 32, or a library thereof, for use in at least one of the above. 35. Below: Diagnosis b. Medicine c. Beauty d. Research and Development An antigen-presenting complex loaded with an antigenic molecule selected by the method according to any one of items 22 to 32 as a cargo and / or an ORF encoding said complex, or a library thereof, for use in at least one of the above.
[0192] 36. Below: Diagnosis b. Medicine c. Beauty d. Research and Development An eAPC or a library of eAPCs selected by the method defined in any one of items 22 to 32 for use in at least one of the above. 37. Below: Diagnosis b. Medicine c. Beauty d. Research and Development An eTPC or a library of eTPCs selected by the method defined in any one of items 12 to 20 for use in at least one of the above. 38. Below: Diagnosis b. Medicine c. Beauty d. Research and Development The device according to any one of items 1 to 10, for use in at least one of the above.
Claims
1. A two-part device constituting an eAPC:eTPC combination analytical system, the first part being an engineered antigen presenting cell system (eAPCS) and the second part being an engineered TCR presenting cell system (eTPCS), The eAPCS a first component (designated component 1A), which is a genetically engineered antigen presenting cell (eAPC), where component 1A has been genetically engineered to lack endogenous surface expression of at least one family of analyte antigen presenting complexes (aAPXs) and / or analyte antigenic molecules (aAMs), and contains a second component (designated component 1B), which is a synthetic genomic acceptor site for integration of one or more ORFs encoding aAPXs and / or aAMs; and A third component (designated component 1C) which is a gene donor vector for the delivery and integration into 1B of an ORF encoding an aAPX and / or an aAM belonging to the family lacking endogenous expression, where component 1C matches component 1B and is designed to deliver one or more ORFs encoding an aAPX and / or an aAM. comprising wherein aAPX and / or aAM can be expressed by component 1A, The eTPCS a first component (designated as component 2A) which is a genetically engineered TCR presenting cell (eTPC), which component 2A has been genetically engineered to lack endogenous surface expression of at least one family of analyte antigen presenting complexes (aAPXs) and / or analyte antigenic molecules (aAMs), to lack endogenous expression of TCR chains α, β, δ and γ, to express a CD3 protein which is displayed on the cell surface only if the cell expresses a complementary pair of TCR chains, and which contains a second component (designated as 2B) which is a genomic acceptor site for integration of a single ORF encoding at least one of the analyte TCR α, β, δ or γ chains and / or two ORFs encoding the analyte TCR chain pair; and A third component (designated component 2C) which is a gene donor vector for delivery of the ORF encoding the analyte TCR chain. comprising Here, component 2C matches component 2B, and component 2C a. a single ORF encoding at least one of the analyte TCR α, β, δ and / or γ chains, and / or b. Two ORFs encoding the analyte TCR chain pair and the analyte TCR chain may be expressed on component 2A as a TCR surface protein (TCRsp) complexed with CD3; In the eAPC:eTPC combination analysis system, the eTPC is a two-part device that responds in a detectable manner to TCR ligation based on the interaction between APX and / or aAM expressed by component 1A and the TCR surface protein (TCRsp) expressed by component 2A.
2. The two-part device of claim 1 , wherein said one or more ORFs and / or a and / or b encode an integrated selectable marker.
3. eAPCS a. eAPC-p, and / or b. eAPC-a, and / or c. eAPC-pa, and / or d. one or more libraries of a and / or b and / or c 3. The two-part device of claim 1 or 2, providing one or more analyte eAPCs selected from:
4. eAPC-p, eAPC-a or eAPC-pa aAPX, or b. aAM, or c. aAPX:aAM, or d. aAPX:CM, or e. Combinations thereof 4. The two-part device of claim 3, which expresses an analyte antigen selected from:
5. eTPCS a. eTPC-t, and / or b. one or more of its libraries 5. The two-part device of claim 1 , providing eTPC of one or more analytes selected from:
6. The two-part device of claim 5 , wherein the analyte TCR chain pair is expressed by the analyte eTPC as a TCR surface protein (analyte TCRsp) complexed with CD3.
7. The two-part device of claim 6, wherein the eTPC contains component 2F, which represents a synthetic TCR signal response element genetically engineered onto the genome of the eTPC, and which is used to report complex formation between an analyte TCRsp and an analyte antigen presented by eAPC-p, -a or -pa, and which generates a signal response in the eTPC.
8. The two-part device of any one of claims 1 to 7, wherein one or more analyte eAPCs are combined with one or more analyte eTPCs.
9. 9. The two-part device of claim 8, wherein the combination results in contact between the analyte TCRsp and the analyte antigen as defined in claim 4, said contact resulting in a signal response.
10. The two-part device of claim 9 , wherein the contact results in complex formation between the analyte TCRsp and the analyte antigen.
11. The two-part device of claim 10 , wherein formation of the complex induces a signal response in the analyte eTPC or the analyte eAPC.
12. A two-part device according to any one of claims 8 to 10 for selecting an analyte eTPC or a pool of analyte eTPCs or an analyte eAPC or a pool of analyte eAPCs based on the signal response.
Citation Information
Patent Citations
Dual-RMCE-mediated (dual-recombinase mediated cassette exchange-mediated) TCR (T cell receptor) gene replacement system and method
CN105316362A
Identification of T cell target antigens
JP2013535209A
Targeted disruption of the T cell receptor gene using an engineered zinc finger protein nuclease
JP2016515822A
Modified antigen-presenting cells
WO2003065977A2
